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Abstract
Drug discovery has overall become less fruitful and more costly, despite vastly increased
biomedical knowledge and evolving approaches to Research and Development (R&D).
One complementary approach to drug discovery is that of drug repositioning which
focusses on identifying novel uses for existing drugs. By focussing on existing drugs
that have already reached the market, drug repositioning has the potential to both
reduce the timeframe and cost of getting a disease treatment to those that need it.
Many marketed examples of repositioned drugs have been found via serendipitous or
rational observations, highlighting the need for more systematic methodologies.
Systems approaches have the potential to enable the development of novel methods to
understand the action of therapeutic compounds, but require an integrative approach
to biological data. Integrated networks can facilitate systems-level analyses by combin-
ing multiple sources of evidence to provide a rich description of drugs, their targets and
their interactions. Classically, such networks can be mined manually where a skilled
person can identify portions of the graph that are indicative of relationships between
drugs and highlight possible repositioning opportunities. However, this approach is
not scalable. Automated procedures are required to mine integrated networks system-
atically for these subgraphs and bring them to the attention of the user. The aim
of this project was the development of novel computational methods to identify new
therapeutic uses for existing drugs (with particular focus on active small molecules)
using data integration.
A framework for integrating disparate data relevant to drug repositioning, Drug Repo-
sitioning Network Integration Framework (DReNInF) was developed as part of this
work. This framework includes a high-level ontology, Drug Repositioning Network
Integration Ontology (DReNInO), to aid integration and subsequent mining; a suite
of parsers; and a generic semantic graph integration platform. This framework enables
the production of integrated networks maintaining strict semantics that are important
in, but not exclusive to, drug repositioning. The DReNInF is then used to create Drug
- A -
Repositioning Network Integration (DReNIn), a semantically-rich Resource Descrip-
tion Framework (RDF) dataset. A Web-based front end was developed, which includes
a SPARQL Protocol and RDF Query Language (SPARQL) endpoint for querying this
dataset.
To automate the mining of drug repositioning datasets, a formal framework for the
definition of semantic subgraphs was established and a method for Drug Reposition-
ing Semantic Mining (DReSMin) was developed. DReSMin is an algorithm for mining
semantically-rich networks for occurrences of a given semantic subgraph. This algo-
rithm allows instances of complex semantic subgraphs that contain data about puta-
tive drug repositioning opportunities to be identified in a computationally tractable
fashion, scaling close to linearly with network data.
The ability of DReSMin to identify novel Drug-Target (D-T) associations was investi-
gated. 9,643,061 putative D-T interactions were identified and ranked, with a strong
correlation between highly scored associations and those supported by literature ob-
served. The 20 top ranked associations were analysed in more detail with 14 found
to be novel and six found to be supported by the literature. It was also shown that
this approach better prioritises known D-T interactions, than other state-of-the-art
methodologies.
The ability of DReSMin to identify novel Drug-Disease (Dr-D) indications was also
investigated. As target-based approaches are utilised heavily in the field of drug dis-
covery, it is necessary to have a systematic method to rank Gene-Disease (G-D) asso-
ciations. Although methods already exist to collect, integrate and score these associa-
tions, these scores are often not a reliable reflection of expert knowledge. Therefore, an
integrated data-driven approach to drug repositioning was developed using a Bayesian
statistics approach and applied to rank 309,885 G-D associations using existing knowl-
edge. Ranked associations were then integrated with other biological data to produce
a semantically-rich drug discovery network. Using this network it was shown that
diseases of the central nervous system (CNS) provide an area of interest. The network
was then systematically mined for semantic subgraphs that capture novel Dr-D rela-
tions. 275,934 Dr-D associations were identified and ranked, with those more likely to
be side-effects filtered.
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Work presented here includes novel tools and algorithms to enable research within
the field of drug repositioning. DReNIn, for example, includes data that previous
comparable datasets relevant to drug repositioning have neglected, such as clinical
trial data and drug indications. Furthermore, the dataset may be easily extended
using DReNInF to include future data as and when it becomes available, such as G-D
association directionality (i.e. is the mutation a loss-of-function or gain-of-function).
Unlike other algorithms and approaches developed for drug repositioning, DReSMin
can be used to infer any types of associations captured in the target semantic network.
Moreover, the approaches presented here should be more generically applicable to
other fields that require algorithms for the integration and mining of semantically rich
networks.
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Glossary
Active Pharmaceutical Ingredient (API) the ingredient in a drug that is biolog-
ically active.
Adverse Drug Reaction (ADR) an appreciably harmful or unpleasant reaction,
resulting from an intervention related to the use of a medicinal product [1].
Attrition the process of reducing something’s strength or effectiveness through sus-
tained attack or pressure.
Antagonist a substance which interferes with or inhibits the physiological action of
another.
Allosteric allosteric regulation (or allosteric control) is the regulation of a protein by
binding an effector molecule at a site other than the enzyme’s active site.
Affinity how tightly a substance binds to the receptor.
Agonist a substance which initiates a physiological response when combined with a
receptor.
Benefit-risk ratio an evaluation of two dimensions. Benefits are measured in terms
of therapeutic efficacy, quality of life, cost or pharmacoeconomic aspects. Risks include
the safety profile (sum of all ADRs) and potential risk of unobserved ADRs.
Blockbuster drug an extremely popular drug that generates annual sales of at least
US$1 billion for the company that creates it.
Disease a condition of the body, or of some part or organ of the body, in which its
functions are disturbed or deranged [2].
Disease (Rare) US - any disease that affects fewer than 200,000 people in the United
States, in Europe- a disease is considered to be rare when it affects 1 person per 2000.
Disease (Common) any disease that is not classed as a rare disease.
Drug Activity (IC50) is a measure of how effective a drug is. It indicates how much
of a particular drug or other substance is needed to inhibit a given biological process.
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Drug Activity (Kd), or dissociation constant, is a specific type of equilibrium con-
stant that measures the propensity of a larger object to separate (dissociate) reversibly
into smaller components, as when a complex falls apart into its component molecules,
or when a salt splits up into its component ions.
Drug Activity (Ki), or inhibitory constant, is an indication of how potent an in-
hibitor is; it is the concentration required to produce half maximum inhibition.
Drug Activity (Potency) amount of drug needed to achieve a specific biological
response.
Druggability the likelihood of being able to modulate a target with a drug [3].
Efficacy measurement of the maximum biological response of a compound.
Genome the complete set of genes or genetic material present in a cell or organism.
Indication of a drug refers to the use of that drug for treating a particular disease.
International Nonproprietary Name (INN) or the generic drug name, such as
sildenafil, as opposed to brand names used for marketing, such as Viagra.
Monogenic designation describes an inherited characteristic that is specified by a
single gene.
Multigenic designation describes an inherited characteristic that is specified by a
combination of multiple genes.
New Molecular Entity (NME) designation describes a new chemical drug [4].
New Biological Entity (NBE) designation describes a new biological drug [4].
New Therapeutic Entity (NTE) the combined designation refers to either an NME
or an NBE [4].
Orphan Drug a pharmaceutical agent that has been developed specifically to treat
a rare disease.
Pharmacogenomics is the study of how genes affect a person’s response to drugs.
Pharmacokinetics is the study of drug ADME (absorption, distribution, metabolism,
and excretion) properties.
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Phenome the set of all phenotypes expressed by a cell, tissue, organ, organism, or
species.
Phenotype an organism’s observable characteristics [5].
Polypharmacology can mean one drug, multiple targets, or several drugs hitting
different targets in one or more pathways.
Semantic is the study of meaning.
Side-effect an effect, whether therapeutic or adverse, that is secondary to the one
intended.
Side-effect (Off-target) side effects caused by a drug hitting ‘other’ targets than
those it was designed to hit.
Side-effect (ADME) side-effects resulting from the drugs process through the ADME
systems.
Symptom is a departure from normal function or feeling which is noticed by a patient,
reflecting the presence of an unusual state, or of a disease.
Topology (Network) a schematic description of the arrangement of a network, or
graph, including its nodes and connecting edges.
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Chapter 1: Introduction
1.1 Motivation
The Oxford English Dictionary defines a disease as:
“ a condition of the body, or of some part or organ of the body, inwhich its functions are disturbed or deranged [2] ”
Diseases can result in a reduced quality of life, increased morbidity, and mortality.
Through the practice of medicine, doctors focus on preventing, diagnosing and treating
diseases. Recent advances in the development of genome editing technologies have
improved the ability to make precise changes in the genomes of eukaryotic cells [6].
It is hoped that in the future, through the application of programmable nucleases,
genome editing will enable the correction of genetic mutations associated with current
life-limiting diseases, such as Cystic fibrosis [6]. Gene editing approaches are still in
their infancy and as such, drugs are the most common form of disease intervention.
Many drugs can treat a plethora of disorders in a relatively safe fashion. Unlike
biologics (which are made up of sugars, proteins, nucleic acids, or a combination of
these) active small molecules are composed of organic and inorganic compounds, and
it is these active small molecules that form the basis of the majority of drugs on the
market. As long as there are diseases or clinical conditions without suitable medical
products available for their treatment, or ideally cure, the motivation for drug discovery
projects will remain [7].
Drug discovery is the process through which potential new medicines and drug targets
are identified. Strategies for drug discovery rely heavily on Research and Develop-
ment (R&D) and may either be target-based (or molecular approaches) or rely on
phenotypic measures of response (also known as empirical approaches) [5]. Since the
pursuit of the human genome project in the 1990s, drug discovery has focussed on
target-based approaches. Emphasis on target-driven approaches has come with reason-
able successes, including, for example, the tyrosine kinase inhibitor for the treatment of
chronic myelogenous leukaemia, imatinib (Glivec, Novartis) [8]. In target-based drug
discovery, a research-driven hypothesis states that altering the functionality of a pro-
tein or pathway will result in a therapeutic effect on a disease state. After a relevant
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target has been identified, a candidate drug is proposed during lead discovery. Before
the advent of target-based approaches, candidate drugs were determined by evaluating
different chemicals against phenotypes. These phenotypic assays identified candidate
drugs and were conducted in biological systems, such as animals or cells, often with
no a priori knowledge of the mechanism of action [5]. After its identification, using
either a target-based or phenotypic R&D approach, a candidate drug then progresses
into preclinical, and if successful, clinical development (phases I-IV) before becoming
a marketed therapeutic [7]. The whole development process can take 12-15 years with
average costs, when including the price of failure and a ‘time cost’, of US$2.6 billion
[7, 9].
Despite a resurgence in productivity in the last two years [10], in 2009, only 26
New Molecular Entities (NMEs) were approved by the Food and Drug Administra-
tion (FDA), despite R&D costs reaching US$168 billion. The increased expenditure
and decreased productivity is not helped by the fact that a large number of candi-
date drugs fail in, or before, the clinic [11]. The situation has left many questioning
the current state of R&D [12, 13]. It is, therefore, crucial to advance strategies that
reduce this time frame while also decreasing associated costs without compromising
safety. One complementary approach to traditional R&D drug discovery is that of
drug repositioning.
Drug repositioning is concerned with the application of existing drugs to a novel thera-
peutic area and is also known as redirecting, repurposing and reprofiling [14]. Although
drug repositioning tends to focus on drugs that have already reached the market, drugs
that have failed to do so for reasons other than safety concerns may also be considered
for potential repositioning opportunities.
Drugs already approved for the treatment of a particular disease will have already
been tested in humans. As a result, detailed information is available on pharmacology,
formulation and toxicity [14]. This prior knowledge greatly reduces the time taken
for an already approved drug to be reviewed by the FDA and subsequently integrated
into health care. Although examples of successfully repositioned drugs exist, these
drugs have often been identified through rational observations [15] or serendipitous
findings [16]. The search space for potential repositioning opportunities is vast and so
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relying on chance or human intervention to identify these opportunities is not efficient.
Systematic approaches can enable the efficient and exhaustive exploration of this search
space. Although numerous systematic methods to aid in drug repositioning have been
proposed, many focus on a single entity type (such as targets) or the inference of a
single interaction type (such as Drug-Target (D-T) interactions).
There is a plethora of biological and pharmacological data available describing multiple
biological entity types and interactions between them. As data availability increases,
especially data from proteomics, transcriptomics and pathway inference, the building
blocks of our knowledge are enhanced. A holistic view of a drug and its associated
entities can be achieved through the integration of these data, potentially providing a
comprehensive understanding of a drug’s actions. Using these rich data sets, inferences
can be made with a higher confidence than approaches utilising a single data type.
A systems approach to the task of drug repositioning is described in this thesis. In this
approach, data integration platforms relevant to drug repositioning were developed to
allow the implementation of appropriate strategies for semantic data integration using
networks. Topological and semantic network structures, termed semantic subgraphs,
were defined. The mappings of these structures were shown to be indicative of reposi-
tioning opportunities. Finally, algorithms and automated approaches were developed
to allow searching for these connected sub-components.
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1.2 Contribution of the work presented
There are three key results of this work: a Drug Repositioning Network Integration
Framework (DReNInF); an integrated data set, Drug Repositioning Network Integra-
tion (DReNIn); and an algorithm for mining integrated data sets, Drug Repositioning
Semantic Mining (DReSMin).
The first of these outcomes, DReNInF, provides a framework for integrating disparate
data relevant to drug repositioning. DReNInF includes a high-level ontology, Drug
Repositioning Network Integration Ontology (DReNInO), to aid integration and sub-
sequent mining; a suite of parsers; and a generic semantic graph integration platform.
This framework allows a user to produce integrated networks maintaining strict se-
mantics that are important in, but not exclusive to, drug repositioning.
The DReNInF is then used to create DReNIn, a semantically-rich Resource Description
Framework (RDF) data set. A web-based front end is provided, which includes a
SPARQL Protocol and RDF Query Language (SPARQL) endpoint for querying this
data set. The user is also provided with the ability to download query results.
DReSMin was developed to systematically mine these semantically-rich integrated drug
repositioning networks. DReSMin allows for the exact, exhaustive searching of seman-
tic subgraphs; connected sub-components of a target network that enable the inference
of edges or associations that are not captured in the network. This algorithm makes
use of the VF2 [17] subgraph isomorphism algorithm, which is optimised and extended
to consider and score the semantics, as well as topology of any potential mappings.
The application of DReSMin to the inference of novel D-T associations using historical
data was also explored. The outcome of this analysis is a set of scored and ranked D-T
associations and of a set of specialised semantic subgraphs. An extended version of
DReSMin, which utilises values attached to attributes, was also implemented. Associ-
ations between Gene-Disease (G-D) were scored using a Bayesian approach and along
with the updated version of DReSMin used to identify novel Drug-Disease (Dr-D)
associations.
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1.3 Aims and objectives
The aim of this project was the:
“ Development of Novel Computational Methods to Identify New Ther-apeutic Targets for Existing Drugs Based on Data Integration ”
The following objectives were defined to help achieve the project aim:
1. To extend existing data integration platforms relevant to drug repositioning.
2. To research and implement appropriate strategies for semantic data integration
of network construction including Ondex, RDF and others.
3. To develop algorithms to search for topological and semantic network structures
indicative of repositioning opportunities.
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1.4 Thesis structure
This thesis is divided into the following chapters:
• Chapter 2 provides background information and a literature review of current
computational approaches to drug repositioning.
• Chapter 3 describes research in the area of data integration with a particu-
lar focus on its application to drug repositioning. Data integration methods
and platforms are introduced and compared. This Chapter also presents data
sources and data types relevant to drug repositioning. Finally, DReNIn, an RDF
data set with a Web-based SPARQL endpoint, to aid in the discovery of drug
repositioning opportunities is described.
• Chapter 4 introduces a framework for mining integrated networks for the infer-
ence of novel associations. The Chapter introduces and defines semantic sub-
graphs, which are connected sub-components of a target network, whose map-
pings allow us to infer novel associations from a target network. An exact, ex-
haustive subgraph matching algorithm, DReSMin, is also described. DReSMin
identifies all mappings of a predefined semantic subgraph that are captured in
a target graph. Mappings maintain exact topological properties of the semantic
subgraph, while semantics are matched to a user defined threshold.
• Chapter 5 describes the application of DReSMin to the identification of novel D-T
associations. An automated framework is described which makes use of historical
data for the development of a set of relevant semantic subgraphs. Furthermore,
a method for the scoring and ranking of inferred D-T associations is described.
• Chapter 6 discusses the application of DReSMin to the identification of novel
Dr-D indications. First, a Bayesian approach for scoring and ranking G-D asso-
ciations from multiple data sources is introduced. Scored G-D associations are
then integrated into the network before a data-driven approach to drug reposi-
tioning that makes use of these G-D associations is taken.
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• Chapter 7 reviews the outcomes of this work in the broader context of drug
repositioning and describes possible future work.
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2.1 Introduction
Over the past decade, Research and Development (R&D) approaches to drug discov-
ery have become less productive while costs continue to rise, in spite of the rapid
advances in genomics, life sciences and technology over the same period [14, 18, 19].
Drug discovery failures are spread across the drug development pipeline [20]; in 2004
it was calculated that only 11% of drugs investigated in clinical trials reach the mar-
ket [21]. Despite some signs of a very recent resurgence over the last two years [10], the
drug development process for successfully marketed drugs can still take between 10-17
years [22]. Disregarding the extensive time scale, the cost of getting a drug to market
is also extreme. When including the price of failure and opportunity cost, it has been
shown that the cost of drug discovery has more than doubled in the past decade [9].
In 2003, it was estimated that the cost of a new drug, including the price of failures
and a ‘time cost’, averaged US$800 million [23]. The cost of a new drug in 2013, when
considering only inflation of the 2003 cost, was projected to be just over US$1 billion.
However, a similar analysis to that completed in 2003, put the average cost to US$2.6
billion per marketed drug in 2013, a rise of 145% [9]. It was also shown, in 2011, that
the minimum cost of developing a drug not containing a previously approved Active
Pharmaceutical Ingredient (API), was US$204 million [24]. Problems resulting in a
reduction in R&D productivity are complex and include escalating clinical trial costs
and an increased aversion to risk [25]. These complex challenges have resulted in only
20 to 30 New Molecular Entities (NMEs) being approved per year by the Food and
Drug Administration (FDA) between 2005 and 2012 [10].
For these reasons, improving R&D productivity remains the most important prior-
ity within the pharmaceutical industry [13]. Recently, frameworks such as the ‘five R’
framework’ from AstraZeneca [25], have been developed to try and increase the lagging
productivity in R&D. These frameworks have contributed to the recent resurgence in
R&D successes of late. 41 drugs (30 NMEs and 11 New Biological Entities (NBEs))
were approved by the FDA in 2014 and a 19 year high of 45 in 2015 (33 NMEs and 12
NBEs) [10]. 2015 represents an approval rate of double the average during 2005-2009
when approvals were at their lowest with an average of 22 drugs per year [10]. Of
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the drugs approved in 2015, 16 are expected to achieve ‘blockbuster’ status includ-
ing the Cystic Fibrosis treatment ivacaftor plus lumacaftor (Orkambi; Vertex) [10].
Oncology drugs, developed for the prevention, diagnosis and treatment of cancer and
associated neoplasms, have accounted for 30% of approved drugs in three of the past
four years [10]. Of the 45 drugs approved in 2015, 14 are oncology drugs such as
palbociclib (Ibrance; Pfizer), approved for the treatment of breast cancer. 21 of the
approved drugs in 2015 are for orphan, or rare, diseases (half of these are for rare
cancers) [10]. An increase in treatments for rare diseases has resulted in a slump of
around 35% in average forecast sales between 2014 and 2015 (US$1.4 billion per 2014
drug and US$900 million per 2015 drug) [10], with rare diseases less rewarding, finan-
cially. Due to economic incentives, such as the FDA Orphan Drug Act (ODA), it is
not coincidental that 2015 represents the highest number of drugs approved for rare
diseases to date.
A disease is considered to be rare in Europe if it has a prevalence of fewer than 1 in
2,000 people. In the US, a disease that affects fewer than 200,000 individuals is consid-
ered rare. Collectively, rare diseases affect 6-7% of the developed world, representing a
small market opportunity for the pharmaceutical industry [26]. Incentives, such as the
FDA Orphan Drug Act (ODA) of 1983, were introduced to encourage pharmaceutical
companies to invest in R&D for the development of rare disease therapies [26]. The
Act grants special status, referred to as orphan designation (or sometimes “orphan
status”), to a drug or biological product to treat a rare disease upon request of a
sponsor. Orphan designation qualifies the sponsor of the drug for various development
incentives of the ODA, including tax credits for qualified clinical testing, more rapid
pipeline progression and market exclusivity for seven years1. Legislation to promote
the development of orphan drugs has also been implemented in other countries, such
as Japan in 1993, Australia in 1998, and Europe in 2000 [27]. As a result of these in-
centives many pharmaceutical companies and specialist biotechnology companies now
have groups focussing on rare diseases, also incentivised by the fact that rare diseases
have highly active focus groups that mean sometimes clinical trials can be easier. More
recent initiatives, such as the 100,000 Genomes Project from Genomics England, focus
1www.fda.gov Accessed:01-03-2016
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on patients with rare diseases as well as their families, and patients with common can-
cers2. Data from the 100,000 Genomes Project will provide a gene mechanistic-based
understanding of multiple rare diseases, a potentially massive opportunity for drug
development for rare diseases.
Despite the recent peak in productivity, R&D approaches to drug discovery remain
incredibly costly. Complementary approaches to the typical R&D paradigm have come
to the fore of late, with examples including personalised medicine to find tailored
therapies for individual patients [28]. Personalised medicine takes into account the
fact that 30% of drugs investigated in clinical trials fail because of a lack of efficacy
(the two foremost reasons for clinical drug attrition are inefficacy and toxicity) [21, 28].
Personalised medicine is particularly interesting when considering the fact that even
the top 10 selling approved drugs in the US help as little as 1 in 25 of those that take
them [29]. Factors such as the bias towards white Western participants in clinical trials,
results in some drugs even being harmful to certain ethnic groups [29]. The idea behind
precision medicine is that stratifying patients and diseases into molecular subtypes
and treating with subtype-specific drugs will improve specificity and efficacy [28]. The
interest in personalised medicine has come at a time when efforts such as the UK
100,000 Genomes Project and the US Precision Medicine Initiative seek to scale up
population-based genome sequencing and integrate it with clinical data [30]. Although
an attractive alternative to R&D, precision medicine is still a young and growing field.
Due to its immaturity, precision medicine faces many immediate problems, not just
the fact that many of the required technologies are still in their infancy. Another
complementary approach to R&D drug discovery is drug repositioning.
2.2 Drug repositioning
A recent analysis of 217 relevant scientific articles, found no standard definition for
drug repositioning [31]. For the purpose of this project the original definition, as
provided by Ashburn and Thor in their landmark paper, will be used to define drug
repositioning as:
2www.genomicsengland.co.uk Accessed:01-03-2016
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“ the process of finding new uses outside the scope of the originalmedical indication for existing drugs [14] ”
The word ‘repositioning’ may also be used interchangeably with ‘redirecting’, ‘repur-
posing’, and ‘reprofiling’ [14]. In this setting, a ‘drug’ is defined as a well-understood
chemical or biological ingredient that regulatory agencies, such as the US FDA or the
European Medicines Agency (EMA), have approved for use in the context of disease.
Furthermore, a drug is a particular combination of API, formulated under defined and
consistent conditions for human use [32].
Drug repositioning has traditionally been part of the drug development process. Dur-
ing drug development, drug repositioning is used as a strategy to preserve and extend
the value of patents through reformulation strategies [33]. However, as R&D ap-
proaches become less efficient and more costly, drug repositioning is becoming ever
more important, providing an effective alternative to traditional R&D approaches in
drug discovery. The savings arise from the fact the drugs have already reached the
market. Marketed drugs will already have established formulations and manufacturing
methods and will have been tested in humans [14, 28]. As a result, detailed informa-
tion will be available describing Absorption, Distribution, Metabolism, Excretion and
Toxicity (ADMET) properties [14, 28] as well Phase IV (post-marketing) safety data,
which are expensive and time-consuming to obtain [34]. Although ‘safety’ to treat one
disease, does not necessarily mean ‘safety’ to treat another, since a significant propor-
tion of drugs are deemed toxic. In fact, around 30-40% of FDA-approved drugs display
such severe side-effects that they are ‘black boxed’ [32] or receive the EMA’s equivalent
(a black triangle along with the statement ‘This medicinal product is subject to addi-
tional monitoring’). ‘Boxing’ is used by the FDA to highlight drugs deemed tolerable
for the situation. Tolerability means the drug is on the favourable side of risk-benefit
analysis, while also carrying a significant risk of serious side-effects [32]. Drug repo-
sitioning offers many benefits to traditional R&D approaches to drug development,
some of which are described below.
As mentioned, approved drugs will have already been tested for safety in humans. The
time taken for an already approved drug to be reviewed by the FDA and their subse-
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A
B
C
Figure 2.1: Typical R&D approaches to drug discovery. (A) Abstract drug-
disease connection, known by some as the central dogma of drug action (drug-target-
disease) [36]. In the red box different approaches, target screening (B) and phenotype
screening (C), to drug discovery are shown in relation to the drug-disease connection.
Figure adapted from [22].
quent integration into health care can be significantly reduced. Potentially, reposition-
ing can reduce the traditional timeline of 10-17 to 3-12 years, making drugs available
to patients much more quickly than following a traditional R&D route [14, 22]. The
financial savings of drug repositioning are also appealing to pharmaceutical compa-
nies. Bringing a repositioned drug to market costs approximately 160 million times
less than typical R&D approaches to developing an NME [35], with a low barrier to
entry [32]. In fact, it takes an average of US$8.4 million dollars to get a repositioned
drug to market [35]. In 2003 sildenafil (Viagra; Pfizer) had a global revenue stream
of US$1.88 billion [14]. Although this is a ‘best case’ situation, it does highlight the
potential disparity in upfront investment and financial gains of a repositioned drug,
supporting the belief that a repositioned drug represents a better return on investment
than an NME [35].
Typically, a drug discovery programme initiates as there is a disease, or clinical con-
dition, missing from the portfolio of a pharmaceutical company, or without suitable
medical products available [7]. An extensive collection of chemicals is then experi-
mentally tested to see if any can produce a relevant effect, in a process known as
screening. Screening may be either target-based (see Fig. 2.1B) or phenotypic (see
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Fig. 2.1C). Target-based screening has been popular since the advent of the genomic
era, and selects chemicals based on their ability to bind to a biological target relevant
to the therapeutic area of interest [22]. These targets are, more often than not, sin-
gle proteins [37]. The more specifically a chemical interacts with the active site of a
target, the ‘cleaner’ the action of the chemical will be. Historically, however, the best
drugs are often promiscuous (e.g. some of the anti-kinases). On the other hand, a
phenotypic screen does not make any assumptions about the underlying pathological
mechanism and proteins involved. Instead, the target is ‘skipped’ and a cell line or
model organism representative of the therapeutic area of interest is directly screened in
a direct attempt to find a chemical that exhibits the desired phenotypic behaviour [22].
Both methods help to efficiently discover active chemicals, or lead drugs. It takes be-
tween 2.5 to 4 years to complete the process of lead discovery; 2 to 3 years for target
discovery and validation and 0.5 to 1 year to screen or design chemicals with biological
activity [22]. Lead drugs are further optimised for efficacy using medicinal chemistry
during lead optimisation, a process which takes 1 to 3 years. Lead optimisation aims
to avoid side-effects due to either off-target binding or unintended physiologic roles of
the target [22]. It then takes 1 to 2 years to ascertain ADMET properties of drugs
using animal models, 5 to 6 years to assess the safety and efficacy of drugs in clinical
trials, and 1 to 2 years to obtain approval [14]. Drug repositioning opportunities can
be derived from three key observations of the traditional workflow as described below.
Clinical trials are expensive and only a small set of diseases are analysed. As a result of
inexhaustive clinical trials, once a drug has reached the market, potential indications
that were not investigated in the clinic can be identified as a repositioning opportunity.
Secondly, the pleiotropic effects of genes and other drug targets mean they may be
involved in diseases other than those that the drug was developed to treat (see Fig.
2.2B). Understanding the involvement of a target in the biological system can help to
identify new roles for a drug. Thirdly, due to drug promiscuity, a drug may also bind
to multiple targets for which it was not primarily designed to affect. Some state that
drug promiscuity is a pre-requisite for drug repositioning [38]. Known as off-target
molecules, a known drug binding to these secondary targets may provide repositioning
opportunities while also highlighting potential side-effects [39] (see Fig. 2.2C).
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B A
Target
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Drug
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C
Figure 2.2: Drug repositioning opportunities arising during typical drug dis-
covery process. (A) The abstract drug-disease connection, also known as the central
dogma of drug action. (B) A drug target may be involved in multiple pathways or
diseases and so a secondary indication may be identified. (C) Often small molecules
bind to other targets (off-targets), allowing for potential new indications, as well as
side-effects, to be highlighted.
In recent years, drug repositioning has become actively supported by governments,
non-trading organisations and academic institutions alike [18, 40]. For example, both
the UK (Medical Research Council) and the US (National Centre for Advancing Trans-
lational Sciences) have launched large-scale funding programs in this area [18]. The
goal of the funding is to extend the indication set for molecules that have already un-
dergone significant R&D in the pharmaceutical industry [18]. Many pharmaceutical
companies, including GSK and Pfizer, have also implemented intense systematic repo-
sitioning efforts. In academia and industry alike there are also substantial economic
incentives to reposition marketed drugs for the treatment of rare disorders [41].
Although examples of successfully repositioned drugs exist, they have often been iden-
tified through rational observations [15] or serendipitous findings [16], such as the
examples provided next.
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2.2.1 Marketed examples
Here, examples of successful repositioning involving approved drugs are described.
Although some investigational drugs have been successfully repositioned, including
thalidomide (Thalidomide Celgene; Celgene) for the treatment of leprosy and multiple
myeloma, and zidovudine (Retrovir; ViiV Healthcare) for the treatment of AIDS,
only examples including approved drugs are discussed here. Focus is placed on the
identification of the repositioning opportunity to highlight the serendipity involved in
these cases.
2.2.1.1 Sildenafil: unexpected side-effects
Pfizer was seeking a drug for the treatment of angina when sildenafil (Viagra; Pfizer)
was developed in the 1980s [14]. Inhibiting phosphdiesterase-5, sildenafil was to re-
lax coronary arteries, allowing greater coronary blood flow and thus reducing patient
symptoms. The desired cardiovascular effects were not observed in the healthy vol-
unteers, with the drug lacking efficacy for angina. Development of sildenafil was thus
discontinued, until, that is, many of the patients involved in the clinical trials reported
that they had unusually strong and persistent erections [14].
This lead to Pfizer setting up a trial on 3,700 impotent men with a total of 1,631 years
of exposure worldwide [42]. In 1998 sildenafil received clearance for the treatment
of erectile dysfunction and the drug was repositioned as a first-in-class accordingly.
By 2003, sildenafil had cemented its position as a blockbuster drug with annual sales
of US$1.88 billion with nearly 8 million men taking sildenafil in the United States
alone [14]. In 2005, after successful clinical trials, sildenafil was also approved for the
treatment of pulmonary arterial hypertension (Revatio; Pfizer) [43].
The repositioning of sildenafil arose from the secondary functions of its targeted en-
zyme, PDE5. The pleiotropy of PDE5 and the mechanism which allowed for reposi-
tioning is represented schematically by Fig. 2.2B.
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2.2.1.2 Duloxetine: pathway involved in multiple diseases
Duloxetine (Cymbalta; Eli Lilly) is a balanced dual serotonin (5-HT)-norepinephrine
(NE) reuptake inhibitor [44]. Discovered in the late 1980’s, duloxetine was the result
of efforts to identify an improved version of the anti-depressant fluoxetine (Prozac;
Eli Lilly) [14]. The action of duloxetine is associated with the re-uptake inhibition
of 5-HT and NE at the presynaptic neurone in Onuf’s nucleus (the pudendal nerve
motor nucleus) of the sacral spinal cord [45]. Duloxetine has also been developed for
the treatment of pain caused by diabetic neuropathy [44].
Duloxetine was also shown to be beneficial in the treatment of stress urinary incon-
tinence (SUI), the most common form of urinary incontinence. With a prevalence
rate of around 50%, SUI is more frequently found in women than in men [44]. The
effectiveness of duloxetine in the treatment of SUI was studied in a cat model of acetic
acid induced bladder irritation [44]. Here in the UK, duloxetine (Yentreve; Eli Lilly),
is approved by the EMA as a first in class add-on medication instead of surgery for
those suffering from SUI [44].
The repositioning of duloxetine resulted from a shared mechanism of action between
the two diseases, depression and SUI [14]. Like sildenafil, the repositioning of duloxe-
tine can be represented schematically by Fig. 2.2B.
2.2.1.3 Imatinib: drug potently inhibits target in another disease
Chronic myelogenous leukaemia (CML) is characterised by the reciprocal transloca-
tion between chromosomes 9 and 22, known as the Philadelphia translocation [8]. A
consequence of this inter-chromosomal exchange is the expression of the BCR-ABL
oncogene [8], a mutation present in 95% of CML patients [46]. Using target-based
approaches, specifically to identify a tyrosine kinase inhibitor for BCR-ABL, ima-
tinib (Glivec; Novartis) was identified as a potent and selective inhibitor of BCR-
ABL. Imatinib was also found to be an inhibitor of the platelet-derived growth factor
(PDGFR) [47] and KIT tyrosine kinases (both the wild and mutant type) [46, 48].
The drug was subsequently approved in 2001 for the treatment of CML by the FDA,
after only a two and a half month review time.
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Accounting for less than 1% of primary gastrointestinal neoplasms, Gastrointestinal
Stromal Tumor (GIST), is a rare, and, therefore, somewhat neglected, disease [49].
Most commonly it originates in the stomach (60%), followed by the small intestine
(30%), the colon and rectum (5%), and the oesophagus (5%) [50]. GIST is associated
with a Gain of Function (GoF) point mutation in the tyrosine kinase proto-oncogene,
KIT, responsible for around 85% of GISTs [49]. Platelet-derived growth factor receptor
alpha PDGFRα point mutations are also found in 5-10% of GISTs [50]. After the early
success of imatinib in chronic phase CML, investigators decided to test its effects on c-
KIT receptor tyrosine kinase activity [48]. Testing was based on rational observations
regarding the sensitivity of KIT to imatinib [46]. The FDA subsequently approved
imatinib for GIST patients in 2002.
The repositioning story of imatinib may be represented schematically, as shown in
Fig. 2.2C. In this case, the drug binds to another target involved in another disease.
2.2.2 Computational approaches
Human intervention and luck have been central to the repositioning success stories
introduced. The search space for potential repositioning opportunities is enormous;
relying on serendipity or rational observations to identify these is, therefore, not ef-
ficient. Systematic approaches can enable the exhaustive exploration of this space.
Although it is assumed that experimental bioassays are more reliable and predictive
than computational assays [32], testing all drugs against all targets experimentally is
extremely costly and, at present, technically infeasible [51]. The lower cost and barrier
to entry, in comparison to experimental methods, have made computational approaches
to drug repositioning of high interest and effort in the research community [32].
Computational repositioning is the process of designing and validating automated
workflows that can generate hypotheses for new indications [22]; providing promising
and efficient tools for discovering new uses for existing drugs [18]. As such a wide range
of computational approaches and strategies have been proposed [32]. These can be
divided, roughly, into five categories: drug-based approaches, protein similarity-based
approaches, genome-based approaches, phenome-based approaches, and computational
strategies, as shown in Fig.2.3.
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Figure 2.3: Computational approaches to drug repositioning. Computational
approaches introduced in this Chapter can roughly be divided into five categories:
drug-based approaches (Drug-based), protein similarity-based approaches (Protein
similarity), genome-based approaches (Genome-based), phenome-based approaches
(Phenome-based), and computational strategies. Above, each methodology is cate-
gorised and shown in context with the elements involved in the drug-disease connec-
tion.
2.2.2.1 Ligand structure-based approaches
Ligand similarity analysis is based on the accepted ‘similar property principle’
(SPP) [52]. The SPP states that similar molecules should have similar biological
activities, affecting proteins and biological systems in similar ways [52]. As such the
use of chemical similarities is a common target-based approach for drug reposition-
ing [53]. There are many methods for measuring the potential similarity between
molecules, including 1-dimensional logP , 2-dimensional topological fingerprints as well
as 3-dimensional conformations [54]. It is these similarity measures that allow for
ligand-based virtual screenings to be performed. When applying the approach to drug
repositioning the aim is to search for, ideally approved, compounds that are struc-
turally similar to other drugs that have known indications. It can then be assumed,
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Figure 2.4: Drug repositioning using compound similarity. If a drug, DrugX,
shares a similar structure to another drug, DrugY, then, using the similar property
principle it can be assumed that DrugY will share similar properties with DrugX. If
DrugX is known to bind to a Target, it can be inferred that DrugY will also bind
that Target. Note: sim = structural similarity between drugs, red relation represents
inferred association.
using the SPP, that the similar compound may also be used to treat the same disorder
(Fig.2.4 shows an abstracted summary of the logic).
Examples include an approach described by Keiser et al. [55], who described a Simi-
larity Ensemble Approach (SEA). Known approved drugs were grouped based on their
known target binding partners and chemical features. The method then calculated,
using a statistical model, the likelihood a molecule will bind to a target based on the
chemical features it shares with those of other known drugs.
There is also a recent trend to integrate chemical structure similarity data with other
types of data [18]. For example, Wang et al. [56] describe a drug repositioning model
that makes use of chemical similarity data integrated with molecular activity and side-
effect data. A kernel function is defined and used by a state vector machine classifier,
with the approach showing high efficiency when compared to others [56].
Tan et al. [57] produced a drug similarity network incorporating 3-dimensional drug
chemical structure similarity data, drug-target interactions and gene similarity data.
Using this network, 33 modules of drugs with similar modes of action and indications
were identified. Using these modules new indications were predicted for 143 drugs.
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Focussing purely on chemical similarity is a risky approach to drug repositioning.
Many drugs differ in structure from database to database as many structures, as well
as other chemical properties of known drug compounds, contain errors, or are held
as proprietary information [58]. Furthermore, many physiological effects cannot be
predicted by chemical properties alone because drugs undergo complex and largely
uncharacterised, metabolic transformations as well as other pharmacokinetic transfor-
mations as they are metabolised and physiologically distributed [58]. The structure of
a ligand that is captured in a database may differ dramatically to that of the active
form— particularly true when considering pro-drugs (a compound that, after admin-
istration, is metabolised into the pharmacologically active drug), such as tamoxifen
(generic drug).
2.2.2.2 Drug combination approaches
Many diseases are driven by complex molecular and environmental interactions [18].
As such, treating a single component, target or pathway may not suffice to dislodge
the mechanisms leading to disease. In cancers, for example, diseases are regulated by
interactions of multiple signalling pathways interacting with one another, as such, it is
not sufficient to target a single pathway. Furthermore, if a single drug is used to target
a disease signalling pathway in cancers, then alternative signalling pathways may be
activated to maintain tumour development, also known as acquired resistance [59].
Acquired resistance is a major problem in cancer patients. To increase cancer treat-
ment outcomes, and reduce the drug resistance effect, drug combinations are seen as
the optimal option. Drug combinations also have the potential to improve efficacy
and reduce side-effects [60]. The majority of strategies in place rely mainly on clinical
and empirical evidence, with most picked manually by clinicians depending on their
experience and expertise [59]. Considering all possible combinations between drugs the
potential search space is huge and impractical [61], as such computational prediction
of combinatorial therapies is of high interest.
For example, Zhao et al. [60] used integrative approaches focussing on molecular and
pharmacological features of drugs. Drugs were represented by sets of their properties,
or features, such as targets or indications. A machine-learning method was then used
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to classify drugs into combinations using these feature patterns trained on pairwise
combinations from the FDA Orange Book. The Orange Book contains information re-
garding drug products approved on the basis of safety and effectiveness by the FDA. 16
possible drug combinations were proposed during their work, with 11 being supported
by the literature.
Huang, H. et al. [61] used clinical side-effects (from post-marketing surveillance and
the drug label) as features for drug-drug combinations. The approach focussed on
the safety of potential combinations and is based on the hypothesis that drugs that
can be co-prescribed usually do not have or share an Adverse Drug Reaction (ADR).
Interestingly they identified three FDA boxed side-effects; ‘Pneumonia’, ‘haemorrhage
rectum’, and ‘retinal bleeding’ as top features contributing to model performance and
thus developed a ‘Rule of Three’ criterion; a candidate drug combination with any
of these side-effects is likely unsafe. The work identified 1,508 ‘safe’ candidate drug
combinations.
Sun et al. [62] made use of genomic profiles to aid the drug combination prediction
task. A model was developed to predict effective drug combinations by integrating
gene-expression profiles of multiple drugs. During this approach existing drug combi-
nations were extracted from the Drug Combination Database (DCDB) [63]. Statistical
methods were used to identify significant features related to drug combinations in terms
of side-effects, genes or disease pathways that would be affected by a known drug com-
bination. These features were then used to construct a machine-learning classifier for
predicting potential drug combinations.
One of the main limitations to identifying drug combinations computationally is the
potential safety aspects. Safety issues are critical for co-prescribing drugs or devel-
oping fix-dose combinations [61]. Although simplifying and abstracting known safety
information allows for unsafe combinations to be pruned, there is a significant risk
that those identified as being safe computationally may indeed act very differently in
vivo, due to an incomplete understanding of off-target effects.
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2.2.2.3 Protein (ligand site) structure-based approaches
Most drugs are known to bind to more than one target [64], and the majority of these
targets are proteins [37]. Drugs, such as the HIV treatment maraviroc (Celsentri;
Pfizer) and the calcium mimicking cinacalcet (Mimpara; Amgen), target the allosteric
areas of targets. However, the majority of drugs bind ligand sites of the target protein.
Furthermore, it has been shown that there is a correlation between drug promiscuity
and the structural similarity, as well as binding site similarity, of protein targets [38].
The interaction between a drug and a protein may be analysed computationally us-
ing an approach known as molecular docking. Molecular docking is a computational
method that predicts how two molecules interact with each other in 3-dimensional
space [51]. Docking allows for the optimisation of binding affinities, which can increase
the potency of a drug. Many pharmaceutical companies, including Genentech and Me-
lior, use docking to identify new indications for drugs [65]. Docking approaches are
popular in drug discovery as they enable researchers to screen drug candidates against
a panel of similar proteins to determine their specificity to the intended target [51]
within a few days [65]. Due to the popularity of docking during the development
process, it has inevitably been applied to the task of drug repositioning.
In the drug repositioning setting, the aim is to identify potential off-targets, based on
similarities between the protein structure or the binding site structure of the on-target
protein [51]. If an off-target is known to be involved in another disease, then the drug
has the potential to treat the second disease (Fig.2.5 shows an abstracted summary
of the logic). As such a series of studies have focussed on comparing the similarity
between binding sites as a means of identifying these potential off-targets.
For example, Haupt et al. [38] used such an approach to identify properties that enable
drug promiscuity. A systematic study of drug promiscuity was carried out based
on structural data of Protein Data Bank (PDB)3 target proteins, using a set of 164
promiscuous drugs. The approach identified 71% of the promiscuous drugs having at
least two targets with similar binding sites.
Kinnings et al. [66] focussed on the repositioning of entacapone (Comtan; Novartis)
3www.rcsb.org/pdb
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Figure 2.5: Drug repositioning using protein structure and/or binding site
similarity. If a protein, ProteinX shares a similar structure (B), or similar ligand
binding site structure (A), to another protein, ProteinY, then it can be assumed that
a Drug that binds to ProteinX may also bind to ProteinY. Note: sim = structural
similarity between proteins, or protein ligand sites, BS = binding sites, has b s = has
binding site, red relation represents inferred association.
to treat multi-drug and extensively drug resistant tuberculosis. A chemicals systems
biology approach to identify off-targets was used to make the prediction. During
this approach, the binding site of a commercially available drug was first identified
from a 3-dimensional structure of the target protein. Next, off-targets with similar
ligand binding sites were identified using an efficient and accurate functional site search
algorithm. Atomic interactions between the putative off-targets and the drug were
then evaluated using protein-ligand docking before the drug was optimised to enhance
potency, selectivity and ADMET properties.
Approaches to drug repositioning utilising only protein structure rely on 3-dimensional
structural data being available. One of the most frequently used sources for such
information is the PDB. The PDB is still far from containing the whole proteome,
limiting inferences to a subset of potential drug targets, and thus cannot be used to
predict new mechanisms beyond the known targets [65]. Furthermore, the structures of
many physiologically relevant proteins are not fully resolved; including whole families
of GPCRs, which are favoured as drug targets for many approved drugs [58]. Protein
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structure methods are also prone to producing great numbers of false positives due to
errors in resolved protein structures and incomplete modelling of atomic and molecular
interactions [58].
2.2.2.4 Gene expression-based approaches
Rapid advances in genomics have led to the generation of large volumes of genomic and
transcriptomic data for a diverse set of disease samples, normal tissue samples, animal
models and cell lines [63]. Much of these data are publicly available. Together with
other phenotypic, and clinical databases, these data sets provide a unique opportunity
to understand disease mechanism, elucidate drug mechanism of actions and identify
new uses for old drugs. Among these, transcriptomic profiles, such as gene expression
data are most widely used [63].
Transcriptional drug-treatment databases, such as the Connectivity Map (CMap) [67]
project and its extended project, Library of Integrated Network-Based Cellular Sig-
natures (LINCS)4 [68], provide measurement data. Measurement data is usually pro-
duced using a microarray with probes for a set of genes of interest. Provided data
includes various experimental factors, including multiple cell types, doses, and time
points [69]. CMap aims to construct a detailed map of functional associations among
diseases, genetic perturbations and drug actions by observing the behaviour of an or-
ganism’s gene expression in a particular setting [70]. Differentially expressed genes can
serve as a proxy to characterise a molecular effect, the so-called gene expression signa-
ture [70]. Comparison of differentially regulated gene expression profiles from cultured
human cells treated with bioactive molecules is enabled as well as cross-platform com-
parisons. The data captured in these databases has been the principal source behind
several drug repositioning studies [63], as well as being integrated with other functional
genomics databases (such as the NCBI Gene Expression Omnibus (GEO) [71]).
One of the most common approaches utilising CMap data involves identifying new
potential interactions based on the mapping of opposite expression profiles of drugs and
diseases. This method is known as ‘signature reversion’ and is depicted in Fig.2.6A.
For example, Dudley et al. [58] systematically compared gene expression signatures
4www.lincsproject.org
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Figure 2.6: Drug repositioning using CMap data. (A) An overview of signature
reversion approaches to drug repositioning using CMap data. (B) Guilt-by-association
approaches using CMap data may allow for novel uses of drugs to be identified. Note:
G = gene, GE = gene expression profile, has ex p = has expression profile, has ind
= has indication, sim = similar expression profile, anti = anti-correlated expression
profile, red relation represents inferred association.
of inflammatory bowel disease (IBD) derived from GEO against a set of drug-gene
expression signatures comprising 164 drug compounds from CMap, inferring several
new interesting drug-disease pairs. One of these pairs was validated in IBD preclinical
models. Jachan et al. [72] used a similar strategy to query a large set of gene expression
profiles. The aim of the study was to reposition antidepressant drugs to the treatment
of small cell lung cancer.
Other approaches apply ‘guilt-by-association’ methodologies to analyse CMap data.
These techniques look at drugs which create similar expression profiles, in the hope that
this indicates a similar mode of action [73]. Fig.2.6B shows an abstracted summary of
the logic used during such an approach.
Although a potentially interesting source for drug repositioning, transcriptomics data
present considerable challenges in terms of statistical analysis [67]. Methods based
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on expression activity similarity rely heavily on the quality and assumptions of the
means used to derive the expression profiles. For example, the CMap date is created
by exposing drug compounds to isolated cell lines. Isolated cell lines likely do not ac-
curately reflect a complete physiological system, leaving the accuracy of the observed
biological activity of the drug in doubt. Many drugs undergo chemical transformations
after they are metabolised in vivo, and it is these drug metabolites that often provide
the eventual therapeutic effect [58]. Furthermore, the pathology of many disease con-
ditions, such as Type 2 diabetes, spans multiple tissues and organ systems; therefore,
it is difficult to represent and compare such diseases on the basis of a single expression
signature.
2.2.2.5 Genetic variation-based approaches
Genetic variations can also provide valuable insights regarding drug repositioning op-
portunities. Due to recent developments in high-throughput DNA sequencing methods
and analysis pipelines, it has become increasingly affordable to sequence individuals
and study their genotypes. From the information generated, common mutations can
be isolated in the DNA that are significantly associated with a phenotypic trait, a
method known as Genome-Wide Association Studies (GWAS). It must also be noted
that historically, GWAS were array-based studies requiring large cohorts and thus were
costly. Sequencing-based approaches are only just beginning to become prevalent, but
still face significant limitations compared to array-based assays.
GWAS data has been used to unveil potential new indications for protein targets.
For example, Sanseau et al. [74] integrated disease associated genes from GWAS with
targets of drugs from pharmaceutical projects. In this approach links between genes
and disease traits were analysed. Using knowledge that a drug targets the given
gene product, the indication of the drug was expected to be the same as the trait
studied in the GWAS. If this was not the case, and a mismatch between the trait
and known indications was present, then a potential repositioning opportunity was
proposed (Fig.2.7 shows an abstracted summary of the logic).
Okada et al. [75] performed a three-stage GWAS meta-analysis of rheumatoid arthritis
(RA) patients, linking the risk loci to known RA drug targets. In the study, logistic
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Figure 2.7: Drug repositioning using GWAS data. An abstract view of how
GWAS data may be used to infer novel drug repositioning opportunities as described
in [74]. Note: en by = encoded by, has va = has variation, ass tr = associated trait,
has ind = has indication, red relation represents inferred association.
regression models assuming additive effects on the allele dosages were used to assess the
relationship of single nucleotide polymorphisms (SNPs) and RA. In total 101 RA risk
loci (42 novel) were identified and showed significant overlap with approved RA drug
targets. Finally, several approved drugs are connected to RA risk genes, indicating
repositioning opportunities.
Any approaches that make use of genetic data are limited to predicting drug reposi-
tioning opportunities for disorders that have been investigated by GWAS studies. It
is also difficult to assess ascertainment bias when using such data [74].
2.2.2.6 Phenotype-based approaches
Phenotype-based approaches to drug repositioning include those that focus on diseases
or side-effects.
Diseases can be linked together based on multiple shared features, such as the cause of
the pathology or the biological dysfunction observed. Approaches generating networks
of diseases and the similarities between these diseases, aim to develop a ‘diseasome’
view. For example, Li et al. [76] used data relating to disease associated genes and
pathway associated diseases, where disease genes were enriched. Diseases were then
linked together based on shared pathways, hypothesising that diseases with commonly
deregulated pathways were similar. Novel disease relationships were then introduced
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in the hope that the work would enable pathway-guided therapeutic interventions for
diseases.
Hoehndorf et al. [77] applied a semantic text-mining approach to identifying the pheno-
types associated with over 6,000 diseases. Furthermore, they made use of a phenotypic
similarity measure to generate a human disease network where clusters contained dis-
eases that had similar signs and symptoms. Finally, the network was used to identify
closely related diseases, based on common etiological, anatomical as well as physiolog-
ical underpinnings. Although not directly addressing drug repositioning, disease maps
can provide insight regarding the usage of a drug.
The phenome-wide association study (PheWAS) has, in recent years, become an in-
creasingly popular approach to identifying relevant genetic associations with human
diseases [78]. Denny et al. performed a large-scale application of the PheWAS using
electronic medical records (EMRs), demonstrating the utility of the PheWAS as a use-
ful tool for detecting novel associations between genetic markers and human diseases.
Side-effects (resulting from off-targets, as opposed to ADMET genes) analysis has
enabled the discovery of novel therapeutic uses of drugs. Methods using the pretence
that similar side-effect profiles may give rise to similar therapeutic profiles have fre-
quently been applied to drug repositioning [79–81]. Yang et al. [80], for example,
used side-effects from SIDER [82] to link diseases and extract drug repositioning op-
portunities. Chemicals were linked to pathologies using information available in the
pharmacogenomics knowledge base. The approach valued evidence showing that drugs
used to treat similar diseases have similar side-effects. In this respect, side-effects can
be indicators of a common underlying mode of action, and two drugs sharing a similar
side-effect profile can be used to treat the same pathology.
Finally, phenotypic information may also be integrated with other data. Hoehndorf et
al. [83] for example, integrated data involving genotype-disease associations with drug-
gene associations. During this work, a semantic similarity-based score was derived to
measure genotype-disease associations.
The most apparent limitation of the side-effect similarity approaches is the necessity
for having well-defined side-effect profiles for a drug [58]. Despite rigorous preclinical
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Figure 2.8: Drug repositioning using side-effect similarity. An abstract view
of how side-effect similarity profiles may be used to infer novel drug repositioning
opportunities. Note: SE = side-effect, S1 = set of side-effects associated with DrugX,
S2= set of side-effects associated with DrugY, sim sep = similar side-effect profiles,
sim f = inferred functional similarity.
assessment, the side-effect profile for a newly approved drug may only be fully dis-
cerned after years of clinical use and post-market surveillance [58]. In addition, the
assumption that similar phenotypic expression of a drug side-effect implies a common
pathophysiological basis may not always hold. For example, the side-effect of ‘hair
loss’ can arise when 1) a drug interferes with hormonal systems that regulate hair
growth, or 2) a drug causes harm to the cells comprising the hair follicle via disrupting
immune function [58].
2.2.2.7 Machine learning approaches
A sub-field of computer science, machine learning evolved from the study of pattern
recognition and computational learning theory in artificial intelligence. Machine learn-
ing and can be defined as:
“The set of computer algorithms that automatically learn from experi-ence [84] ”
In the field of drug repositioning, machine learning models can leverage various relevant
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data to study the underlying systems for the prediction of novel uses for drugs [18].
Such approaches provide a way to combine various descriptors into one statistical
model, with the aim of increasing the accuracy of the predictions. A great number of
machine learning methodologies have been developed.
For example, Gottileb et al. [85] introduced PREDICT, a method capable of inferring
novel indications for both approved drugs and novel compounds. Based on disease-
related features, drug-drug similarities (characterised by the structure and the associ-
ated side-effects) and disease-disease similarities (characterised based on their semantic
similarities calculated over the Human Phenotype Ontology) measures were computed
to construct classification features. A logistic regression classifier was then used to
predict novel drug indications. Inferred indications were then validated against known
indications. However, negative samples are needed in their model to implement the
prediction procedure. Experimentally verified negative drug-disease associations are
not available due to lack of research value.
Napolitano et al. [86] focussed on a drug-centric approach. Within this methodology,
the therapeutic class of FDA-approved compounds were predicted. Making use of data
integration drug-related features (drug structure similarity, target structure similarity,
drug-gene expression similarity) were merged into a single drug similarity matrix. In
turn, this similarity matrix was used as a kernel for Support Vector Machine (SVM)
classification. The algorithm was used to predict therapeutic categories of the Anatom-
ical Therapeutic Classification System (ATC), with misclassification, interpreted as a
potential repositioning opportunity.
Menden et al. [87] developed machine-learning models to predict the response of cancer
cell lines to drug treatment, quantified through IC50. In the model cancer genomic
features (oncogenes) and chemical properties (structural fingerprints) were used to
build a feed-forward perception neural network model and a random forest regression
model. Models were used to optimise the experimental design of drug-cell screening
by estimating a significant proportion of missing IC50 values rather than needing
to measure them experimentally. Predicted IC50 values were further validated by a
cross-validation and an independent blind test. It was proposed that this work could
be used as a computational framework for the identification of new drug repositioning
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opportunities as well as aiding personalised medicine, by linking the genomic traits of
patients to drug sensitivity.
Finally, Zhang et al. [88] proposed a computational framework for integrating multiple
aspects of drug similarity and disease similarity. Genome (e.g. drug target protein, dis-
ease gene), phenome (e.g. disease phenotype, drug side-effect) and chemical structure
(e.g. drug chemical structure) data were integrated to create multiple drug similarity
networks, multiple disease similarity networks, and known drug-disease associations.
Using all this information, the authors turned the drug-disease network analysis into
an optimisation problem. In addition, the authors showed how three of the top ten
drug-disease inferences involving Alzheimer’s disease were supported by clinical trials.
Machine learning approaches to drug repositioning come with their caveats. Essentially
the statistical model used in machine learning is a black box, hiding the rational pieces
of evidence of why a compound, or indeed a disease, may have been chosen, meaning
interpreting the repositioning hypothesis is a difficult task.
2.2.2.8 Network theory-based inference methods
Iorio et al. [89] developed a network theory-based approach that exploits similarity
in gene expression profiles following drug treatment. This technique was also imple-
mented in and released as a tool; MANTRA. Using multiple cell lines and dosages,
similarities in drug effect and mode of action (MoA) were first predicted. A ‘drug
network’ was then constructed; made up of 1,302 drugs (nodes) and 41,047 drug sim-
ilarity scores (edges). Network theory, in particular a clustering algorithm, was then
used to partition the network into groups, or communities, of densely connected nodes.
Communities were significantly enriched for compounds with similar MoAs. Using this
approach, the MoA for nine anti-cancer compounds were correctly identified. It was
also proposed that the potent Rho-kinase inhibitor and vasodilator, Fasudil (approved
in Japan and China but not in Europe or the US), may be repositioned as an enhancer
of cellular autophagy.
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2.2.2.9 Text mining
It is unrealistic to expect manual curations to keep up with the amount of data reported
in the literature. As such automated approaches for the extraction of data, be it
biomedical terms or their inter-relations, are greatly beneficial [90]. This automated
analysis of the literature essentially allows for the access of information that would
otherwise be ‘locked’ in a plethora of free-text documents. Central to these automated
approaches are the ontologies that are used as controlled vocabularies to provide a
framework for mapping relations between concepts [90]. Although the accuracy of such
data is not as high as for manually curated sources, the systematic approach to the
methodologies means that they are more inclusive of true positives. It is hypothesised
that finding relevant knowledge through text mining may allow for the identification
of novel indications for existing drugs [91].
The potential for literature mining to be used in drug discovery was initially identified
in the 1980s. Swanson [92] used multiple lines of evidence to propose the use of fish
oil to treat Raynaud’s syndrome, a hypothesis that was later validated in a clinical
trial [22]. The model used was referred to as the ABC model. For example, a study
finds that disease A was caused by a loss of function mutation of gene B. Furthermore,
another study, from another scientific discipline, reports that drug C is an agonist of
gene B. Using the ABC model, an implicit link between A and C may be made— drug
C may be repositioned to treat disease A.
In this tool gene names as well as other biomedical concepts are extracted from Medline
abstracts. Furthermore, these concepts are related to each other using co-occurrence.
A mutual information-based metric was used to assess the strength of co-citations.
Finally, a series of case studies with novel open and closed model discoveries were
presented. These included disease-gene, drug-disease, drug-biological process and bio-
logical process-drug relationships. The latter scenario resulted in the novel association
between two drugs and cell proliferation: dephostatin, a tyrosine phosphatase inhibitor;
and damnacanthal, a tyrosine kinase inhibitor. In vitro cell proliferation experiments
validated the influence of these two compounds in the process of cell proliferation at
low micromolar concentrations. In vitro cell proliferation experiments validated the
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influence of these two compounds in the process of cell proliferation at low micro molar
concentrations.
Although text mining approaches are highly sensitive, their specificity is questionable.
Any hypotheses formed using text mining approaches will need to be followed by
manual curation [90]. Furthermore, methods making use of the ABC model will have
to be wary of inferring potential side-effects.
2.2.2.10 Summary of computational approaches described
Each of the aforementioned computational repositioning approaches described has
their methodological advantages and limitations. A combination of these methods
is often desired for achieving better results [18]. As such, there is a belief that drug
discovery, and by proxy, drug repositioning, may be improved by taking a holistic in-
tegrative approach, considering the interaction of existing drugs with target proteins
as well as other biological molecules [93]. Holistic approaches are enabled by the ever-
increasing volumes of drug-related and -omics data, such as pharmacological, genetic,
chemical, or clinical data [18]. As such, bioinformatics finds itself with an increasingly
important role in the discovery of new drug indications [94]. By considering a wider
range of data, holistic approaches can produce more confident predictions in compar-
ison to methods that utilise a single, or even only a few different data types. In this
work the term ‘systems approach’ is used to describe an integrative approach that
enables a holistic view of a drug. Systems approaches provide a method of utilising
data increase and can accumulate evidence supporting the discovery of new uses for
existing drugs [18].
2.2.3 Systems opportunities
At this point a clear differentiation between ‘systems biology’ and the term ‘systems
approach’ must be made. Systems biology, a term first coined in the 1960s, was ini-
tially used to describe the mathematical models created by theoretical biologists to
model biological systems [95]. Nowadays, systems biology is a term used to describe
many areas of work, including: (i) network reconstruction through data integration
(often involving a single type of entity, such as a protein-protein interaction network)
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(ii) network analysis methods (iii) modelling (be it mechanistic or Bayesian) (iv) sim-
ulations (such as stochastic and deterministic simulations) [95]. In this thesis the term
‘systems approach’ will be used to describe the development of integrative, holistic
representations of drugs (with regard to pharmaceutical, genotypic and phenotypic
entities) as well as methodologies that consider all data captured in such represen-
tations. Unlike systems biology approaches, the systems approach defined does not
consider modelling or simulation.
An essential part of systems approaches is data integration. The importance of data
integration in the drug discovery setting has not gone unnoticed with numerous data
integration projects in place. Commercial efforts include DistilBio5, developed by
Metaome6, which provides an integrated view of over 30 life science focussed data
sources. DistilBio provides a graph-based data set using a custom ontology and al-
lows for queries to be created visually, directed by their ontology. Open source ef-
forts include Open PHACTS7. Providing an example of a large-scale data integration
project relevant to drug discovery, Open PHACTS is funded by the European Inno-
vative Medicines Initiative (IMI). Open PHACTS aims to provide an integrated view
of drugs and their targets and pulls together data from multiple pharmacological data
sources. Another chemical-based open integration effort is ChEMBL8, from the Euro-
pean Bioinformatics Institute (EBI). ChEMBL previously included mostly chemistry
data that was accessed systematically using tools from vendors only. Although Open
PHACTS and ChEMBL collate a large amount of information regarding a compound
and its pharmacology, they miss data that would be useful to the drug repositioning
setting and, as such, further integration of data is required to enable systems ap-
proaches to be taken in the drug repositioning setting. Relevant data are deposited in
many distributed, heterogeneous and voluminous data sources, and thus, integration
must be achieved to produce homogeneous technical, semantic and syntactic data.
Taking a state-of-the-art snapshot of drugs and their known interactions with other
biological entities can allow for more confident predictions of possible novel uses to be
5www.distillbio.com
6www.metaome.com
7www.openphacts.org
8www.ebi.ac.uk/chembl
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made. For this reason, the work presented in this thesis focusses on systems approaches
to drug repositioning. In order to take a systems approach, a clear data representation
must be defined. The chosen data format to be used during this work is the graph.
Network-theory, a subset of graph-theory, approaches have been introduced in this
Chapter. There are different definitions for graphs and networks, with each providing
subtle differences between the two structures. For example, a graph is said to be the
mathematical definition of nodes and edges whilst a network is said to have discrete
labels. As a graph can also, and in the case of this work does have, discrete labels, the
terms graph and network will be used interchangeably.
2.2.4 The benefits of graph-based data representation
Graph representations of complex systems are widely used in computer science, social
and technological network analysis science, and is especially relevant to many studies
in bioinformatics [96]. In semantic graphs both edges (or relations) and vertices (or
nodes) are typed : each vertex and/or edge in the graph is assigned a type from a
predefined set, vertices and edges are also attributed : vertices and edges are annotated
with attributes. The properties of graphs make them ideal for use in data integration
applications as they enable data from multiple sources to be stored and interconnected.
For example, for each computational approach described in Section 2.2.2, an abstract
graph-based summary of the underlying logic was provided. In every image, there is
at least one node of type drug, with edges of different types connecting these drug
nodes to other nodes of alternative data types. It is, therefore, easy to imagine how
all the types of data presented in these images may be collated, or integrated, into one
graph-based representation. At the centre of this graph would be a node of type drug,
with edges connecting this drug to nodes representing all the other data types present
in the images. With a single data set containing all of these data a single query can
cover multiple data sources.
To extract any useful information that may be captured by a graph-based integrated
data set, querying, or data mining, techniques must be applied. Such techniques fall
under the umbrella of graph theory, where graph pattern matching, including subgraph
isomorphism, allows for the direct extraction of subgraphs that may be representative
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of a particular function or process. Since the data in this project is presented as
graphs, one of the main computational challenges of the work was the development
of novel graph mining techniques. Furthermore, novel graph-based mining approaches
that make maximum use of semantically marked up graphs were required to most
efficiently mine integrated data.
2.3 Conclusion
In this Chapter the concept of drug repositioning was introduced with the benefits
and opportunities in relation to typical R&D approaches to drug discovery discussed.
Marketed examples of drug repositioning have been described and the need for sys-
tematic methodologies to enable this field of research highlighted. Current systematic
computational approaches have been categorised and described, and examples pro-
vided. Furthermore, the advantages and limitations of each computational approach
have been detailed. Although many approaches have been described it can be seen
that many of these are limited to the inference of a particular type of association.
Although machine learning methods tend to take a more integrative approach to data
than other approaches, the fact that they make use of a ‘black box’ leaves questions
regarding the accuracy, or at least provenance, of assumptions made.
Integrative approaches, such as system approaches, enable a holistic view of pharam-
ceutical and biological entities and have the potential to provide more confident infer-
ences, whereby the evidence used in the prediction can be decomposed and critically
analysed. System opportunities have been characterised in this Chapter and identified
as a methodology with the potential to enable a holistic approach to drug reposition-
ing. A systems approach can enable the integration of all data types considered in
the approaches described in this Chapter, allowing for more confident inferences to be
made.
For a systems approach to drug repositioning to be taken, a holistic view of a drug
and its interactions is required and is achieved using data integration techniques. Data
mining techniques, based on graph theory, can then be used to make novel inferences
from an integrated data set captured in a graph-based representation. These novel
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inferences are often a result of emergent properties of an integrated network. As
such, data integration for drug repositioning is discussed in Chapter 3, before an
algorithm for the inference of novel associations from the resulting integrated data
sets is introduced in Chapter 4.
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3.1 Introduction
High-throughput sequencing technologies have revolutionised life sciences and lead to
a dramatic expansion of data-rich resources for bioinformatics [97]. The shift to large-
scale sequencing of individual genomes and the availability of new techniques such as
positional cloning and microarray analysis allows probing of thousands of genes that
can return tens to hundreds of candidate Gene-Disease (G-D) associations [98]. As a
result of this data explosion, there are now more than 1,500 publicly available data
sources in the life sciences [99]. Research in the life sciences has a general goal to iden-
tify the components that make up a living system and to understand the interactions
among them that result in the (dys)functioning of the system [100]. The collection
of biological data is, therefore, a method to catalogue the elements of life, but un-
derstanding a system requires the integration of these data to describe the relations
between their components [100]. Systems-based approaches enable a holistic view of
an organism to be realised and is achieved through the task of data integration.
In this Chapter, data integration is introduced along with challenges facing its usage,
focusing on its application to the field of drug repositioning. Methods and platforms
used for data integration, such as Ondex and Neo4j, are described as well as relevant
data formats such as Resource Description Framework (RDF) and ontologies. An
integrated data set previously developed in Ondex for in silico approaches to drug
discovery [101] is first detailed and is then extended as part of this work to include
data types relevant to drug repositioning. A comparison between Ondex and Neo4j,
regarding performance, is presented— highlighting Neo4j as a more scalable platform
for data set development. As Neo4j has no innate means of controlling semantics,
Bioinformatics Semantic Integration Platform (BioSSIP) is introduced. BioSSIP is a
light-weight module that sits in front of a datastore ‘backend’, such as Neo4j, and
allows for integration projects to be created independently of the users datastore of
choice. A Drug Repositioning Network Integration Framework (DReNInF) is then
outlined. This framework makes use of BioSSIP and is made up of: Drug Repositioning
Network Integration Ontology (DReNInO), a high-level drug repositioning ontology; a
suite of more than 20 parsers for drug repositioning relevant data sources; and a data
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integration strategy. Finally, an RDF exposed data set, Drug Repositioning Network
Integration (DReNIn), is characterised. DReNIn is accessible via a dedicated Web
site at www.drenin.ncl.ac.uk and can be queried using a SPARQL Protocol and RDF
Query Language (SPARQL) endpoint.
3.2 Background
3.2.1 Data integration
The term ‘data integration’ refers to the situation where, for a given system, multiple
sources and types of data are available, and it is beneficial to study them integratively
to improve knowledge discovery [100]. Data integration describes the process used
to produce a homogeneous syntactic and semantic representation of multiple, often
heterogeneous, data sources, that ideally provides a single, unified query interface.
Data integration was born out of necessity and aims to provide a redundancy-free rep-
resentation of information from a collection of data sources with overlapping content.
Used to bring together data from multiple data sources, data integration enables a
non-redundant, normalised, holistic view of a system. 1,062 papers mentioned ‘data
integration’ in their abstract or title in 2006. By 2013, this number had more than dou-
bled to 2,365 [100]. Despite the widespread application of data integration to multiple
fields including the life sciences, data integration also poses multiple challenges [100].
3.2.2 Challenges involved in data integration
Data integration in the life sciences is particularly burdensome for a number of reasons.
As data sets continue to grow the term ‘Big Data’ becomes ever more widespread, de-
scribing data sets infeasible for processing on a single machine. Furthermore, these
data are spread across a plethora of databases accessible via a multitude of conven-
tions and available in varying data formats. As a result, multiple challenges must be
considered prior to a data integration project. A non-exhaustive overview of these
difficulties is provided here.
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Identification of quality data sources The first question to ask is ‘what data
sources are to be included?’. Data is produced by a multitude of research communities
and subfields, with varying levels of expertise and aims. It is, therefore, important to
understand the quality of the source that is to be used. Does the data source contain
primary data (stored in operational or working databases) or derived / secondary data
(refined and presented at a higher level) [102]? One must also be aware of the fact
that data sets are constantly updated and may vary dramatically from one release to
the next, whether that be in data format or data content.
Data heterogeneity, syntax and semantics At higher levels of integration the
heterogeneity of data increasingly becomes the major issue, if only because the more
disparate the data types the more likely there are to be mismatches [102]. Mixing data
types from disparate sources almost inevitably creates issues related not just to the
format, or syntax of the data, but also its semantics, or underlying meaning.
Inference of equivalence Combining data sources requires recognising data ‘types’,
such as genes or diseases and identifying equivalence, or mappings, between entries of
the same type stored in two different data sources. This task can be straight forward
if there are unique simple keys and a standardised accession for the data (e.g. HGNC
for genes), but this is not often the case for more complex entities (e.g. diseases)
[102]. For example, achondroplasia, the most common form of chondrodysplasia, in
Orphanet Rare Disease Ontology (ORDO) has the label Orphanet 15, whereas, in the
Medical Subject Headings (MeSH) hierarchy, it has the label D000130. Both of these
entries refer to the same disease in different vocabularies and so it can be stated that
Orphanet 15 ≡ D000130. During an exercise of graph-based data integration, this
disease would be captured as a single node containing both labels Orphanet 15 and
D000130, respectively.
The size of a data set It is important to understand, prior to any integration
project, any limitations that may affect the size of the data set. If data is to be stored
on a local machine, for example, one must be aware of the amount of memory available.
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The ability of a system to handle a growing amount of work, known as scalability, as
well as data set size, should be well managed.
Metadata management To manage variations in sources, an integrated data source
needs to provide meta-data (data that describes the data) including data provenance
(describing where the data has come from and when). Provenance becomes even more
necessary when one wishes to integrate multiple versions of the same data set and
compare updates. The amount of metadata provided can vary between different data
sources.
Representation and access Different types of data representation may be required
depending on the origin of the data, the method of access and the manner in which
the data is to be queried or visualised [102]. There is no single method of access
to biological databases with access points including Representational State Transfer
(REST) services, SQL databases, flat files via File Transfer Protocol (FTP), screen
scraping as well as many others.
What questions are to be asked? Before starting an exercise in data integration,
it is important to understand the use of and questions to be asked of, the resulting
integrated data set. These questions will provide direction to the task and can help
when considering all of the challenges described above. For example, if the research
question was ‘identify all proteins that interact with proteinX that is encoded by
geneY’ data describing tissue types would be redundant.
Once challenges facing a data integration project have been identified and considered
it is important to select a data integration platform that will allow for all objectives
to be achieved.
3.2.3 Data integration methods and platforms
Many integration approaches and platforms have been designed to solve different types
of integration problems. For example, federated approaches to data integration involve
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leaving data on several, distributed servers. An integrated view is then produced
by drawing these data sources together within a client application, usually located
on a different machine. Alternatively, data warehousing relies on centralised data
management and retrieval. In this case, the task of data integration results in a
homogeneous data set which may be stored using a number of different database
models with a common schema. Both approaches require either consistency in IDs
so that data items can be matched across data sets or IDs that map onto a common
ontology.
3.2.3.1 Database models
There are three main database models used for data storage and mining tasks in
computing: in-memory, relational (SQL) and key-value (or NoSQL) stores. There
are, however, situations whereby some crossover may exist, for example, in-memory
SQL databases. In-memory formats, such as those employed by Cytoscape [103],
Gephi [104] and Ondex [105] are fast when used to their strengths. However, they are
designed to enable the complex analyses of ‘small’ data sets i.e. small enough to fit in
the memory of a single machine. Thus, in-memory approaches are limited by memory
availability. Due to their ability to handle structured and semi-structured data, graphs
are often the data representation of choice for integrated data sets in bioinformatics.
Often, graphs are made up of too many nodes and edges to represent in RAM and are
consequently stored in databases [106].
Traditionally, relational databases such as MySQL1and PostgreSQL2 have been used
for this purpose. Developed in the late 1960s, relational databases have decades of
research toward their query optimisation [106]. Relational databases maintain tables
which are defined by sets of rows and columns. A row can be perceived as an ob-
ject whose columns are attributes/ properties of that object [107]. The strengths and
limitations of relational databases are well known, and a wide talent pool of trained
professionals exists. However, an innate inability to explicitly capture required seman-
tics limits the application of the relational database. Schema-based data models put in
1www.mysql.com
2www.postgresql.org
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place limits as to how data will be stored, with a manual process of redesign required
to adapt to new data. Relational databases are a better option when complex queries
and set operations are needed [106] and are optimised for aggregated data, whereas
graph databases are optimised for highly connected data.
The term ‘NoSQL’ refers to schema-less databases such as: key/value stores (e.g.
Apache Cassandra3); document stores (e.g. MongoDB4); and graph databases (e.g.
Neo4j5 and Virtuoso6). These databases, which do not fit within the traditional re-
lational paradigm, are gaining popularity due to their scalability and flexibility in
comparison to the relational approach [106]. Graph databases store edges as directed
pointers between nodes which, in turn, depending on implementation, can be traversed
in constant time. When information about data interconnectivity or topology is im-
portant, graph databases become increasingly relevant and are optimised for graph
traversals (degrees of separation or shortest path algorithms) [106].
Like graph databases, triplestores, which handle a specific data format, RDF, are
designed to store linked data. Data points are called nodes, and the relationship
between one data point, and another is an edge. Triplestores are a kind of specialised
graph database with some subtle differences. Unlike graph databases, which are node,
or property-centric, triplestores store lists of graph edges, many of which are just
node ‘properties’ and not critical to the underlying graph structure. Graph databases
are capable of storing a variety of different graph types, including undirected graphs,
whereas triplestores specifically handle edge labelled directed graphs. Most graph
databases do not possess a declarative query language (Neo4j is an exception, with
its query language, Cypher, designed for expressing graph queries, being currently
under development), whereas triplestores can be semantically queried using SPARQL
and also allow for inferences to be made between nodes. The cost of traversing an
edge, using SPARQL, tends to be logarithmic. To use a triplestore directly, one must
understand the RDF data format.
3www.cassandra.apache.org
4www.mongodb.com
5www.neo4j.com
6www.virtuoso.openlinksw.com
- 46 -
Chapter 3: Data integration for drug repositioning
3.2.3.2 Data formats
There is no single standardised data format for the storage or exchange of data within
the life sciences and a plethora of different data representations are used. RDF, how-
ever, is becoming increasingly popular as a common data format for describing, pub-
lishing and linking data. For example, several databases and knowledge bases such
as UniProt, ChEMBL [108] and Reactome [109] now provide their data in RDF for-
mat [110].
RDF A W3C7 backed data format, RDF, exists as a set of triples, which are state-
ments about entities in a model. Triples take the form of subject-predicate-object.
RDF identifies entities using Web identifiers known as Uniform Resource Identifiers
(URIs), and describes resources with properties (a resource that has a name, such
as “UniProtID”) and property values (the value of the property, such as “Q96HD9”).
RDF has a graph-based structure that provides a schema-less model. In these di-
rected graphs, nodes represent resources and property values, while the edges represent
properties. An RDF document can be serialised for storage and exchange, in several
machine-readable formats, such as XML, Turtle and N3.
Fig.3.1A shows how RDF describing the UniProtKB entry ‘Q96HD9’ is repre-
sented in XML. The first line of the RDF document is the XML declaration, fol-
lowed by the root element <rdf:RDF>. The <xmlns:rdf>, <xmlns:uniprot> and
<xmlns:drenin> namepsaces specify that elements with the rdf, uniprot and drenin
prefixes are from the namespaces http://www.w3.org/1999/02/22-rdf-syntax-ns#,
http://identifiers.org/uniprot# and http://ncl.ac.uk/drenin# respectively.
The <drenin:Protein> element contains the description of the resource identified
by the rdf:about attribute. The elements <drenin:AASeq>, <drenin:UniProtID>,
<drenin:UniProtUID>, <drenin:label> and <drenin:STRING> are properties of the
resource.
As previously mentioned, an RDF document can be serialised in several syntaxes.
Many triplestores are available to allow for the efficient storage of RDF using these
7www.w3.org
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Figure 3.1: RDF example. (A) An example XML serialised RDF document for a
single protein, Q96HD9 (B) Triples from A in the form subject-predicate-object (C)
Graph representation of RDF in A. Edges show predicates from the protein object to
every property value (attribute). Note: Images were produced using the W3C RDF
validation service8.
serialised formats. Services are provided for the efficient querying of triplestores, known
as endpoints. These endpoints provide a means of querying the RDF using standard
query languages, such as SPARQL.
A SPARQL query is a graph pattern used to find matching RDF triples. In these
queries the subject, predicate, or object of a triple can be substituted for query vari-
ables. Although RDF documents can be effectively queried based on their graph
structures, RDF annotation of resources is not expressive enough to facilitate complex
queries. Raw RDF annotations are meaningless to a machine. To provide machine-
understandable annotations, ontology languages and data formats have been devel-
oped.
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Ontologies A specification of conceptualization, ontologies provide an abstract or
simplified view of a domain of interest [111]. Furthermore, ontologies provide a de-
scription of concepts and relationships that can exist for elements within a particular
domain [111]. Ontologies enable the organisation of information in a machine inter-
pretable fashion; ontologies are not simply dictionaries prepared for humans. Common
components of an ontology include classes (or concepts), individuals, attributes and
object properties. Classes represent types of objects within a domain, such as Disease
where individuals represent instances of classes, for example, Crohn’s Disease as a
Disease individual. Attributes describe features of a class or instances. For example,
Disease instances, such as Crohn’s Disease may have an attribute definition containing
a string such as An intestinal disease that involves inflammation located in intestine.
Object properties, represent relations and describe the way in which classes and in-
dividuals can be related to one another. Terms (i.e. classes and instances) within
an ontology are structured hierarchically with higher level terms have more general
meanings than their lower level counterparts (see Fig.3.2).
Formal languages used to encode ontologies (and describe RDF data) include both
the RDF Schema (RDFS) and Web Ontology Language (OWL). The RDFS language
defines a vocabulary to describe objects in an RDF data model, extending RDF in
order to define special RDF resources, such as Class and subClassOf. These special
resources are used to describe a hierarchy of other RDF resources. It is, however,
OWL that is recommended by the W3C Consortium for expressing ontologies. This
recommendation is made due to OWL being more expressive and having a far greater
vocabulary than RDFS.
3.2.3.3 Ondex
Ondex is an in-memory graph tool that combines semantic data integration with
graph-based analysis techniques [105]. Designed to both model and integrate (biolog-
ical) data as networks, Ondex also provides tools to visualise and analyse resulting
integrated data sets [105]. More recently, a Web-based implementation of Ondex,
Ondex-Web, has been released [112]. In Ondex networks, nodes, termed concepts
represent the biological entities, such as ‘genes’ or ‘diseases’, while edges, termed rela-
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Figure 3.2: Ontology example. An example of a hierarchical ontology of terms. The
diagram shows the Crohn’s disease term and its parents from the Disease Ontology9.
Classes are shown in green while instances are shown in red.
tions represent the interactions between these entities, such as geneX ‘is involved in’
diseaseY.
All elements within an Ondex graph (both concepts and relations) are annotated with
semantically rich metadata. Each concept is assigned a c ∈ C, where C is a finite set
of concept_classes. Similarly, each relation is assigned an r ∈ R where R is a finite
set of relation_types. The types that nodes are mapped to are captured in a strict
fashion, with an XML metadata file describing a hierarchical representation of the
biological ‘types’ that may be included in an Ondex network. This metadata is not an
ontology, rather a hierarchical description of terms, and is limited to a handful of types.
Although metadata may be extended depending on a particular set of requirements,
there is no strict framework for doing so.
Data from external sources are transformed into the Ondex graph-based data model
using custom parsers. Data is stored in a custom XML format designed for the ex-
change of Ondex integrated data sets, Ondex Exchange Language (OXL). There is
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also a framework to enable the development of plugins, allowing for the development
of Ondex specific:
1. Mappers allow biological concepts to be linked.
2. Filters enable the removal of unwanted/ redundant elements from the graph.
3. Transformers enable graphs to be either topologically or semantically altered.
4. Exporters allow for Ondex graphs to be exported in custom formats, such as
comma-separated files, tab-delimited files and the Systems Biology Markup Lan-
guage.
In Ondex, data integration strategies are explicitly described in custom workflows.
These workflows, in turn, make calls to parsers, mappers, transformers, filters and
exporters to allow for the production and manipulation of integrated data sets.
Work carried out at Newcastle University led to the creation of an Ondex data set
for in silico drug discovery [101]. The data set includes Compound and Target con-
cept_classes from DrugBank10 [113] and Protein concept_classes integrated from
UniProtKB11 [114], as well as information from eleven other databases and analysis
methods [101]. The data set contains 150,853 concepts from 17 concept_classes
which are linked via 787,360 relations from 37 relation_types. The data set was
successfully used to highlight known examples of repositioned drugs, including chlor-
promazine. Chlorpromazine is marketed as a non-sedating tranquillizer but is also
known to be effective as an antihistamine. Although there was no relation indicative
of a binding between Chlorpromazine and the H1 Histamine receptor in the graph,
Chlorpromazine was shown to be similar to Trimeprazine, for which there was a bind-
ing to the receptor [101].
Although this data set provides a comprehensive representation of drugs at a systems
level, it has not been updated since its production in 2010. The data set was also
missing important data types required for it to be used in the identification of novel
drug repositioning opportunities. Fig. 2.1 highlights the minimal types of data used in
10www.drugbank.ca
11www.uniprot.org
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drug repositioning prediction tasks and the possible interactions that can be inferred.
Using this model, three data types were highlighted as being missing from the original
data set:
1. Disease concepts. The Disease concept_class in the data set was taken from
the Online Mendelian Inheritance in Man (OMIM) (see 3.2.4.2), an online cata-
logue of human genes and genetic disorders.
2. Target (Gene)-Disease relations. The involved_in associations, which link a
Disease and Gene, were extracted from OMIM. Although OMIM is a reliable
source of such data, if the Disease concept_class was to be updated it was
also necessary to identify a data source capturing associations between genes and
the up-to-date disease representation.
3. Drug-Disease relations. In order for novel uses of a drug to be identified it
is important to capture data detailing the diseases it is currently marketed to
treat. In Ondex terms that would require a has_indication association between
a Compound and a Disease.
As well as the above data types, the data set included data taken from the Kyoto
Encyclopedia of Genes and Genomes (KEGG). KEGG is now a subscription-based
system and no longer an open source database. Furthermore, the data set takes all
targets from DrugBank, regardless of the species, yet only includes proteins from
UniProtKB that are from Homo sapiens.
3.2.3.4 Neo4j
Neo4j is an open source NoSQL graph database implemented in Java and is a popular
graph Database Management System (DBMS). Unlike Ondex, Neo4j uses a disk-
backed storage system, enabling it to store complex and dynamic data (including
images, videos, etc.). Like all graph databases, Neo4j stores edges as direct pointers
between nodes, which, depending on connectivity, can thus be traversed in constant
time. Neo4j makes use of a property graph model meaning that nodes and edges
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can have properties associated with them. Neo4j provides a varied set of integration
possibilities for Java Virtual Machine (JVM)-based languages.
There are two ways of using Neo4j from the JVM. First of all the standalone Neo4j
Server can be installed on any machine and then accessed via its HTTP API, using
a REST library of choice. Alternatively, Neo4j can be embedded in a JVM process.
The second approach is best suited for unit testing, as well as high performance and
no-network set-ups.
3.2.4 Relevant data sources
As described in Section 3.2.2, one of the most important aspects to be considered
before an exercise in data integration is the identification of relevant and reliable
data sources. Many relevant data sets exist that could potentially be used to enable a
systems approach to drug repositioning. These data sources can be categorised as being
either protein-related, disease-related, drug-related, pathway-related or additional and
examples of each are detailed below.
3.2.4.1 Protein-related data sources
UniProtKB UniProtKB12 [115] is one of the most comprehensive, high quality and
freely available resources for proteins and functional information. UniProtKB assigns
IDs for each of the Protein entries in the database. Each UniProtKB ID consists
of 6 or 10 alphanumerical characters (e.g. O95264). As well as primary accessions,
a protein entry also contains multiple secondary accessions and maps to many other
databases, such as STRING. UniProtKB also details the gene, using the common
HGNC ID (e.g. 5298) that a given protein is encoded by. The data set is available
for download in multiple formats, including XML.
STRING The STRING13 database is an integrated database that includes known
and putative protein-protein interactions, such as binding, gene fusion, co-occurrence
12www.uniprot.org
13www.string-db.org
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and co-expression [116]. Data in STRING are integrated from high-throughput exper-
imental data sets and databases such as KEGG, HPRD14, Reactome and many others.
Available for download in multiple formats, STRING provides confidence scores for
each interaction it provides, which is based on the source(s) from which the association
is derived.
GO The Gene Ontology (GO)15 was developed as a means of standardising the
annotation of proteins [117]. The GO Project was founded in 1998 to address the
challenges of interpreting functional information attached to gene product entries in
databases. The GO includes three ontologies that describe: the molecular function
that a gene product normally carries out; the biological process that gene products are
involved in; and the subcellular locations (or cellular component) that gene products
are located in [118]. To make full use of the ontology, it is important to have a means
of linking these to the relevant gene products, such as proteins.
Gene Ontology Annotation Database (GOA) The Gene Ontology Annota-
tion (GOA)16 provides algorithmic and manual annotations of GO terms to UniProtKB
protein entries [119]. Annotations are provided from the GOA project (based at the
European Bioinformatics Institute (EBI)) and are collated with those from many ex-
ternal databases to provide an extensive publicly available GO annotation resource.
From the GOA, GO terms can be linked to a protein.
3.2.4.2 Disease-related data sources
MeSH R© MeSH [120]17 is a controlled vocabulary thesaurus developed by the U.S.
National Library of Medicine (NLM). MeSH consists of sets of naming descriptors in
a hierarchical structure, thus permitting searching at various levels of specificity. The
vocabulary is made up of ‘descriptor’ records that contain a heading and multiple entry
terms. For example, the descriptor ‘Ascorbic Acid’ has the entry term ‘Vitamin C’. In
addition to these headings are the Supplementary Concept Records (SCR), supplied
14www.hprd.org
15www.geneontology.org
16www.ebi.ac.uk/GOA
17www.nlm.nih.gov/mesh
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in a separate file. These SCRs contain specific examples of headings and are updated
more regularly than the ‘descriptors’. Each SCR is assigned to a related descriptor
via the heading. To identify which of the MeSH concepts describe common diseases
and which are rare diseases, it is important to determine a good representation of
rare disease and to identify the crossover of these with diseases captured in the MeSH
hierarchy.
ORDO The ORDO18, a joint venture between EBI and Orphanet. This data set
provides a structured vocabulary for rare diseases and also captures relationships be-
tween these diseases, genes and other relevant features. ORDO is derived from the
Orphanet database.
Having identified representations of common diseases and rare diseases, it is important
to find sources linking these to genes involved in these diseases. Many different data
sources that include these associations, derived from differing approaches, such as
those:
1. Manually curated from the literature.
2. Automatically extracted from the literature via text mining methods.
3. Taken directly from genetic studies.
4. Inferred from mammalian models.
Many sources must be considered to create an integrated view of G-D associations
that span all four of the above approaches.
OMIM R© and Orphanet OMIM R©19 and Orphanet are examples of data sources
that contain manually curated G-D associations. OMIM is one of the original sources
of G-D associations and provides a catalogue of human genes, genetic disorders and
traits. OMIM particularly focusses on the molecular relationship between genetic
variation and phenotypic expression [121]. Updates to the OMIM data set are done
18www.orphadata.org
19www.omim.org
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manually by biocurators. The Orphanet database, on the other hand, is a multilingual
database dedicated to rare diseases. Populated from the available literature Orphanet
is validated by international experts. Orphanet includes a classification of rare diseases,
G-D relations and connections/ mappings with other terminologies and also includes
a proportion of associations taken from OMIM.
GWAS Catalogue The National Human Genome Research Institute (NHGRI)
Catalogue of Genome-Wide Association Studies (GWAS)20 contains G-D associations
taken directly from genetic studies. The catalogue provides a publicly available set
of manually curated, published GWAS assays [122]. All Single-Nucleotide Polymor-
phism (SNP) data and SNP-trait associations with a p ≤ 1× 10−5 are provided [123].
BeFree and SemRep BeFree21 [124] and SemRep22 [125] extract G-D associations
from the literature using automated text mining approaches. This automated analysis
of the literature essentially allows for the access of information that would otherwise be
‘locked’ in a plethora of free-text documents. BeFree, along with supporting statements
and provenance, is available for download and uses the EU-ADT and GAD corpora to
extract associations from the text. It is worth noting that any associations documented
in the full text or supplementary of articles will be missed by BeFree. SemRep differs
from BeFree, as it has been designed to identify a broad range of semantic predictions
that take into account the hierarchical relationships between concepts. SemRep allows
for relations between the same entity types as BeFree to be extracted from the literature
(G-D, drug-disease and drug-target). When using the same corpus as BeFree, SemRep
has a higher precision but a lower recall [124].
MGD and RGD The Mouse Genome Database (MGD)23 [126] and the Rat Genome
Database (RGD)24 contain G-D associations that have been identified in animal models
but are statistically inferred to represent human associations.
20www.ebi.ac.uk/gwas
21www.ibi.imim.es/befree
22www.semrep.nlm.nih.gov
23www.informatics.jax.org
24www.rgd.mcw.edu
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ClinicalTrials.gov ClinicalTrials.gov25 is a database of publicly and privately sup-
ported studies of human participants from all around the world. Law (section 801 of
the Food and Drug Administration (FDA) Administration Amendments Act in the
U.S26 and the Clinical Trials Directive 2001/20/EC, Article 1127 in the EU) requires
certain clinical trials to submit their trials and results to a publicly accessible database.
ClinicalTrials.gov, therefore, provides access to these trials, meaning the novel uses of
drugs that are currently being investigated can be determined. From this data source
the clinical trials, and the associated drugs and diseases are captured.
3.2.4.3 Drug-related data sources
DrugBank DrugBank28 is an online database containing biochemical and pharma-
cological information about drugs, their mechanisms and their targets [127]. The
database is maintained and enhanced by extensive literature mining performed by
domain-specific experts and biocurators. Most of the data in DrugBank are curated
from primary literature sources, and it is thus used as the primary drug data source
for many databases (e.g. PharmGKB, PDB, PubChem, KEGG). DrugBank classes
drugs as either small molecules or bio tech drugs, while also containing many binds
to associations between drugs and target proteins. Although DrugBank offers a rich
data set, it does not capture any activity values that may be associated to the binds
to associations.
ChEMBL ChEMBL29 is a large-scale bioactivity database containing data mainly
manually curated from the medicinal chemistry literature [128]. ChEMBL contains
data regarding compounds, targets, and the biological or physicochemical assays from
which the data was extracted. Unlike DrugBank, ChEMBL captures activity values
that may be associated to the compound-target binds to associations.
25www.clinicaltrials.gov
26www.gpo.gov
27www.eortc.be
28www.drugbank.ca
29www.ebi.ac.uk/chembl
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SIDER Side-Effect Resource (SIDER)30 is a resource containing drugs and their
adverse drug reactions (ADR)— containing both side-effects and known indications
[82] [129].
NDF-RT The National Drug File - Reference Terminology (NDF-RT)31 is produced
by the U.S. Department of Veterans Affairs, Veterans Health Administration (VHA).
NDF-RT is an extension of the VHA National Drug File, and organises the drug
list into a formal representation and is updated monthly. From here, known indica-
tions can be extracted via a RESTful API. The NDF-RT representation contains 18
semantic types (including ‘Clinical Drug’ and ‘Disease or Syndrome’), 20 attributes
and 44 relation types. For example, two of the relation types included in NDF-RT
are ‘may treat’ and ‘may prevent’, linking ‘Clinical Drug’ to ‘Disease or Syndrome’.
NDF-RT also provides a hierarchical representation of the ‘Disease or Syndrome’ terms
used in the data representation, linked via has_parent and has_child relations.
3.2.4.4 Pathway-related data sources
Open PHACTS One collaborative project that is dedicated to data integration
within the field of pharmacology is Open PHACTS [130]. A linked data platform
for integrating multiple pharmacology data sets, Open PHACTS forms the basis for
several drug discovery applications. Driven by real business questions gathered from
the projects partners, the project provides an Open Pharmacological Space (OPS). The
OPS integrates data from a total of 9 distributed open pharmacological and biomedical
databases and is accessible via a RESTful API.
The OPS platform builds on previous work delivered by the Semantic Web community
in creating Resource Description Framework (RDF)-based data sources. In recent
years, several key data sets for drug discovery have been published in Semantic Web
formats including those provided by Chem2Bio2RDF and Linking Open Drug Data
(LODD). These two data sets, as well as the Bio2RDF, Neurocommons and Linked
Life Data, have all made important sets of biology and chemistry data available in
RDF [130].
30www.sideeffects.embl.de
31www.nlm.nih.gov
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The Open PHACTS API wraps a number of ‘canned’ SPARQL queries that applica-
tions can call. As a result, application developers do not need to formulate their own
SPARQL queries for many commonly-used operations [130].
ConceptWiki, included in Open PHACTS, offers a more thorough mapping of elements
to alternative accessions and is far beyond what could have been achieved during this
project. However, at the time of this work, there are relatively few mappings for genes
in this data source, while some that have been mapped appear to have been done so
incorrectly (see Fig. A.1).
3.2.4.5 Additional data sources
CTD The Comparative Toxicogenomics Database (CTD)32 is a publicly available
database whose initial aim was to annotate the response of genes and proteins from
diverse species to various toxic agents [131]. The scope of the database has some-
what expanded since its inauguration and at present captures data involving chemical-
disease, chemical-gene and G-D interactions, as well as pathway data. Interactions are
curated from the scientific literature by professional biocurators who are aided in the
task by controlled vocabularies, ontologies and structured notation [131].
3.3 Materials and methods
All Ondex development was done using the compiled source code from v0.5.033. For up-
dating the original data set a bespoke Ondex parser was developed for the integration
of disease concept types from NDF-RT. The parser made calls to the NDF-RT REST-
ful API34. First, all DISEASE KIND concepts were extracted using the ‘/allconcepts’
REST resource which returned the Alphanumeric Unique Identifier (NUI) identifier for
each DISEASE in NDF-RT. Next, for every disease NUI, the ‘/allInfo’ REST resource
was used to retrieve all information associated to that concept, including the parent
and child DISEASES (Table 3.1).
32www.ctdbase.org
33www.ondex.org
34www.rxnav.nlm.nih.gov Accessed: 22-09-2013
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Relations of type may_treat and may_prevent were integrated in a two-step process.
First, the relations were extracted from NDF-RT using calls to their RESTful API.
All DRUG KIND concepts were extracted using the ‘/allconcepts’ REST resource
which returned the NUI identifier for each drug. To ensure that all drugs searched for
could be mapped to the drugs captured in the data set, an external mapping between
NUI and DrugBank accessions was performed using the drugs mapping file available
from PharmGKB35. For every NDF-RT drug that mapped to a DrugBank compound,
a call to the ‘/allInfo’ REST resource was used to retrieve all concept information,
including the may_treat and may_prevent relations. A mapper was then developed
to integrate these relations using the relation_types may_treat and may_prevent,
using the Disease NUI and the DrugBank accessions (Table 3.1). DisGeNET G-D
associations that contained a UniProtKB ID corresponding to a known Target or
Protein in the Ondex network were then extracted. A bespoke Ondex mapper was
written to integrate the involved_in associations, using the UniProtKB IDs to map
to the outgoing Protein or Target nodes, while the incoming Indication nodes were
identified using the Unified Medical Language System (UMLS) ID present on diseases
in DisGeNET (Table 3.1).
Table 3.1: Data sources used to extend Dat .
Type Name Number Source From-To
concept_class Indication 4,463 NDF-RT36 -
relation_type has_parent 6,553 NDF-RT36 Indication-Indication
relation_type has_child 2,018 NDF-RT36 Indication-Indication
relation_type may_treat 3,744 NDF-RT36 Compound-Indication
relation_type may_prevent 343 NDF-RT36 Compound-Indication
relation_type involved_in 16,098 DisGeNET37 Target-Indication
For Ondex and Neo4j performance testing, the command line accessible ondex-mini
(snapshot 0.5.0) was used. For convenience (and to minimise the risk of exposing
potentially sensitive data), the embedded approach of Neo4j was used throughout the
work described in this Chapter. Neo4j Core-java-API38 v2.1.2 was used. For Ondex,
a single parser was developed that took graph type and graph size arguments and
35 www.pharmgkb.org Accessed: 22-09-2013
36www.rxnav.nlm.nih.gov Accessed: 22-09-2013
37www.disgenet.org Accessed: 22-09-2013
38www.neo4j.com
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ran from the command line. Similarly, for Neo4j a single parser was developed, with
transactions limited to 10,000 nodes. All performance tests were single-threaded and
ran on an 8GB RAM Mac (1.8 GHz Intel Core i5) with an allocated heap size of 6GB
with five repeats.
For DReNInF, the DReNInO was created in OWL using the open-source ontology
editor, Protege39 v4.3. Parsers and mappers were developed as sub-components of a
BioSSIP maven archetype. Written in Java, parsers and mappers enabled data sources
to be converted from their accessible format to BioSSIP nodes and edges. Finally, the
data integration strategy was also implemented in Java.
An RDF exporter for BioSSIP was implemented in Java. The RDF exporter made
use of the Apache Jena RDF API40 v2.11.2. To store and query the DReNIn RDF
data set, the triplestore Sesame41 v2.8.6 was used. An Apache Tomcat server42 v8.0.26
was used to allow remote access to the stored data and the user interface. Tomcat
was installed on a Ubuntu v15.04 virtual machine and the openrdf-sesame.war and
openrdf-workbench.war copied to the webapps sub-folder of the Tomcat installation.
A Web-based user interface was developed for the RDF data set. The interface was
implemented in JSP (java server pages) and is a Web site made up of five main pages.
The project makes use of Maven and the WAR (web application archive) architecture.
The compiled WAR file was added to the webapps/ROOT sub-folder of the Tomcat
installation.
3.4 Results
An update of the original Ondex data set described by Cockell et al. [101] was carried
out as part of this work. A comparison between Ondex and Neo4j, regarding per-
formance, is presented— highlighting Neo4j as a more scalable platform for data set
development. As Neo4j has no innate means of controlling semantics, BioSSIP was also
developed during this project. BioSSIP is a light-weight module that sits in front of
39www.protege.stanford.edu
40www.jena.apache.org
41www.rdf4j.org
42www.tomcat.apache.org
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a datastore ‘backend’, such as Neo4j, and allows for integration projects to be created
independently of the users datastore of choice. A framework for data integration in the
drug repositioning setting (DReNInF) is then outlined. This framework makes use of
BioSSIP and is made up of three components, comprising: (i) DReNInO, a high-level
drug repositioning ontology (ii) A suite of more than 20 parsers for drug repositioning
relevant data sources and (iii) A data integration strategy. Finally, an RDF exposed
data set, DReNIn, is characterised.
3.4.1 Updating the original Ondex data set
Figure 3.3: Metagraph of Dat , the Ondex drug discovery data set. Metagraph
of Dat , the updated data set for in silico drug discovery. Nodes represent the concept
classes and edges the relation types included. Note: due to space, the relation
types are not labelled above and are instead listed in Table A.3.
4,463 NDF-RT ‘Disease or Syndrome’ concepts were integrated into the initial data
set using the concept_class Indication so as to differentiate between the diseases
from NDF-RT and those from OMIM. Therefore, the updated data set, Dat , had
an additional 4,463 vertices (totalling 155,316) made up of one (and a total of 19)
concept_classes (see Table A.1) in comparison to the original. Furthermore, Dat
has an additional 28,736 edges (total of 816,096), representing an additional five (to-
tal of 42 relation_types) (see Table A.2). Fig 3.4 captures the neighbourhood of
chlorpromazine in Dat after the update. Dat shows a high degree of connectivity with
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a dS(G) (average node degree) of 10.42, whereby degrees of vertices range from δ(G)
(minimum degree) of 1 and ∆(G) (highest degree) of 15,004. Average Connectivity
differs between each concept_class, with Protein displaying the highest dS(G) of
any concept_class at ∼ 45. Other notable connectivity averages include Target
∼ 13, Compound ∼ 7 and Disease ∼ 4.
!
Figure 3.4: Chlorpromazine neighbourhood as captured in Dat . Nearest neigh-
bours of chlorpromazine from the updated data set, Dat . Already included are the
symmetrical similar_to associations between trimeprazine, prochlorperazine, per-
phenazine and promazine as well as three binds_to relations to Serum Albumin, D-2
Dopamine Receptor and 5HT2A Receptor (captured in the red box). Nine indications
are included after the update, linked to chlorpromazine via may_treat relations includ-
ing Nausea, Tetanus, ADHD, Hiccup, Anxiety Disorders, Schizophrenia and Psychotic
disorders. Also present is an involved_in association between the 5HT2A receptor
and Psychotic disorders and the has_parent relationship from Psychotic disorders to
Schizophrenia and Disorders with Psychotic Features. Note: yellow = Indication,
blue = Target and red = Compound.
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3.4.2 Ondex V Neo4j performance testing
Performance tests were completed on linear as well as more complex (with a higher
connectivity) graphs and are shown below in Fig 3.5. In linear graphs, every v ∈ G|V |
is connected by a relation to the previously created v. In the more complex graphs,
every v ∈ G|V | is connected to the previously created v ∈ G|V | and one other random
v ∈ G|V |.
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Figure 3.5: Ondex V Neo4j build performance. Comparison of Ondex and Neo4J
build statistics. (A), (B), (C) Data from linear graph builds (v ∈ G|V | is connected
by a relation to the previously created v). (D), (E), (F) Data from more complex
graph builds (v ∈ G|V | is connected to the previous v ∈ G|V | and one other random
v ∈ G|V |). (A) and (D) Time taken to complete a graph build. (B) and (E) How much
of the allocated RAM was used as an average during the build. (C) and (F) Show, as
a proportion of a GB what size the graphs were when stored to disk. Graph storage
was linear for both platforms, and so a single value is used. Note: All performance
tests were single-threaded, ran on a 8GB RAM Mac, with an allocated heap of 6GB.
At least 5 replicates per G|V | with Neo4j transactions limited to 10,000 nodes.
3.4.3 BioSSIP: a light-weight semantic handling module
BioSSIP is a light-weight module that sits in front of but is completely separate to,
a datastore ‘backend’ of choice. The module provides a framework for parsers, data
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integration strategies and mining strategies to be developed independently of the stor-
age system. Central to BioSSIP is a user provided application-specific ontology. This
ontology has two main purposes: (1) to manage the semantics of the data included
in BioSSIP integrated data sets and (2) as a means of expanding queries used to ex-
plore the resulting integrated data. BioSSIP can be used for both integration and
subsequent querying, even if the datastore of choice does not have an innate means of
implementing and defining these semantics. Parsers, exporters, integration strategies
and mining strategies can be developed in the BioSSIP module, packaged, and used
to run the same analysis pipeline using differing data storage solutions.
BioSSIP was a collaboration with my colleague Matthew Collison (MC) at Newcastle
University. Although the majority of the implementation was carried out by MC, this
project contributed ideas and discussions and contributed to the implementation of
metadata classes and exporters. BioSSIP is an open source project developed in Java
using Maven, and the overall architecture of the system is presented in Fig. 3.6.
For data integration using BioSSIP, a ParserInterface is defined, which defines
three basic methods; parseFile, setHandler and setFilePath. During a process
of integration, multiple parsers will be created, this collection of application-specific
parsers is referred to as a ‘suite’ of parsers. An ‘integration strategy’ defines the order
in which parsers are to be executed in the main class of a BioSSIP project. Parsers
are written to convert data of any format to BioSSIP java ‘beans’. In BioSSIP, a
MetaDataInterface is used to define these java beans, whose instances essentially
represent elements (nodes and edges) of the integrated graph, defined in the SSIPNode
and SSIPRelation classes. These BioSSIP Java beans are then converted to the
specific datastore format and stored via the data access layer. The BackendInterface
defines methods to be used when creating a data access layer. The interface includes
methods such as initialiseDatabaseConnection, addNode, returnAllNodes and
finaliseDatabaseConnection.
Once an integrated data set has been produced, ‘step descriptions’ are used as the
basic building block to define queries in BioSSIP. These step descriptions contain the
information to allow for a simple graph traversal during a query, such as a depth-first
traversal of has_neighbour relation types at a depth of one. Step descriptions make
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."
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."
Figure 3.6: BioSSIP architecture. BioSSIP architecture is captured inside the
central red box. ‘I/O’ refers to data from external data sources, such as UniProt,
DrugBank, ChEMBL, and many more. The ‘Datastore Backend’ is interchangeable,
however, currently, there is a single Neo4j implementation. BioSSIP provides a frame-
work for parser development and allows for the creation of an application-specific suite
of parsers. Data, nodes and relations, are represented as Java Beans, where types are
dictated by an ontological representation of semantics. A data access layer allows for
these Java beans to be converted to the specific datatore format. BioSSIP also provides
graph traversal rules, accessing data via the data access layer. These traversal rules
can be adjoined to allow for the design of more complex mining strategies, and can
also use the high-level ontology for tasks such as ‘query’ expansion. Finally, multiple
exporters are available which allow for part of, or indeed the entirety of the integrated
network to be analysed or stored in alternative data formats that can be visualised.
The orange box highlights the elements of BioSSIP concerned with data integration
and the blue box highlights the components of BioSSIP concerned with querying and
exporting.
use of the data access layer to convert the BioSSIP query into one that is recognised
by the datastore ‘backend’. Furthermore, these step descriptions may be used to
create more complex ‘mining strategies’ or algorithms, such as a subgraph isomorphism
algorithm. Finally, exporters have been implemented for integrated data sets to be
exported from BioSSIP to Gephi and RDF, with the former allowing for visualisation
of the integrated network or indeed the results of a query.
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3.4.4 DReNInF: a data integration framework
DReNInF enables the production of integrated data sets relevant to drug repositioning.
The project is open source and is made up of three main components:
1. DReNInO: A high-level drug repositioning ontology (3.4.4.1).
2. A suite of parsers to transform data sources relevant to the data types captured
in DReNInO into BioSSIP.
3. A data integration strategy (3.4.4.3).
The domain (or more specifically, application) specific ontology DReNInO captures
the semantics of both the nodes and the edges to be included in any data sets created
using the framework. A suite of parsers convert data from external sources to a format
recognisable by the integration platform BioSSIP. With over 20 parsers developed for
the inclusion of multiple data types a data integration strategy defines which parsers
will be called and when. Ultimately this framework allows for the production of drug
repositioning data sets with a strict semantics. Each of the three most important
components of DReNInF will now be introduced in more detail.
3.4.4.1 DReNInO: a high-level drug repositioning ontology
First of all, semantic data types that were to be included in DReNInF and the types
of interactions that would capture relevant associations between these were identified.
These terms were used to create a metagraph depicted in Fig. 3.7. The design of the
metagraph was an iterative process and took inspiration from the original Ondex data
set [101], the metadata captured in Ondex [105] and considered the research questions
that were to be asked of the data set. For the sake of consistency, the same notation
used by Ondex to discuss semantic types (3.2.3.3) is used here, as such the metagraph
can be said to contain 15 concept_classes and 18 relation_types.
Data in the metagraph was then formalised in the high-level DReNInO. DReNInO
is made of 25 classes (defining concept_classes) and 18 object classes (defining re-
lation_types), as shown in Fig 3.8. The requirements for the ontology were not
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Figure 3.7: DReNInF metagraph. Metagraph includes the 15 Concept classes and
18 relation types included in DReNInF. Boxes represent the types of biological con-
cepts, for example, Rare_Disease represents the type rare diseases in the data set.
Directional edges represent the type of interactions between biological and pharmaco-
logical concepts, for example, the is_encoded_by association between Protein and
Gene describes a situation whereby the protein (from node) that is encoded by a gene
(to node).
necessarily to correctly capture all data types to be included in a strict ontological
fashion, but to reflect the data types included in the central dogma of drug action
(drug-target-disease), shown in Fig. 2.1. The central dogma of drug action is an ab-
stract representation of the drug-disease connection and drug repositioning approaches
aim to ‘fill in the blanks’ between these data types (e.g. identify drug-target associa-
tions or drug-disease associations). It, therefore, makes sense to utilise this represen-
tation when aggregating data relevant to the drug repositioning setting and it is for
this reason that DReNInO makes clear distinctions between drugs (Drug_Molecule),
targets (Biological_Molecule) and diseases (Disease).
DReNInO allows for queries involving a parent type, such as Disease to include
its child terms, Common_Disease and Rare_Disease (see Fig. A.2A for illustration).
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Figure 3.8: Classes included in DReNInO. The high-level ontology, DReNInO
contains 25 classes, representing the concept_classes to be included in DReNInF,
with relation_types captured as 18 object properties.
Object properties capture Relation_Types to be included. For example, there are
two associations between Biological_Molecule and Disease in DReNInO— in-
volved_in_common_disease and involved_in_rare_disease, and these are cap-
tured as object properties (see Fig. A.2B for illustration).
3.4.4.2 Suite of parsers
21 parsers were developed for external data sources described in Section 3.2.4, four
mappers for the extraneous mapping sources listed in Table. 3.2 and two mappers
for the internal mapping sources43 (used to map OMIM terms to MeSH terms and
GWAS traits to MeSH terms, see Table. 3.2). To produce heterogeneous data sources
using the semantics captured in DReNInO and the suite of parsers, a data integration
strategy was next defined.
43kindly provided by GSK
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3.4.4.3 Data integration strategy
Similar in purpose to an Ondex workflow, BioSSIP integration strategies define which
parsers are to be used and in what order. The data integration strategy used in
DReNInF is shown in Fig 3.9. A characteristic of bioinformatics data sets is the
existence of various types of ‘standard’ identifiers. The data sources that were primarily
integrated (as described in previous sections) often use different accession IDs. To
effectively integrate these data sets, a set of additional data sources were used as
ID-ID mapping resources (Table. 3.2).
Table 3.2: Mapping sources used in DReNIn.
Source Version/Accessed Source ID from Source ID to
Metathesaurus R©[132] UMLS R© MeSH R©
UniChem44 [133] 26-08-15 DBID ChEMBL
PharmGKB45 [134] 05-08-2015 NDF-RT (NUI) DBID
ORDO [135] 31-07-2015 OMIM MeSH
in-house data - OMIM MeSH
in-house data - GWAS trait MeSH
3.4.5 DReNIn: an RDF exposed data set
An integrated data set was then created using DReNInF, creating a Neo4j graph
containing 466,540 nodes, connected via 2,688,436 relations. In Neo4j, the data set
uses 3.26 GB of disk space and takes 100 minutes to build. In order to provide a simple
access point to the community, an RDF version of the graph was created using the
RDF exporter. In RDF, the integrated data set is made up of over 8.5 million triples
and is 660 MB in disk size.
3.4.5.1 User interface
The five pages include home, about (detailing data sets included in DReNIn), meta-
graph (displays a count of each datatype in the network), ontology (details the classes
and relations captured in DReNInO) and a query page. The query page of the Web site
allows a user to submit either one of the predefined SPARQL queries, or to compose
their own query. Query results are presented in tabular format but may be downloaded
in RDF for further analysis or visualisation tasks.
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Figure 3.9: Integration strategy utilised in DReNInF. Strategy makes use of
all data sources described in 3.2.4 as well as the mapping sources listed in Table. 3.2.
Red circles represent strategy steps, parsers, which involves the integration of the two
input sources. Node types and edge types taken from each source as well as the concept
types used to integrate the data for each source is also provided.
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Figure 3.10: DReNIn query interface. The DReNIn Web site is made up of five
pages: home; about; metagraph; ontology; and the query page which is shown above.
The query page provides a user with pre-canned SPARQL queries as well as an open
text field for user specified queries SPARQL.
3.4.5.2 Example queries
Some predefined sample queries are presented on the query page (Fig. 3.10), while a
text box is also given to allow input of user-specified queries. The data set allows a
user to ask questions that would otherwise not be possible to answer systematically,
such as those described in Fig. 3.11, Fig. 3.12 and Fig. 3.13.
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Figure 3.11: DReNIn SPARQL example 1. A SPARQL representation of the
following research question: “I am interested in inferring novel uses for drugX. Identify
all targets that drugX potently binds to and the rare diseases associated to these targets.
Do not include diseases that drugX is marketed to treat or are known off-target effects
of the drug”. Query line numbers are shown in red. Line 1 defines the data to be
returned by the query: Target refers to the id of the target; RareDiseaseID refers to
the id of the rare disease; and DiseaseName refers to the name of the rare disease. Line
2 specifies drugX as drugbank:DB00203 (sildenafil). Lines 3-7 of the query describe
the type of association required between the drug and the potential targets. It is stated
that a binds_to association (line 3) derived from ChEMBL (line 5) is required, and
that this association should be annotated with a Ki ActivityType (line 6). Line 8
removes any associations that have an ActivityValue less than 10.0nM. Next, targets
that the drug bind to and that are encoded by a gene (line 9) and associated with a
rare disease (line 10) are identified. Finally, line 12 removes diseases that the drug is
already known to treat and line 13 removes diseases that are known to be a side-effect
of the drug.
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Figure 3.12: DReNIn SPARQL example 2. A SPARQL representation of the
following research question: “I have a potential indication, diseaseX, for a known
drug, drugY, and I would like to check if this indication for drugY has been investigated
previously. Identify the id, title, phase and status of clinical trials that involve both
drugY and diseaseX”. Query line numbers are shown in red. Line 1 defines the data
to be returned by the query to describe relevant clinical trials: TrialID refers to the
id of the clinical trial as provided by clinicaltrials.gov; Title refers to the title of the
trial; Phase refers to the phase that the trial has reached; and Status refers to the
status of the trial. Furthermore, in line 2 diseaseX is defined as drenin:D008171
(Lung Diseases) and in line 3 drugY is defined as drugbank:DB00203 (sildenafil).
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Figure 3.13: DReNIn SPARQL example 3. A SPARQL representation of the
following research question: “I would like to identify a therapeutic area of interest for
my upcoming study. Identify all common diseases for which there are currently no
marketed drugs but that have known genetic associations that can be targeted by a
potential treatment”. Query line numbers are shown in red. Line 1 defines the data
to be returned by the query: DiseaseID refers to the id of the common disease; and
DiseaseName refers to the name of the common disease. Line 2 gets the DiseaseID
of all common diseases in the dataset, while line 3 retrieves the DiseaseName of these
diseases. Line 4 retrieves all of the genes that are associated with the set of diseases.
Finally, the MINUS function of the query (lines 5-9) discards all of the diseases that
have a drug known to treat them in the dataset.
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3.5 Discussion
In this section the work that has been presented in the Chapter will be discussed and
summarised. Furthermore, limitations will be presented as well as potential future
directions.
3.5.1 Updated Ondex data set, Dat
DISEASE KIND concepts from NDF-RT were used to represent the Indication con-
cept_class in Dat . The NDF-RT uses a relatively shallow vocabulary to capture
DISEASE KIND concepts, which explains why there is a limited number of G-D as-
sociations included from DisGeNET that map to diseases in Dat . It must also be
noted that there exists a plethora of data sources storing G-D associations derived us-
ing many different approaches. Although DisGENet includes data from multiple G-D
sources and provides a score for these associations, it is done so using an arbitrary
metric. In future iterations of the data set a broader view of the G-D landscape needs
to be taken; with a method to integrate and score these essential.
Dat is used as the test bed for much of the preliminary work described in further
Chapters. However, this data set has several limitations. First and foremost is the
fact that the data included is outdated. Some data sets, such as KEGG, are now
unavailable, making a rebuild of the data set impossible. Dat includes DrugBank v2.5
data, which is only available for download as a text file46. Newer versions of this data
set are now available for download, but it is now distributed in XML format only;
leaving the original Ondex parsers incapable of parsing newer versions.
More important than the data release formats are the limitations imposed by the ini-
tial design of the semantics. Dat uses DrugBank as the focal point for all Compound
and Target concepts and the binds_to interactions between these. A Target taken
from DrugBank is a single protein known to bind a drug, and so should be assigned
the type Protein. The original semantic definition of a Target has repercussions
when trying to mine Dat for novel interactions, such as Drug-Target (D-T) interac-
tions. The process of inferring novel targets is made more difficult since known targets
46www.drugbank.ca/downloads/archived Accessed: 22-12-2015
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would be overrepresented when data mining for novel D-T inferences. A more thor-
oughly designed semantics would need to remove the abstracted Target type. Instead,
binds_to relations should be between the drug and the type of target. In most cases,
the target types will be single proteins, or genes, but could also be protein families,
protein complexes or more generally tissues or organisms [136].
DrugBank contains a comprehensive set of D-T associations. However, there are no
details regarding the activity type and values associated with these associations (e.g.
IC50, Kd, Ki and Potency). Targets are also included from multiple species, yet the
proteins included in Dat are limited to those from Homo sapiens. Also missing is
knowledge regarding the currently marketed state of the drug, i.e. what it is used to
treat, whether there are known side-effects of the drug and if the drug is currently being
investigated to treat any disease. These are all questions that need to be addressed in
later iterations of the data set.
3.5.2 Ondex V Neo4j performance testing
Ondex was used as the integration platform for both the initial data set and Dat . As
previously mentioned (see Section 3.2.3.3), Ondex is capable of implementing a strict
semantics which can be used to aid data integration tasks via a controlled vocabulary
captured in an XML file. This controlled vocabulary is essentially a list of terms and
not a full ontological representation. With this limitation in mind, further aspects of
Ondex are discussed to evaluate systematically the benefits of using Ondex during the
development of further data sets.
Although a compiled jar is available for Ondex, to develop against the project the
source code must be downloaded and compiled. Compiling Ondex on a local machine
is not an easy task and takes, at best, numerous attempts. Although well documented,
one must have a well-rounded understanding of the Ondex framework to build any
type of plugin (parser, mapper, etc.) and this task can take a day of development
time for more complex implementations. Building integrated networks that include a
significant number of individual data sets, each with subtle differences in their data
format, can result in months of development time. Even after the production of a data
set, rather counter-intuitively (Ondex holds the graph in memory), exploring the graph
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using filters is a time-consuming task. It can take up to an hour to correctly filter and
visualise even the nearest neighbours of a node of interest (for example, Fig.3.4 took
an hour to produce). The poor performance is likely due to a combination of poorly
implemented code along with the size of the graph that was held in memory (around
a million graph entities, that is nodes plus edges).
Ondex shows linear scalability with linear graphs (see Fig.3.5A), with a time complex-
ity of O(n). For more complex graphs, this time complexity shows properties closer
to polynomial growth O(n2) (see Fig.3.5D). Memory usage, taken as a measure of the
average RAM used during a graph build, in the Ondex system remains linear for both
linear and more complex networks. Available RAM is quickly saturated, however, with
linear graphs able to reach a |V | of 2.1M (see Fig.3.5B) and more complex networks
a |V | of 1.2M (see Fig.3.5E) before the 6GB is saturated. To save an Ondex graph
to disk an extra plugin must be called from the XML workflow, the OXL exporter.
The amount of memory used to save graphs, with a |V | of 500,000, in OXL format to
disk differs quite dramatically between the two graph types. For linear graphs this is
236MB, reaching 330MB for more complex graphs of the same size.
Due to the fact that the development of a data set for drug repositioning would likely
take numerous iterations and be highly connected (no doubt displaying similar topo-
logical attributes to Dat), it was decided that an alternative integration platform would
be investigated.
The development times and build performance of the highly popular Neo4j were, there-
fore, investigated. The aim of this comparison is to directly contrast the two platforms
to identify which offers a more viable platform for the development of integrated data
sets. Unlike Ondex, there is very little pre-requisite in terms of knowledge required.
As long as a user has a basic understanding of Java and Maven development then the
learning curve is minimal. A simple parser for Neo4j may be developed in a couple of
hours, however, it must be pointed out that this is mainly due to the fact that there
is no mechanism for strictly controlling semantics and no framework to guide a user
during parser development, and so there is no need to consider a formal model.
Neo4j displays linear scalability for both linear (see Fig.3.5A), and more complex
graphs (see Fig.3.5D). Memory usage, taken as a measure of the average RAM used
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during a graph build, in Neo4j does not display the same linear pattern as observed
in Ondex. Available RAM allows for linear graphs with a |V | of 10M (see Fig.3.5B)
and more complex networks a |V | of 7M (see Fig.3.5E) to be built on a local machine.
The amount of memory used to save graphs, with a |V | of 500,000, in Neo4j is a lot
lower than in Ondex, 80MB for a linear graph and 131MB for more complex graphs
of the same size.
Although Neo4j, when compared to Ondex, allows for a more scalable approach to
data set development, unlike Ondex, semantics are not controlled in a strict fashion
in Neo4j. To make use of the inherent scalability of Neo4j, a lightweight layer for
handling semantics was developed. The aim of the semantic layer was to allow for
directed integration and querying with reference to an ontological representation of
semantic types captured in any subsequent integrated data sets for drug repositioning.
3.5.3 BioSSIP: a light-weight semantic handling module
The BioSSIP module enables users to build and analyse the same data set using differ-
ent data storage solutions with the same code, encouraging reproducibility. Having one
code base to learn to produce, and analyse, integrated semantic graphs using a multi-
tude of datastores can dramatically reduce the upfront learning costs associated with
moving an integration project to another data storage solution. BioSSIP makes use of
the inherent scalability of integration platforms, such as Neo4j, while also allowing for
the semantics to be controlled by a high-level, application-specific ontology.
At present, there are only data access layers for the in-memory JVM and the NoSQL
Neo4j graph database. Although it would be relatively simple to develop alternative
data access layers for alternative ‘backends’, such as a relational database, this is yet
to be implemented. Through allowing alternate backends to be used, the same data set
utilising a suite of parsers and a BioSSIP integration strategy may be implemented and
recreated in different platforms, supporting the idea of data reproducibility. BioSSIP
mining strategies are self-contained, and so providing a data access layer has been cre-
ated, the same query strategies can be executed on multiple ‘backends’. Ultimately,
this means that a BioSSIP application may be released as a suite of parsers, an in-
tegration strategy and a mining strategy. Anyone can then recreate the data set and
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analyses regardless of his or her choice of ‘backend’.
3.5.4 DReNInF: a data integration framework
DReNInF enables the production of integrated data sets relevant to drug repositioning.
These system representative data sets allow a holistic view of drugs in mammalian
systems to be realised.
Central to DReNInF is the DReNInO which provides a high-level view of data types
relevant to drug repositioning. Although many ontologies exist, none captured all the
data relevant to this project. DReNInO allows semantics to be controlled in a strict
fashion during integration and querying alike. The ontology has been created in such
a manner that it can be extended by the community and allows for both systems
relevant data as well as validation (annotation) data to be combined. DReNInO was
developed in order to provide a simple framework to capture entities relating to the
central dogma of drug action (see Fig. 2.1).
Furthermore, it was important that the concept_class Target was not included (see
page 76) in DReNInO. Instead, as many drug targets are indeed single proteins, the in-
teractions between drugs (be it Small_Molecules, Bio_Tech or Drug_Combinations)
are instead captured in binds_to associations from these drug types directly to a
Protein or a Gene. Rare diseases affect a small percentage of the population and as
such there exists a number of economic incentives for the development of treatments
for rare diseases (see Section 2.1). Furthermore, they tend to be genetic in origin and
monogenic— resulting from modifications of a single gene. Although not always the
case, more common diseases, such as Crohn’s disease, tend to have a more complex
genetic causation and are said to be multigenic. For these reasons it was decided that
the data set would make a clear semantic difference between these and so two disease
types are defined in DReNInO; Common_Disease and Rare_Disease.
The ultimate goal of any drug repositioning data set is to aid in the inference of novel
associations between types of data in the network (such as a has_indication associ-
ation between a Small_Molecule and a Rare_Disease). It was, therefore, important
to include data types in DReNInO that would allow for some form of validation, or
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indeed filtering, to be achieved. For this reason, has_side_effect associations be-
tween drugs and diseases were also included. Also included were Clinical_Trials,
with this data allowing for any inferences to be systematically checked to see if any
studies are currently investigating the drug for the inferred use.
The Pathway concept_class and ConceptWiki URLs for both the Protein and Gene
concepts were taken from Open PHACTS. ConceptWiki, included in Open PHACTS,
offers a more thorough mapping of elements to alternative accessions and is far beyond
what could have been achieved during this project. However, ConceptWiki mapping
to genes was not included. ConceptWiki mappings to genes are relatively few, while
some that have been mapped appear to have been done so incorrectly (see Fig. A.1).
As an Associated Partner of the Open PHACTS project, many webinars and workshops
were attended during this project to identify any overlap between the hugely funded
consortium and the project presented in this thesis. Although the project offers a great
deal of interesting data, until recently this data was only accessible via its RESTful
API (it has recently enabled local download and a Docker instance of the RDF data set
in a Virtuoso triplestore). Using REST requests meant exhaustive querying of the data
was intractable— something that would have been necessary for extending the data
set. At the start of this project, Open PHACTS did not include any side-effect data,
indication infomation nor clinical trial data, although side-effects are now included—
the other data types are still missing. The timeline of the project co-incided with this
project. With a massive team of support staff, the project quickly gained momentum
which made identifying an area for collaboration difficult— new releases were never
far away. Furthermore, the focus of this project was pharmacologial annotation of
entities represented and not so much the more abstract concept of the topological
properties of highly connected data. It was for these reasons, as well as political factors
(Open PHACTS had commercial partners whose requirements were more pressing than
others), that it was decided that Open PHACTS would not be utilised as the sole data
source for this project and that collaboration was not pursued.
During the development of DReNInF challenges of data integration, as described in
Section 3.2.2, were addressed. Although there are certain limitations to open source
data in terms of quality, by using only sources that are heavily utilised within the field
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one would assume that data sets created using DReNInF provide a relatively accurate
representation of drugs and their interactions with other biological entities. Through
the development of novel mining methods, data sets created using the DReNInF will
ultimately be used to aid the identification of novel uses for existing drugs.
3.5.5 DReNIn: an RDF exposed data set
DReNIn, a homogeneous syntactic and semantic RDF representation of multiple, het-
erogeneous data sources with a single, unified query interface, was developed using
DReNInF. Although large projects exist, such as Open PHACTS, they do not capture
as many types of data as DReNIn. Open PHACTS does not include information that
may be beneficial to the validation of predicted Drug-Disease (Dr-D) inferences, with
no indication information included, a vital piece of information in any drug reposition-
ing prediction task. As well as the lack of indication data, Open PHACTS does not
contain any clinical trial information and, because of the size of the project, struggles
with the mapping between particular entities (such as those described in A.1). Equiv-
alence in DReNIn is inferred using sources listed in Table. 3.2. Four of these sources
are heavily utilised in the field, and DReNIn is also able to extend mappings using
manually created equivalences. Provenance, recognised as a vital aspect of a task in
data integration is provided for every edge and node in the data set, with the source
as well as version, date accessed and even the data format from which it was extracted
is provided.
Due to the fact that the data set is hosted locally on a university server (unlike commer-
cial projects that would have access to dedicated software), large SPARQL queries may
prove troublesome. For this reason, it may be useful to implement a query ‘checker’
before accepting queries. One caveat to the data set is, due to the large number of data
sources included, updates must be completed on a regular basis, to ensure a state-of-
the-art view is provided. It takes a relatively long time to pull all clinical trials locally,
and extracting data from Open PHACTS is also a time-consuming task. To ensure
the future of the project, an automated workflow will need to be implemented which
will also need to inform of any changes to data formats included in the data set.
The fact that DReNIn allows for queries that are not possible in other open source drug
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repositioning data sets (such as those presented in Fig. 3.11, Fig. 3.12 and Fig. 3.13),
means it has the potential to become an important source of information for the
research field in the future.
3.6 Conclusion
This Chapter has introduced data integration for drug repositioning, various data sets,
a platform for integration and the application of that platform to the generation of
an integrated data set for drug repositioning. A historical Ondex data set for in silico
drug discovery was extended for the purpose of drug repositioning. It was shown that
the limited scalability of the Ondex platform was not present in other data integration
platforms, including Neo4j. However, Neo4j lacks a means for strictly controlling
semantics. With this in mind, a lightweight framework to handle semantics, BioSSIP
was developed, which utilises Neo4j as the underlying datastore. A drug repositioning
data integration framework (DReNInF) was then described. DReNInF is made up
of a high-level ontology (DReNInO), a suite of parsers and an integration strategy.
DReNInF was used to produce an up-to-date semantically-rich drug repositioning data
set, DReNIn. Finally, this data set was exposed as an RDF data set, and made
accessible through a dedicated web front end, with a SPARQL endpoint, allowing for
the data set to be queried.
It is hoped that in the future BioSSIP can gain some traction in the wider integration
field. For this to happen it will be necessary for more ‘backends’ to be implemented as
well as a wider range of parsers, covering more than just the specialised area of drug
repositioning. Although the DReNIn RDF data set has enabled questions to be asked
that were previously beyond current integrative efforts in the field, the interface could
be improved. Improvements would centre around the creation of SPARQL queries,
which require a certain level of expertise from the user. Integrating work such as that
completed by General Electric Company in SPARQLgraph47 would allow for SPARQL
queries to be developed visually, removing any barriers that may currently be present.
The framework introduced in this Chapter has been used to create subsequent drug
47www.semtk.research.ge.com
- 83 -
Chapter 3: Data integration for drug repositioning
repositioning networks as described in Chapter 6. However, in order for integrated
data sets to be useful to the area of drug repositioning, systematic approaches to min-
ing for sub-components that may be indicative of repositioning opportunities must
be identified. To this regard, in the next Chapter, semantic subgraphs are formally
introduced. These semantic subgraphs are sub-components of an integrated network
that can be used to capture the functionality that describes a potential drug reposi-
tioning opportunity. Furthermore, Drug Repositioning Semantic Mining (DReSMin),
an exact, exhaustive algorithm for the identification of semantic subgraphs is also
detailed.
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4.1 Introduction
In graph theory, a graph is defined as a set of ordered pairs G = (V,E) where V
is a set of vertices, or nodes, and E, a set of edges. The order of a graph is |V |
(number of nodes), and the size is |E| (the number of edges). All graphs share these
essential structural elements, while other structural and semantic graph properties vary
amongst applications [137]. A graph can be constructed in various ways by allowing or
disallowing: (i) directed or undirected edges; (ii) weights on edges (simply a number
assigned to each edge); (iii) multiple edges between a pair of nodes (multigraphs); (iv)
edges that connect a single node to itself (self-loops) [137].
A
A
BC
B
Figure 4.1: Network motifs and coloured motifs. (A) An example of a feed-
forward loop network motif and (B) One of the most over-represented coloured motifs
of |V | = 3 in the Caenorhabditis elegans neuronal network [138]. Although A and B
share the same topology, through the inclusion of semantics, understanding of func-
tionality can also be achieved. Note: In B, Green: sensory neurone; red: interneuron.
Arrows represent the direction that the signal travels between the two cells.
All graphs, whether representing biological, social or technological data can be decom-
posed into subgraphs. Formally, a subgraph G′, of a graph G, is a graph G′ = (V ′, E ′)
where G′|V ′| ⊂ G|V | and G′|E ′| ⊂ G|E|. These subgraphs formally capture local
relationships between nodes in a graph. Often, in the life sciences, the relationships
and nodes in a given subgraph are indicative of a particular biological phenomenon
or function [139]. Analysis of these subgraphs allows for a greater understanding of
the network as a whole and the roles that specific concepts may play. Subgraphs may
capture topological information, i.e. the way in which constituent parts are interre-
lated or arranged structurally, and/or semantics, i.e. relating to the meaning of the
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sub-structure. From a topological perspective, Network Motifs (NMs), for example,
are subgraphs that are statistically overrepresented in comparison to their prevalence
in randomised networks [140, 141]. NMs are recognised as the simple building blocks of
complex networks. A biological example, often captured in gene regulatory networks,
are feed-forward loops (Fig. 4.1A) [142]. A feed-forward loop is a three gene pattern,
composed of two input genes, one of which regulates the other, both jointly regulating
a target gene [142]. The application of NMs is acceptable when analysing networks
containing limited semantic types such as gene regulatory networks or topological anal-
ysis of the Internet, in particular, social network analysis [143]. NMs, however, are
not suitable for the analysis of more semantically complex networks, such as metabolic
networks or, of more relevance to this work, drug networks. This limitation is due to
the fact that similar topologies can give rise to very different functions.
Extensions of NMs approaches have been described which allow the inclusion of se-
mantic information, such as the list coloured motif problem [144, 145]. In this case, a
motif (M ) is defined as a multiset of colours (types). An occurrence of M is a subset of
nodes that forms a connected subgraph whose multiset of colours, matches that of M,
exactly [145]. An example of a coloured motif is shown in Fig. 4.1B, which illustrates
one of the most over-represented coloured motifs captured in the Caenorhabditis ele-
gans neuronal network [138]. Although this coloured motif shares the same topology
as the NMs presented in Fig. 4.1A, the introduction of semantic types allows for a more
detailed description of the functionality that is captured. This approach demonstrates
how NMs, the simple building blocks of complex networks, may be extended to incorpo-
rate semantic information, allowing for statistically over-represented semantic patterns
to be identified. Although this extension highlights the importance of including se-
mantics in subgraphs, there is no reason to assume that semantic subgraphs capturing
potential drug repositioning opportunities will be statistically overrepresented in the
target network. Therefore, an alternative approach to identifying subgraphs that also
incorporate topology and semantics is required for the drug repositioning setting.
As described in Chapter 3, in the case of drug repositioning networks, the types of
relationships include amongst others: interactions between drugs and their targets,
interactions between targets, and the diseases associated with particular targets. Fur-
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thermore, multiple types of interactions can exist between the same entity types (e.g.
between drug and disease there may be side effect associations as well as indication
associations) capturing a plethora of biological functions. Subgraphs that describe
repositioning opportunities as a result of their semantic and topological properties
have been previously introduced as semantic subgraphs by Cockell et al. [101].
In this Chapter, a formal definition for semantic subgraphs is first provided. An
exhaustive algorithm for the identification of these semantic subgraphs is then intro-
duced. This algorithm, Drug Repositioning Semantic Mining (DReSMin), allows for
mappings of a semantic subgraph that are topologically exact and semantically ‘sim-
ilar’ to the query to be identified; meaning that functionally similar sub-components
can be identified from a target network. DReSMin is made up of novel components, in
particular a graph pruning step and a graph splitting component, that enable previ-
ously intractable subgraphs to be identified. The work presented in this Chapter has
also been described in Mullen et al. [146]. A Java implementation of the algorithm is
available at https://bitbucket.org/jmullen/dresminalgorithm.
4.2 Background
4.2.1 Semantic subgraphs
As part of this work, building on the work Cockell et al. [101], a formal representation
of semantic subgraphs has been defined and can be found in [146]. In this paper a
semantic subgraph is defined as: Q = (V,E, Tv, fv, Te, fe), where V is a set of nodes,
E is a set of edges, Tv is a set of node types and Te is a set of edge types. fv : V  Tv
and fe : E  Te are surjective (every element of the codomain is mapped to by at
least one element of the domain) functions; each node is assigned a node type, and
each edge has an edge type from Tv and Te respectively. A semantic subgraph, Q,
may be designed in such a manner that mappings, or occurrences, of Q in G can
aid in the inference of potential relations between nodes of particular types, where a
relation does not exist. Semantic subgraphs may be manually created through the
identification of known repositioning examples within an integrated network. For
example, the semantic subgraph presented in Fig. 4.2A was developed by identifying
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Figure 4.2: The drug repositioning of chlorpromazine as captured in an in
silico data set for drug development [101] (A) and the subsequent seman-
tic subgraph representation (B). Chlorpromazine is marketed as a non-sedating
tranquilliser [147]. In DrugBankv2.5 no association between chlorpromazine and the
Histamine H1 receptor is curated despite the drug also being an effective antihis-
tamine [147]. Trimeprazine has a similar 2D structure to chlorpromazine (shown in
the sim relations) and an association between the drug, and the Histamine H1 receptor
is captured in DrugBankv2.5. Due to the similar structures of the drugs, it may be
inferred that chlorpromazine is also likely to bind to the target and this inferred edge
is captured as a dashed line. Figure is adapted from [101].
the known repositioning example of chlorpromazine (generic medication) within the
integrated network presented in [101]. The semantic subgraph depicted in Fig. 4.2B
was then derived from the chlorpromazine example in Fig. 4.2A and can be used to
infer interactions between a node of type compound and a node of type target.
Chlorpromazine is an anti-psychotic drug that is also approved as an antihis-
tamine [148]. The interactions of chlorpromazine can be captured in an integrated
network (Fig. 4.2A). Data from DrugBank version 2.5 (DBv2.5) [113] provides three
interactions between chlorpromazine and single protein targets; none of these inter-
actions explain the antihistaminic affects of the drug. Structurally, chlorpromazine
is very similar to the antiemetic trimeprazine. DBv2.5 captures an interaction be-
tween trimeprazine and the Histamine H1 receptor, a known target for antihistamines.
Through guilt-by-association, we can, therefore, predict the Histamine H1 receptor as
a target for chlorpromazine, an interaction captured in the latest editions of the Drug-
Bank database. Fig. 4.2B describes a situation whereby a compound, structurally
- 89 -
Chapter 4: A novel algorithm for mining integrated data sets
similar to a compound with a known target, may also bind to the same target (the in-
ference is represented by the dashed red line). The topological and semantic properties
of the depicted subgraph describe a repositioning relationship that could be generically
applicable to any two drugs and a target. This real example can, therefore, be used to
derive a template semantic subgraph that can be used to search Drug-Target (D-T)
associations involving different drugs and targets. The template semantic subgraph,
therefore, describes a pattern indicative of a drugs interaction with a target, highlight-
ing potential new indications for the drug.
Fig. 4.2 shows a simple triad, however, semantic subgraphs that represent potential
repositioning opportunities are likely to be highly complex. In the context of drug
repositioning, manual identification of potential repositioning opportunities from large
target networks is possible, though not efficient for systematic analysis. Instead, auto-
mated approaches to the identification of mappings of a particular semantic subgraph
can allow for large-scale exploration of target networks.
To identify instances of semantic subgraphs, a means of identifying all topological
mappings of the subgraph is first required. Identifying mappings which maintain the
topological properties of a predefined subgraph in a target network is known as the
graph matching problem [137].
4.2.2 The graph matching problem
There are different variations of the graph-matching problem. For example, exact
matching occurs when the mapping between the nodes of the two graphs is edge-
preserving ; a mapping contains all edges defined by the query. One of the most
stringent forms of exact matching is subgraph isomorphism [149] which aims to find
all occurrences of a query graph and is a Nondeterministic Polynomial Time (NP)-
complete problem [150]. A decision problem is defined as NP-complete when it is both
NP and NP-hard, which essentially means that no fast solution is known.
Subgraph isomorphism is a task in which two graphs, G & Q are given as input, and
one must determine whether G contains a subgraph that is isomorphic to Q: is there a
subgraph G′(V ′, E ′) : V ′ ⊆ V,E ′ ⊆ E? During the search of a query graph, a mapping
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(M ) is expressed as the set of ordered pairs (v,m) (with v ∈ V (G) and m ∈ V (Q))
and so M = {(v,m) ∈ V (G)× V (Q)|v is mapped onto m}; that is M : G′ 7→ Q.
Currently, algorithms addressing this problem are exponential in performance relative
to the size of the input graphs [137]. Many algorithms which have been developed
to address the subgraph isomorphism problem are based on the exhaustive algorithm
developed by Ullman (1976) [151]. Applying an exhaustive method to the identifi-
cation of drug repositioning opportunities is important to ensure all possible novel
applications for a drug are investigated. Using a backtracking approach, Ullman’s
algorithm finds solutions by incrementing partial solutions or abandoning them when
determining they cannot be completed [151]. Many algorithms addressing the problem
of subgraph isomorphism build on Ullman’s work [151]. These applications include:
GraphQL [152], GADDI [153] and, one of the most efficient, the VF algorithm [17].
Performance is increased in these algorithms by exploiting different join orders, prun-
ing rules and auxiliary information to prune negative candidate subgraphs as early as
possible. Furthermore, extensions of the Ullman approach which incorporate the se-
mantics of a graph have also been developed. These extensions have been implemented
using inexact [154], as well as exact approaches [155, 156]. However, none of these ap-
proaches has been adapted to aid the automated identification of drug repositioning
opportunities.
Since subgraph isomorphism algorithms are only concerned with matching topology,
they must be extended to also consider semantics, if they are to be used to identify
mappings of a semantic subgraph successfully.
4.2.3 Semantic similarity
A simple semantic subgraph, Q, made up of two nodes and a single edge can be used to
describe a drug that is marketed to treat a particular disease, consisting of a Compound
node and an outgoing edge of type may_treat linked to a node of type Disease. With-
out considering semantic similarity, an exact search for Q in G would return all exact
mappings, i.e. all instances whereby a Compound and a Disease share a may_treat
edge. However, if one were able to apply a less stringent semantic matching the same
search could also return instances whereby a node of type Compound and a node of
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type Disease share a may_prevent edge. Therefore, we can see that when searching
for semantic subgraphs, it is important to consider the semantic similarity between
the query subgraph and the potential mapping, as well as topological similarity. By
introducing a semantic similarity measure, mappings of a semantic subgraph whose
semantics are similar but not necessarily exact may be achieved. Semantic similar-
ity becomes even more valuable as semantic subgraphs increase in size. Mappings of
larger semantic subgraphs that contain a single entity with a differing type (to that
described in the semantic subgraph being searched for) are less likely to produce a
subgraph representing a different functionality to that captured in Q.
Therefore, a measurement of semantic similarity between elements of a mapping and
the equivalent element in a query must be introduced to the search. A degree of similar-
ity can be expressed as a semantic distance. Numerous measures have been developed
to score the semantic similarity between two ontological concepts [157, 158]. Previous
work in the area of intelligence link analysis has used ontology-based semantic simi-
larity scoring methods for pattern matching [159]. In Seid and Mehrotra’s algorithm,
an inexact topological search is carried out with matches semantically scored based on
their Least Common Ancestor (LCA) within an ontology. Topological and semantic
scores are then combined and k ranked matches returned. Although these measures
are fine when considering approaches that utilise standardised ontologies it is likely
that non-obvious semantic types may be included in the network— these types may
not be captured in a standard ontology. It is, therefore, important to enable semantic
similarities scores to be manually curated via a domain expert. In this instance the
semantic similarity scores can be represented, in the simplist form, as an n×n matrix.
While approaches described are adequate for their particular setting, here a new ex-
haustive graph matching approach for the identification of semantic subgraphs relevant
to drug repositioning is presented.
4.3 Materials and methods
DReSMin was implemented as a Maven project in Java and is available for download
from www.bitbucket.org/ncl-intbio/dresmin. The project makes use of the JGraphT
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library1 v0.8.3 for in-memory representation of the target network and query semantic
networks. As such, a target graph is first converted to a JGraphT format before
querying. JGraphT uses a bespoke Java representation of graph objects and can,
therefore, be serialised and deserialized using the native Java serializable interface.
During semantic subgraph splitting, the shortest path is calculated using the imple-
mentation of Dijkstra’s shortest path algorithm [160] provided by the JGraphT library.
DReSMin also provides a simple visualisation framework for: presentation of the un-
derlying data structure during a search; semantic subgraphs; as well as user specified
subcomponents of the target network (e.g. nearest neighbourhood), visualisation is
achieved using the GraphStream library2 v1.2.
4.4 Results
An algorithm for the detection of semantic subgraphs, DReSMin, was developed to al-
low integrative networks to be searched for semantic subgraphs. The algorithm returns
all mappings of a semantic subgraph that match at a level equal to, or above a given
semantic threshold. DReSMin was specifically designed to work with semantically-rich
target networks which possess particular properties. Specifically, DReSMin requires a
directed graph (edges have a direction associated with them) where nodes and edges
are given types from Tv and Te respectively. Tv and Te may be drawn from a finite
hierarchy of types H, and can be annotated with attributes. The algorithm allows for
multigraphs and for nodes to contain self-loops.
4.4.1 The DReSMin algorithm
DReSMin is an exhaustive algorithm for the detection of mappings of a predefined
query semantic subgraph in an integrated target network. Mappings that are identified
are topologically identical to the query graph, but may differ semantically depending
on a user defined threshold. DReSMin requires three inputs: a target graph (G); a
semantic subgraph (Q), that will be searched for in G ; and a Semantic Threshold (ST),
1www.jgrapht.org
2www.graphstream-project.org
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Semantic subgraph split (Q)Semantic Graph Pruning (G)
Topological search (G,Q)
Semantic subgraph distance exclusion (ST, Q, M’)
Ranked M
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Figure 4.3: Overview of the DReSMin algorithm developed for the detection
of semantic subgraphs. DReSMin requires three inputs: a target graph (G); a query
semantic subgraph (Q); and a semantic threshold (ST). The DReSMin algorithm is
made up of four main components: semantic graph prune (red); topological search
(blue); semantic subgraph distance exclusion (yellow); and semantic subgraph splitting
(green). The output of DReSMin is a set of ranked inferences.
ranging from 0-1. DReSMin is made up of four main components which are described
in Fig. 4.3. These components comprise: (i) Semantic graph pruning (ii) Topological
search (iii) Semantic subgraph distance exclusion (iv) Semantic subgraph splitting.
DReSMin may be executed in two modes. The first requires that every element that is
added to a mapping must be greater than the ST. The second allows for elements that
are lower than the ST to be added to potential mappings, as long as the cumulative
score for a mapping is greater than the ST.
4.4.1.1 Semantic graph pruning
The approach presented is concerned with identifying semantic subgraphs that match,
semantically, at a level equal to, or above a semantic threshold. (Note: The semantic
distance between two graph entities is calculated using the semantic distance calculator
described in the ‘Semantic subgraph distance exclusion’ Section on page 96). In the
graph pruning component of the algorithm, any nodes (and their associated edges) in
G, which are above a certain semantic distance from all of those in Q, are removed
from G. This step allows any nodes that are semantically distant from the query to be
removed from the target graph prior to a search, cutting down the initial search space.
Taking G, Q and an ST each tv ∈ Tv(Q) are sent to the semantic subgraph distance
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calculator (termed Semantic Distance Calculator (SDC) and described on page 96),
and scored against every tv ∈ Tv(G). If SDC(tv(Q), tv(G)) < ST then all v ∈ V (G) of
type tv are removed from G as well as any e ∈ E where v = vi or v = vj. Finally, after
all semantically insignificant elements are removed from G, all disconnected v ∈ V (G)
that may have resulted from the edge pruning step are also removed.
4.4.1.2 Topological search
Here, topological matching is carried out using a variation of the VF algorithm [17].
The VF algorithm is exhaustive and suitable for working with ‘large’ graphs (up to
3 × 104 nodes), employing a depth-first strategy implemented in a recursive fash-
ion [17]. During a search using the VF algorithm, the search space is minimised via
the introduction of topological pruning rules [17]. Integrated networks typically sur-
pass the aforementioned ‘large’ graphs in size, particularly true within the biological
and pharmaceutical settings. As data volumes continue to grow (e.g. omics technolo-
gies continue to mature) it is important to develop exhaustive algorithms capable of
scaling with the data.
An initial implementation of the VF algorithm showed poor scalability and so, as an
enhancement to the VF algorithm, three steps to improve the efficiency of searching
for topological subgraphs were developed. These three steps are: a set of rules used
to determine the appropriate nodes at which an instance of the search is started (ini-
tial candidate set), as described in (1) below; a topological pruning rule, based on a
closed world assumption, as described in (2) below; and a semantic thresholding step
(described in Section 4.4.1.3). Although DReSMin can be applied to any setting, the
focus of this thesis is on the identification of new indications for existing compounds.
It is, therefore, essential that mappings of semantic subgraphs, in this work, contain a
compound.
1. When considering an initial candidate set of nodes from the target graph G at
which to initiate the search, it is desirable to ensure that the set consists of
nodes of a type, X, such as Compound; ensuring relevant portions of the graph
are being searched. Therefore, to identify an initial candidate set for the search,
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the highest connected node, v, of type X, from Q, is first identified. Next, all
nodes from G that have a degree greater than or equal to v, whilst also being
of type X (an exact semantic type match), are included in the initial candidate
set.
2. When mining with a given semantic subgraph that describes a potential repo-
sitioning situation it is assumed that the lack of a relationship between nodes
indicates the absence of a relationship between the two nodes (a closed world
assumption). As a result, when searching for a given semantic subgraph, Q, we
only consider a match if there exists no additional edges between the nodes in
a mapping M from the target graph G and their equivalent nodes in Q. There-
fore, a mapping M is expressed as a set of ordered pairs and the closed world
assumption requires (M = match) ∨ (deg(v) ∈ V (G) ≡ deg(m) ∈ V (Q)).
4.4.1.3 Semantic subgraph distance exclusion
Semantic thresholding is used to exclude matches found in G that are below a given
semantic distance from Q. This process is achieved through a semantic subgraph dis-
tance calculator (SDC). An SDC is graph specific and comprises of two distance
matrices, one for the nodes types captured in G (tv ∈ Tv(G)) and one for the edge
types captured in G (te ∈ Te(G)). The n×n matrix for the node types (n = |Tv|) and
the m×m for the edge types (m = |Te|) are each represented as P ′ = [pij]. Matrices
contain manually curated scores ranging from -1 to 1, with a score of 1 returned when
both entities are of the same type, 0 returned if the entities have unrelated semantic
types (such as a Protein and a Publication), and -1 returned if the entities are se-
mantically opposite (such as the edge types has_function and has_not_function).
The values used in the matrices are defined in Equation 4.1.
pij =

1 if pi is semantically identical to pj;
0 if pi is semantically unrelated to pj;
−1 if pi is semantically opposite to pj.
(4.1)
During the matching process each element of M = (Vm, Em) is scored against its
equivalent in Q = (Vq, Eq) using the two matrices via a call to the SDC. The resulting
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Semantic Score (SS) of M is defined in Equation 4.2.
SS(M,Q) =
∑n
i=1 SDC(mi, qi)
n
(4.2)
An ST is defined by the user prior to a search as a value ranging from 0 (semantics in
mappings are not required to be similar to those in the query— essentially a purely
topological search) to 1 (semantics in mappings must be identical to those in the query;
essentially a trivial task).
4.4.1.4 Semantic subgraph splitting
This component of DReSMin takes a semantic subgraph, Q, and returns a set of se-
mantic subgraphs, D, whose |V | < 4. Semantic subgraphs in D share an overlapping
node (ON). Semantic subgraph splitting aims to address, or at least bypass, the expo-
nential increase in the time taken for subgraph isomorphism algorithms to search for
larger subgraphs. This step of DReSMin is described in detail in Algorithm 1.
In Fig. 4.3, we see how this step is applied in context with the other compo-
nents of DReSMin. The graph splitting component allows smaller subgraphs to be
searched, before post-searching steps merge mappings that share a common ON.
The most connected node, vmax(Q), is first identified and used as ON. Q is then
checked to see if it is either a clique (fully connected network) in which case the
graph is randomly partitioned. Next, Q is converted to an undirected graph. Of
all the remaining v ∈ V (Q), the two most distant nodes (v1, v2) from Q are se-
lected. Two new graphs (D1&D2) are then created and populated with nodes as
such: V (D1) ∪ v ∈ δ(v1, ON), V (D2) ∪ v ∈ δ(v2, ON), that is every node in the short-
est path from v1 to ON is included in D1 and every node in the shortest path from
v2 to ON is included in D2. Remaining nodes are then allocated using the following
rules:
1. If a node shares an edge with only one of D1 or D2, it will be allocated to that
subgraph.
2. If a node shares an edge with nodes from both D1 and D2, it will be assigned to
the subgraph with which it shares the greatest number of edges.
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Algorithm 1 Graph Splitting. Algorithm takes a semantic subgraph (Q) and returns
a set of semantic subgraphs (D) whose node set is less than four. Q is first converted
to an undirected graph before it is checked for a clique, if Q is a clique then splitting
is completed randomly. Next, an overlapping node (ON) is identified. The two most
distant nodes in Q are then identified (v1 and v2) and new subgraphs (D1 and D2) are
populated with all nodes that fall between ON and v1 and v2, respectively. Finally, all
left over nodes are allocated, and D returned. If the node set of either D1 and D2 are
still greater than four, then the algorithm may be called iteratively.
Input: Semantic Subgraph, Q
1: if |V (Q)| > 3 then
2: D = {Q}
3: else
4: if cliqueCheck (Q) then
5: cliqueSplit (Q)
6: else
7: ON = vmax(Q); v1; v2;max = −1
8: Q is converted to an undirected graph
9: for i ∈ V (∀j(j ∈ V ∧ i 6= j)) do
10: if shortestPath (i, j) > max then
11: max = shortestPath (i, j); v1 = i; v2 = j
12: end if
13: end for
14: D1 = all nodes in δ(v1, ON)
15: D2 = all nodes in δ(v2, ON)
16: for v ∈ V do
17: if v /∈ (V (D1) ∪ V (D2)) then
18: allocate left over nodes
19: end if
20: end for
21: D = {D1, D2}
22: while |(V )d| ∈ D > 3 do
23: return Graph Splitting(d)
24: end while
25: end if
26: end if
Output: D
3. If a node shares an equal number of edges with nodes in D1 and D2, it will be
designated to the subgraph containing the fewest nodes.
4. If a node shares an equal number of edges with nodes in D1 and D2 and D1 and
D2 have an equal number of nodes, it will be allocated to D1.
Edges are then distributed as such: ∀e ∈ E(Q) if either V (D1) or V (D2) contains
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both (vi, vj) of e; e is allocated to that graph. When vi, vj are not present in the same
graph then e is not included in the split graphs. Instead, e is checked for during the
post-searching steps, which are described below. Splitting may be called iteratively if
either D1 or D2 still possess a |V | > 3 after the first round of splitting, as demonstrated
in Fig. 4.4.
v3
v6
D2
v4
v5
v3
v3
v6v5
v4
D2.1
D2.2
v6
v1
v2
v3 v4
v5
Q
v1 v2 v3
D1
Figure 4.4: Subgraph split procedure takes an initial semantic subgraph (Q)
and produces two smaller semantic subgraphs (D1 and D2) using all nodes
(v) from (Q). The overlapping node (ON ) is identified in Q (v3) and used as the
overlapping node in both D1 and D2. The two most distant nodes in Q are then
identified (v1 and v6) and nodes in the path between these and ON added to the
corresponding graphs (D1 and D2). We also see that |V (D2)| > 3 and so a second call
is made to graph split giving us D21 and D22.
As a result of this process two graphs are produced, D1 and D2 as well as the original
semantic subgraph, Q. A search is then initiated with D1 or D2, depending on which
has the smallest |V | (ensuring the quickest search is completed first). The first search
is started using ON, maintaining the edgeset it possessed in Q ; reducing the initial
candidate set. The edgeset ON possesses in Q will be greater than the edgeset it
possesses in the split graphs (D1 and D2), as Q is the larger subgraph, and ON is
the highest connected node from this subgraph. Therefore, by using the edgeset ON
possesses in Q, fewer candidate nodes will be identified in the target graph, resulting in
the search being initiated at fewer locations. All starting nodes that lead to a mapping
being identified in the first search are then passed to the second search; reducing the
initial candidate set once more by excluding nodes from the starting set that did not
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lead to a mapping in the first search.
After a split search has been completed, the mappings from D1 and D2 must be
consolidated in order to return mappings reflective of the original query graph, Q.
This process is done using two post-searching steps:
1. The first post-searching step merges all mappings of D1 and D2 that share an
ON and returns M, the set of potential mappings of Q found in target graph, G.
2. The second post-searching step involves re-scoring the merged mappings and
making some final checks. This post-searching step requires: (1) all merged
mappings in M from the first post-searching step (2) the original query graph,
Q, and (3) ∀ m ∈ M , the edgeset that each node in m possesses in the target
graph, G. In this step, ∀ m ∈ M , some final checks are carried out. First, a
check is made to ensure any e ∈ E(Q) that were not allocated to either D1 or
D2 in the graph split step are present in G ; done using the edgesets from G. m is
also checked to ensure that the closed world assumption still holds after merging
(described on page 2), again using the edgesets from G. If m passes these initial
tests it is then re-scored, using the SDC (Section 4.4.1.3).
4.4.2 Defining a semantic threshold
To identify an ST that would allow for semantically similar mappings of a semantic
subgraph to be returned during a search, while also limiting this set to those that still
capture the desired functionality represented in the semantic subgraph. To do this,
first of all, a means of measuring the Semantic Simplicity (SE) of a semantic subgraph
Q, was developed:
SE(Q) =
∑
vi,vj∈V (Q),vi 6=vj SDC(vi, vj) +
∑
ei,ej∈E(Q),ei 6=ej SDC(ei, ej)
|V (Q)|+ |E(Q)| (4.3)
The SE (Equation 4.3) utilises the SDC described previously (Section 4.4.1.3) and
allows for a measure from 0-1 to be calculated for a semantic subgraph. This
score is based on the cumulative distance of all node types against all node types
(
∑
vi,vj∈V (Q),vi 6=vj SDC(vi, vj)) plus the cumulative distance of all edge types against
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Figure 4.5: Calculating semantic threshold (ST) to be used during searches.
Note: Semantic subgraphs with semantic simplicities ranging from 0-1 were created
with five replicates for each point. The ST at which only the 100 spikes were returned
was determined. The algorithm was executed on random graphs with a node set size of
1 x 103 using two alternate parameters where (A) every element of the match needed to
pass the ST, and (B) all elements had to pass the ST cumulatively. When ST reached
0.8 the # mappings, not members of the spiked subgraphs, was reduced dramatically.
Subgraphs were created at random with node sets between three and six.
all edge types (
∑
ei,ej∈E(Q),ei 6=ej SDC(ei, ej)) divided by the total number of elements
(nodes plus edges) in the subgraph (|V (Q)| + |E(Q)|). For example, if Q contained
three nodes, of which all were of type Protein and six edges, of which all were simi-
lar_to then the SE score would be 1; the semantic types of elements in the subgraph
are the same for all nodes and the same for all edges. If however, the three node
semantic subgraph were made up Protein, Compound and Disease with three edges,
binds_to, involved_in and has_indication the SE score of this semantic subgraph
would be 0; all elements are semantically different and return scores of 0 when com-
pared using the SDC.
The SE allowed for the effects of altering the ST before a search to be investigated.
In Fig. 4.5 we can see that an ST of 0.8 allows for semantically similar mappings
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to be returned while also limiting these dramatically when comparing to other SEs.
Therefore, it was decided that an ST of 0.8 would be used as the default for searches
using DReSMin. It is also noted that the ST becomes increasingly important as the
SE is reduced; less spurious mappings are evident with an increased SE. An ST of 0.8
was, therefore, used during the characterisation and performance section.
4.4.3 Characterisation and performance
To characterise the performance of DReSMin random semantic target graphs (Ran) as
well as random semantic subgraphs were produced in order to evaluate the performance
of the semantic subgraph search strategy. These random graphs were formulated using
an approach that attempted to replicate the semantic and topological properties of the
integrated drug repositioning data set, Dat, described in Chapter 3. In these random
target graphs ∀v ∈ V (Ran) of type tv, the average deg−(tv) and the average deg+(tv)
were maintained ∀tv ∈ Tv(Dat).
For performance analysis, DReSMin was implemented on a 20 node Ivy-Bridge bioin-
formatics cluster. The SDC and graph-pruning step display linear running times of
O(n). The SDC was found to be capable of scoring 8 × 104 concept pairs per sec-
ond and the graph pruning step took < 1 second to prune a graph G, with |V (G)|
of 1 × 106. Furthermore, the effectiveness of each step of DReSMin was calculated
by adding each step (initial candidate set selection, topological pruning and semantic
distance thresholding) sequentially to the basic topological search algorithm and then
comparing the efficiency of each modified version to the VF2 topological search. The
performance was measured as the time taken for a complete search for a semantic
subgraph, Q, within a given target graph, G. Experiments were repeated 10 times and
presented in Fig. 4.9.
A comparison of the number of initial nodes used during a standard DReSMin search
and a semantic subgraph split search is presented in Fig. 4.6. In Fig. 4.6 it is shown
that when searching for subgraphs with a |V (Q)| of 3, the initial candidate set size
is around 36% lower when using a graph split approach as opposed to a standard
DReSMin search, when looking for the first split graph. It is also shown that the initial
candidate set is reduced, on average, by 5% after the first search in a split search is
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completed (the second search in a split search is started on 5% fewer nodes than the
first search). An analysis of search time and the number of mappings returned, when
using a standard DReSMin search compared to a semantic subgraph split search, is
also presented in Fig. 4.7, showing that the number of mappings returned using a graph
split search is identical to the number of mappings identified when using a standard
DReSMin search while a reduced search time is achieved. Furthermore, a comparison
of search time when using a topological, a standard DReSMin search and the semantic
subgraph split search for semantic subgraphs with a |V (Q)| of 7 is presented in Fig. 4.8.
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Figure 4.6: Initial candidate set sizes when using the graph split algorithm
compared to a standard DReSMin search. Target graphs were created at random
where |V (G)| ranged from 1× 104 and 1× 105. Semantic subgraphs with a |V (Q)| of
5 were created at random. A graph split search was then completed, which resulted
in two subgraphs with a |V (Q)| of 3 (D1 and D2). The initial candidate set size
for both of the split graphs were counted during the split graph search (‘SPLIT D1’
and ‘SPLIT D2’). A standard DReSMin search was then completed for both D1
and D2 and the initial candidate set counted and the average taken (‘STANDARD’).
Experiments were repeated 5 times.
The effect on search time when altering semantic subgraph edgeset size was also ex-
amined and is presented in Fig. B.1. It is shown that when searching for a semantic
subgraph with a |V (G)| of 4 and a |V (E)| edgeset of 6 DReSMin performs better than
when searching for a semantic subgraph with the same |V (G)| but with fewer edges.
To test the impact of target graph connectivity and target graph size on performance,
semantic subgraphs were created at random with a |V (Q)| of between 3 and 6 and
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Figure 4.7: Overview of the performance and accuracy of the graph split
algorithm compared to a standard DReSMin search. Semantic subgraphs were
created at random with a |V (Q)| of 5, 6 and 7. Target graphs were created at random
where |V (G)| ranged from 1 × 103 and 1 × 105. Semantic searches for the random
subgraphs were then completed using a standard DReSMin search and a graph split
search (both using an ST of 0.8). (A, C and E) The average time taken for a normal
search (grey) and a graph split search (red) to be completed. (B, D and F) The average
number of mappings found for each random subgraph (grey) and the difference in the
number of mappings returned by a normal search and a graph split search (red). (G)
Performance increase observed when using a graph split search in comparison to a
normal search for semantic subgraphs with a |V (Q)| of 5, 6 and 7.
searched for in the target network with i. altering graph connectivity and ii. altering
target graph node set size. The target network was then spiked with 100 of the semantic
subgraphs and searches repeated. It was shown that the number of mappings returned
before and after spiking of the target graph differed only by the number of spikes.
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Figure 4.8: Comparison of topological (Standard 0.0), non-split (Stan-
dard 0.8 GP) and graph splitting (Split GP) search times. Semantic sub-
graphs were created at random with a |V (Q)| of 7. A purely topological search was then
completed using the DReSMin algorithm (Standard 0.0). Semantic searches were then
carried out using graph prune, without semantic graph splitting (Standard 0.8 GP),
and finally, with the semantic graph splitting (Split GP). Searches were carried out
on random target graphs where |V (G)| was between 1 × 103 and 1 × 105. Note: GP
= graph prune was used.
4.5 Discussion
In this section the performance of DReSMin will first be discussed. Considerations for
future work will then be introduced before the approach is described in the context of
the drug repositioning field.
Fig. 4.9 shows each novel step of the algorithm reducing search time and highlights
some key observations regarding the performance of DReSMin. First, when looking
at the initial candidate set it is seen that once semantic subgraphs reach a |V (Q)|
of 4 then restricting the initial candidate set to include only Compounds improves
performance. It is at this point the benefits of reducing the initial candidate set
successfully reduce the search space, concomitantly increasing performance. A similar
phenomenon was observed with the introduction of the closed world check, whereby the
real performance benefits were apparent when semantic subgraphs reached a |V (Q)| of
4. By restricting the initial candidate set, as well as using the closed world assumption
a two-fold increase in performance in comparison to a purely topological approach was
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Figure 4.9: Overview of algorithm performance with semantic subgraph (Q)
queries node set |V (Q)| ranging from 3-5. (A) DReSMin performance when
searching for a semantic subgraph whose |V (Q)|=3. (B) DReSMin performance when
searching for a semantic subgraph whose |V (Q)|=4. (C) DReSMin performance when
searching for a semantic subgraph whose |V (Q)|=5. (D) Best performance of an
exact, exhaustive search using DReSMin for semantic subgraphs with a |V (G)| of
3,4,5,6 and 7 respectively. Abbreviations: VMAX = initial candidate set contained
the highest connected nodes in Q, regardless of the type, COMP = compound makes
up the initial candidate set, CW = closed world check implemented, SDC = semantic
distance calculator used during search, GP = semantic graph prune step implemented,
GS = graph split used.
observed. Performance was further enhanced when utilising the SDC, demonstrating
an almost three-fold performance boost when compared to the topological approach.
Furthermore, the semantic graph prune step introduced around a 50% increase in
performance to DReSMin. However, the graph prune step also introduced a further
subtle cost; any potential matches containing an element that scores < ST when
passed to the SDC are not returned. Semantic graph pruning is most useful when one
wishes to return matches that are semantically exact to the semantic subgraph being
used as Q, or when all elements of the match need to be above the ST (as opposed to
the average score of all elements having to be above the ST ).
When using all of the above steps as well as the graph split step of DReSMin the search
time for a semantic subgraph, Q, with a |V (Q)| of 6 can be reduced to one closer to
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the sum of a search for a subgraph with a |V (Q)| of 3 and a subgraph with a |V (Q)|
of 4. For example, when using the SDC to search for Q, where |V (Q)| = 6 in G when
|V (G)| = 1 × 105, takes 60 seconds (Fig. 4.7). Using the graph split method reduces
this search time to just under 14 seconds, a 4 fold increase in performance. This
observation is further supported by the data presented in Fig. 4.8 which demonstrates
that searching a target graph with a node set size of 2 x 103 for instances of a subgraph
with a |V (Q)| of 7 using a purely topological approach (Standard 0.0) is intractable.
The performance of the algorithm was improved when searching using a standard
DReSMin search with an ST of 0.8 (Standard 0.8 GP), however, when searching for
a semantic subgraph where |V (Q)| = 7 in a target graph where |V (G)| = 1× 105, still
takes 100 seconds. When using the graph split method during a DReSMin semantic
search with an ST of 0.8 (Split GP), a search for semantic subgraphs with a |V (Q)| of
7 could be completed on a large target graph (1 x 105) in just over 20 seconds. These
results show that the semantic graph splitting step, when used in conjunction with
the other steps in DReSMin, allows larger subgraphs to be used as queries which were
previously intractable using an exact exhaustive approach.
Although making use of the graph split step of DReSMin can enable an increase in
performance by dramatically reducing the search space investigated during a DReSMin
search (Fig. 4.6), some caveats must be discussed. Although the results presented in
Fig. 4.7 show that a graph split approach returns exactly the same mappings as those
achieved using a standard DReSMin search, there are potential situations where a
graph split approach would not return the same set of mappings as a standard search.
Firstly, there are two settings in which the DReSMin algorithm can be executed. The
first setting states all elements in a mapping must be greater than the ST (the setting
that has been investigated in this Chapter), whilst the second setting simply states
that the average score of all elements of a mapping must be above a the ST. The
performance analysis presented in Fig. 4.7 was done using the former setting. If a
graph split approach was to be run whereby the average score of elements had to
be greater than the ST then the graph split approach would not accurately capture
the same mappings that would be identified using a standard search, and in such
a situation would become a heuristic. The reason for this discrepancy is the fact
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that the split subgraphs will contain fewer elements, and so potential mappings of
large queries containing low scoring entities will be lost, with low scoring entities
affecting the average score of smaller graphs more than larger ones. Secondly, the
initial candidate set for a split search is populated with nodes from the target graph
that are semantically identical to the highest connected node in the query graph (i.e.
the same type). This will likely become a problem when the semantics of a graph
become more complex than those of Dat, described in Chapter 3 and used as the test
bed for the work presented in this Chapter. If the ON is of a type that has many
semantically similar types in the network then there are potentially many different
semantic types that could map to this node in any potential mappings. As a standard
search starts with nodes of type Compound, if a split search were to start on a different
node type in a more semantically complex network, mappings returned by a split
search and a standard DReSMin search would not be identical.
Perhaps counter intuitively, an improvement in performance was observed as the edge-
set size of a semantic subgraph also increased. The performance increase is likely due
to fewer nodes satisfying the more stringent topological rules. With more stringent
pruning during a run of the algorithm the search space at each state is reduced. A
reduction in search space means that a search involving a semantic subgraph with
more edges will take less time to complete in comparison to a semantic subgraph of
the same node set size but fewer edges.
Overall, when using all of the algorithmic steps in DReSMin, the algorithm showed
performance characteristics approximating a linear scale, close to O(n). The perfor-
mance of DReSMin is in contrast to the exponential scaling characteristics observed
for the purely topological search algorithm, VF2. Using DReSMin, with the previously
described hardware, it was possible to complete an exact, exhaustive search for a six-
node semantic subgraph in a target graph containing > 1.5 × 105 nodes in just over
14 seconds. It was also shown, as expected, that the accuracy of the algorithm (it is
exhaustive) does not decrease as the target graph connectivity, or |E|, increases or as
the target graph |V | increases. Although the performance of DReSMin is impressive,
there are still limitations to the approach that need to be discussed.
DReSMin scores semantics based on types of nodes and edges; it may also prove
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beneficial to include scoring metrics based on node and edge attributes as well as the
data sources from which they are retrieved. For example, during the process of data
integration, data sets could be assigned a quality score providing a measurement of
confidence in a given interaction or attribute. Such modifications would allow the
scoring of semantic subgraphs to be not only topological and semantic but also based
on the reliability of the source of each element.
As well as introducing additional scoring metrics to the approach the semantic sub-
graphs being searched for also require considerable thought. As described, these seman-
tic subgraphs can be drawn from real life repositioning examples via manual curation.
Manually developing semantic subgraphs is time-consuming, however, they may allow
for the creation of more accurate representations of a functional module representative
of a drug repositioning opportunity than those automatically developed. A library of
semantic subgraphs curated from real world examples of repositioned drugs would be
beneficial to the approach.
Concerning the mining algorithm, as new graph mining frameworks emerge with ef-
ficient graph searching algorithms (e.g. Neo4J), it may be possible to exploit these
built-in algorithms to implement sections of DReSMin. However, necessarily, the na-
ture of these implementations will depend on the specific graph database.
Unlike other approaches to drug repositioning, semantic subgraphs may be designed to
infer relations between any node types in a data set. DReSMin enables the discovery of
any relations that are captured in the abstracted drug-disease connection (as presented
in Fig. 2.1) so long as suitable semantic subgraphs are identified. This is in contrast to
many of the computational approaches to drug repositioning described in Section 2.2.2.
For example, ligand structure-based approaches as well as protein structure-based are
limited to the inference of drug-target associations; gene expression-based approaches
along with genetic variation-based approaches have been limited to the application
of the inference of drug-disease associations; similarly phenotype-based approaches
(including disease and side-effect) tend to be used for the inference of drug-disease
associations. Although machine learning based approaches, such as those described in
Section 2.2.2, tend to take a more integrative approach to data and, therefore, have
the ability to infer a wider range of associations and even properties, the fact that
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this is done using statistical ‘black boxes’ means that interpreting the repositioning
hypothesis is a difficult task. Using semantic subgraphs and DReSMin allows for
human interpretable hypotheses to be derived and for all evidence supporting a claim
to be judged. It is hoped that the systems approach described here will allow for a
more accurate, holistic, systematic approach to drug repositioning.
4.6 Conclusion
In this Chapter, a formalised framework for the definition of semantic subgraphs,
connected sub-components of a semantically-rich target network was developed. Iden-
tifying these subgraphs may aid in the inference of novel interactions not immediately
evident in the target network. DReSMin, an algorithm for searching integrated net-
works for occurrences of a given semantic subgraph using semantic distance thresholds
was also presented. DReSMin optimises the search time for larger subgraphs by in-
cluding a novel semantic graph pruning step and applying a method for splitting large
semantic subgraphs into a set of smaller subgraphs before searching. The optimisations
presented make searching for instances of complicated semantic subgraphs computa-
tionally tractable and scalable. Furthermore, the approach presented in this Chapter
is not limited to the field of drug repositioning. DReSMin can be used to search for
semantic subgraphs representing functional modules from any area of research, so long
as the graph properties described in Section 4.4 are maintained.
As described, future work would involve extending the algorithm to consider more than
the abstract semantic ‘types’ that the work presented supports. Furthermore, as graph-
based algorithms are implemented in well supported projects, it may prove beneficial
to utilise these, for example as a replacement for the topological searching steps in
DReSMin. Unlike other computational approaches to drug repositioning, DReSMin is
capable of inferring edges of any semantic type from an integrated semantic network.
To investigate the usefulness and utility of DReSMin in the field of drug reposition-
ing, the algorithm was used to search for relevant semantic subgraphs. First of all, in
Chapter 5, DReSMin is applied to the task of inferring novel D-T interactions; with the
top ranked associations used to infer novel uses for the drug. Secondly, in Chapter 6,
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DReSMin is used to enable the inference of novel Drug-Disease (Dr-D) associations
from a Gene-Disease (G-D) centric integrated network. It is shown in these exemplars
that DReSMin can be used successfully to identify and rank novel interactions. Fur-
thermore, in the case of D-T interaction inference it is shown that DReSMin is capable
of outperforming a state-of-the-art methodology developed purely for this purpose (as
opposed to DReSMin which can be applied to any area of interest).
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5.1 Introduction
Drug discovery has moved on from the once accepted ‘one drug, one target’ paradigm.
In fact, the therapeutic efficacy of many drugs, including psychiatric and modern
anticancer therapies are reliant on their ‘promiscuity’ [39, 161]. Drug promiscuity,
or polypharmacology, describes the property of a drug to act on multiple molecular
targets and exhibit distinct pharmacological effects [39].
The first association in the drug-target-phenotype-disease pathway (described in
Fig. 2.1) is between a drug and its target. Prediction of these Drug-Target (D-T)
associations plays a pivotal role in the drug discovery process [162]. Inference of such
associations allows for novel uses of a drug to be identified as well as potentially ad-
verse side-effects to be highlighted [163, 164]. In vitro approaches to determining D-T
interactions are no different to other aspects of drug development and remain costly
and time-consuming [162, 165]. It is infeasible to screen all drugs manually against
all genes in the human genome (over 21,000), and so automated computational ap-
proaches are desired [39]. Using systematic in silico prediction methods allows for the
D-T interaction search space to be reduced, highlighting areas of focus [164]. Many
computational approaches have been described to aid in this task and are introduced
below.
Molecular docking methodologies are heavily applied to D-T interaction prediction.
These methods aim to give a prediction of the drug-target (or ligand-receptor) com-
plex structure using computational methods [166]. However, molecular docking ap-
proaches require a significant amount of computational resources, are time-consuming
and are known to return high numbers of false positives [165]. Other approaches in-
volve the application of machine learning, which may use a feature vector approach
(see background) or, more commonly, similarity-based approaches which exploit the
similarity between drugs and proteins [162, 165]. Similarity-based approaches allow
for the production of predictive models, and such approaches can be ligand-similarity-
based, target-similarity-based, or a hybrid of the two [167]. For example, ligand in-
formation may be used to create models that learn which sub-structural features of
a ligand correlate with activity against a particular target [168]. Other similarity-
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based approaches make use of a network, or more specifically a bipartite graph, data
representation [164, 165, 169–171]. Within a bipartite graph, nodes are divided into
two disjoint sets, proteins and drugs. Data from multiple publicly accessible data sets
are integrated during the construction of these networks [172]. However, in most ap-
proaches to D-T interaction prediction, data is limited to the inclusion of the two data
types; drugs, and their targets. Limiting data to these two types can restrict accurate
prediction of D-T associations. As such, there is a belief that drug discovery may be
improved by taking a systems approach, considering the interaction of existing drugs
with target proteins as well as other biological molecules [93]. Protein targets, which
make up the majority of drug targets, can be categorised into multiple classes.
The majority of current primary drug targets are: (1) membrane-bound proteins (in-
cluding G protein-coupled receptors (GPCR) and ion channels); (2) enzymes (including
kinases and proteases); and (3) nuclear hormone receptors [37, 64]. Membrane-bound
proteins account for 60% of drug targets [39], with approximately 40% of all marketed
drugs said to target a GPCR [173]. Although GPCR make up only 4% of the hu-
man genome, the prominent role they play in many pharmacological processes means
they represent the most abundant class of validated pharmacological targets [136].
Ion channels are popular targets for pharmacological intervention with high potential.
However, due to the plethora of physiological activities controlled by ion channels, drug
development in this area remains challenging, with many drugs targeting this class dis-
playing poor selectivity, suboptimal efficacy and even significant toxicity [174]. Like
the membrane-bound proteins, enzymes, such as kinases and proteases, also make up a
large proportion of drug targets [136]. One of the largest families of evolutionarily re-
lated proteins are the protein kinases which make up around 2% of the human genome.
Kinases are highly conserved, involved in many cellular processes and comprise 20%
of putative D-T associations [175]. Proteases make up 5-10% of targets being pursued
in drug development [176]. Of the target classes introduced GPCR and ion channels
are well investigated, with an abundance of information available to describe their
actions and properties [177]. However, others, such as kinases, have less specific data
available (the term specific is used here as there is an abundance of data regarding
kinases because they are oncology targets, but most is general).
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In the work described in this Chapter, the utility of Drug Repositioning Semantic
Mining (DReSMin) was demonstrated, with a focus on the inference of novel D-T as-
sociations. Using the drug repositioning data set, Dat, a method for the automated
identification of 194 semantic subgraphs is presented. Furthermore, the semantic sub-
graphs were then used to infer novel potential D-T interactions from the same data
set, using DReSMin. Central to the approach described is the use of historical D-T
data. Dat includes D-T interactions from DrugBank v2.5 and so more recent versions
of DrugBank data sets were utilised in this work (version 3 for the creation of semantic
subgraphs and version 4.2 for validation). It was shown that DReSMin could be suc-
cessfully used to predict putative D-T interactions that were not explicitly represented
in the Dat and that cover multiple protein target classes. Furthermore, the potential
value, to the drug repositioning field, of inferences made by the approach can be in-
vestigated as and when they are made, as opposed to the future. The work presented
in this Chapter has also been described in Mullen et al. [146].
5.2 Materials and methods
The integrated drug repositioning data set, Dat, introduced in Section 3.4.1 was
used as the target network for this work. A Java implementation of DReSMin,
as described in Chapter 4, was used for searching Dat for instances of seman-
tic subgraphs. A semantic threshold of 0.8 was used during searches (see Sec-
tion 4.4.2). All analysis code was written in a Java Maven project and is available
for download, along with scored D-T associations and scored semantic subgraphs from
https://bitbucket.org/ncl-intbio/dresmin. To determine the shortest semantic paths,
Dat was converted to an undirected graph and a Java implementation of Dijkstra’s
shortest path algorithm [160], from the JGraphT1 library used. Three versions of
DrugBank were used in this work; 2.5, 3.0; and 4.22.
Mappings between DrugBank and ChEMBL compounds were retrieved from
UniChem [133] via whole source mapping3. UniChem maps chemical identifiers from
1www.jgrapht.org
2 www.drugbank.ca/downloads/archived
3www.ebi.ac.uk/unichem Accessed:22-06-2015
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multiple sources if they share the same Standard InChI. The mapping from UniChem
provides a set of 3,765 drugs that are contained in both data sets, of which 57 of the
ChEMBL ids mapped to >1 DrugBank ID (one to four, five to three, and 51 to two).
For each drug that DReSMin inferred D-T associations for, the top 100 protein target
predictions were extracted from the ChEMBL Web resource client4.
As the approach described in this chapter is exhaustive, it is not enough to simply
count the number of true positives identified as a means of validation. It was, there-
fore, important to identify a statistical test that evaluated the ability of the approach
to ‘prioritise’ these knowns. One such approach is the hypergeometric distribution, a
discrete probability distribution. The hypergeometric distribution describes the prob-
ability of k successes in n draws without replacement, from a finite population of size
N that contains exactly K successes, wherein each draw is either a success or a failure.
During validation, inferred interactions were first ranked based on the scores that they
achieved. Using a sliding window of x interactions, the phyper function (from the
statistical computing language ‘R’) was then used (lower.tail set to false) to calculate
the P [X > x] at each position of the sliding window. The P [X > x] represents the
probability of identifying more true positives than were actually observed at a given
position in the ranked list. By using this measure, it was possible to evaluate the
ability of the approach to consistently score known D-T interactions more favourably.
For target class comparison, five human protein target classes were identified based on
their sizes and importance, as described by [136]. Proteins were classified as one of the
following: GPCR; ion channels; kinases; proteases; and other. To do this, the same
approach described by [136] was used. Protein family membership was determined
using multiple protein sources. The first is the ID attribute of a keyword (k) element
within a UniProt5 entry, E. All keywords assigned to E are captured in the set K.
If “KW-0297” in E (K ) then E is classed as a GPCR; if “KW-1071”, “KW-0851”,
“KW-0107”, “KW-0869”, “KW-0407”, “KW-0631” or “KW-0894” is in E (K ) then E is
classed as an ion channel; if “KW-0418”, “KW-0723” or “KW-0829” is in E (K ) then E
is classed as a kinase; if “KW-0031”, “KW-0064”, “KW-0121”, “KW-0224”, “KW-0482”,
4www.github.com/chembl/chembl webresource client Accessed:22-06-2015
5www.uniprot.org Accessed:30-07-2015
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“KW-0645”, “KW-0720”, “KW-0788” or “KW-0888” is in E (K ) then E is classed as a
protease; and finally all other proteins are classed as ‘other’. A protein is also classified
as a GPCR, kinase or protease if it appears in the UniProt GPCR6, kinase7 or protease8
family files, respectively.
5.3 Results
An approach to identify novel D-T associations from an integrated target network was
developed as part of this project. The approach is made up of three main components
which are: (i) Automating the development of semantic subgraphs (ii) Mining an in-
tegrated net drug repositioning network, Dat , for instances of the semantic subgraphs
and (iii) Ranking inferred interactions. Furthermore, the ability of the approach to
identify novel D-T associations was evaluated in four aspects, comprising: (i) A com-
parison of the inferences made to those made by a state-of-the-art method for D-T
association prediction (ii) A comparison of the ability to infer associations involving
numerous target (protein) classes was carried out (iii) One of the highest ranked D-T
inferences is presented and used to complete the drug-target-disease pathway to enable
repositioning hypotheses to be identified and finally (iv) The effect instance informa-
tion had on the approach was also investigated. Central to the approach described in
this section is the availability of historical DrugBank data.
5.3.1 Managing DrugBank data
DBv2.5 was used to construct Dat even though later releases of DrugBank are avail-
able; v3.0 (DBv3) and v4.2 (DBv4.2) [127]. D-T interactions from DBv2.5 that were
integrated into Dat were retrieved and captured in the set DatRel. DBv3 contains
additional drugs, targets and their interactions to those contained in Dat (Table 5.1)
with 8,768 additional D-T interactions. Of these interactions, 2,919 involve drugs
and targets that are present in Dat, but the interaction relationship had not yet been
defined (i.e. the D-T interaction had not been annotated in DBv2.5).
6www.uniprot.org/docs/7tmrlist.txt Accessed:11-11-2015
7www.uniprot.org/docs/pkinfam.txt Accessed:11-11-2015
8www.uniprot.org/docs/peptides.txt Accessed:11-11-2015
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Table 5.1: Drug, target and drug-target (D-T) interactions present in Dat, DBv3 and
DBv4.2.
Drug Target D-T Interaction Unique Relevant
Dat (DBv2.5) 4,772 3,037 9,227 - -
DBv3 6,180 4,080 14,570 8,768 2,919
DBv4.2 6,377 3,601 14,157 8,673 2,940*
Note: Unique: refers to interactions not found in Dat, Relevant: subset of Unique
interactions, whereby both the drug and target can be found in Dat. *Of these 333
are unique to DBv4.2 (i.e they are not captured in DBv3).
The 2,919 interactions from DBv3 are referred to as being ‘relevant’ as they are of
interest to the work. These relevant interactions are represented in the set DBv3Rel
(Equation 5.1) and were used to derive a query set of semantic subgraphs that were
in turn used to mine Dat. DBv4.2 was then used as a reference to validate the new
repositioning opportunities identified through the mining of Dat.
DBv3Rel = {DatRel ∪ Unique(DBv3) | d ∈ DatRel(d) ∧ t ∈ DatRel(t)} (5.1)
Table 5.1 shows 2,940 D-T associations from DBv4.2 as being ‘relevant’. These relevant
associations are unique to DBv4.2 (in comparison to DBv2.5) whilst also being made
up of a drug and a target that is captured in Dat. Furthermore, of these 2,940 D-T
associations, 333 interactions are not captured in DBv3. These 333 associations are
represented in the set DBv4Rel (Equation 5.2) and are used in this work to validate
inferred D-T associations.
DBv4Rel = {(DatRel ∪ Unique(DBv4.2)) ∩DBv3Rel | d ∈ DatRel(d) ∧ t ∈ DatRel(t)}
(5.2)
5.3.2 Automating the development of semantic subgraphs
Semantic subgraphs can be derived through manual exploration of the graph and by
reference to known repositioning examples. However, in this work, semantic subgraphs
were derived using an automated method. These semantic subgraphs are appropriate
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Figure 5.1: Semantic subgraphs were derived from the semantic shortest
paths between a drug and a target pair captured in DBv3Rel (A) A drug-
target interaction captured in DBv3Rel made up of a drug (D1) and a target (T1) that
are both present in the network, Dat. To create semantic subgraphs D1 and T1 are lo-
cated in Dat (highlighted in green in (B)) and the semantic shortest paths between the
two nodes calculated (highlighted in red in (B)). Finally, all semantic node types and
edge types that fall on the semantic shortest path are used to create a query graph (C).
Note: Dashed red line represents the inferred binds_to relations, square represents a
Compound, circle a Target, diamond a Protein and hectagon a Disease. For relation
types: bi to = binds_to, sim = similar_to, h s s = has_similar_sequence.
for systematic mining for new D-T interactions. To produce such a set, portions of
the Dat network that contained drugs and targets from the 2,919 D-T interactions
captured in DBv3Rel were extracted. To extract the subnetworks, each drug and
target pair was identified in Dat and the subnetwork represented by the shortest path
between them was extracted as a semantic subgraph (Fig. 5.1).
On carrying out the semantic subgraph identification exercise, 194 different subgraphs
with a |V | >10 were found cumulatively to identify more than 95% of the D-T in-
teractions in DBv3Rel. The 194 semantic subgraphs were used as queries to search
Dat using DReSMin to test the ability of the algorithm to identify D-T interactions
in Dat that had not yet been annotated in DBv2.5 (but are present in DBv3). The
ten subgraphs that represent the shortest path between the most D-T associations in
DB3Rel, as well a larger illustrative subgraph, are shown in Fig. 5.2. Furthermore,
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Figure 5.2: Examples of semantic subgraphs drawn from the semantic short-
est paths. Q1 -Q10 are drawn from the semantic shortest paths that represented the
shortest path between the greatest number of D-T interactions in DBv3Rel and Q108
is an example of a more complex semantic subgraph. Note: Dashed red lines repre-
sent the inferred binds_to relations, a square represents a Compound, circle a Target,
diamond a Protein and octagon a Diseases. For relation types: bi to = binds_to,
sim = similar_to, h s s = has_similar_sequence, ma tr = may_treat, inv in =
involved_in and is a = is_a.
eight randomly selected subgraphs from the set of 194 are introduced and described
below.
5.3.2.1 Automated semantic subgraphs in a biological context
In this section, eight randomly selected semantic subgraphs (created using the semantic
shortest path approach described in Section 5.3.2) will be presented and analysed
in a biological context. Each semantic subgraph will be evaluated based on their
likely ability to capture a functional semantic sub-component containing potential
D-T associations. Semantic subgraphs were ranked based on the number of D-T pairs
in DB3Rel (Equation 5.1) for which they represent the semantic shortest path. It
is this ranking position that is used to name the semantic subgraphs. For example,
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subgraph Q1 represented the semantic shortest path for the most D-T pairs in DB3Rel
(687) and subgraph Q194 represented the semantic shortest path for the least D-T
pairs in DB3Rel (1).
Target
TargetCompound
bi_to
h_s_s
h_s_s
bi_to
Q1
Figure 5.3: Q1, a three node semantic subgraph created using the semantic
shortest path. Dashed red line represents the inferred binds_to relations, square
represents a Compound and circle a Target. For relation types: bi to = binds_to and
h s s = has_similar_sequence.
Subgraph Q1, shown in Fig. 5.3, shows a three node semantic subgraph derived using
the semantic shortest path approach. This subgraph represented the semantic short-
est path for 687 D-T pairs in DB3Rel. This simple triad is similar to the subgraph
described in Fig. 4.2, which makes use of the ‘similar properties principle’ (SPP) [52].
The SPP states that similar molecules should have similar biological activities, af-
fecting proteins and biological systems in similar ways [52]. Instead of looking at the
similarity between compounds, subgraph Q1, makes inferences using the assumption
that targets with similar sequences will bind the same compound. There exists a mul-
titude of computational approaches to drug repositioning that make use of protein
similarity to make novel drug inferences (described in Section 2.2.2.3). It is, therefore,
quite reasonable to assume that similarity measures between targets can be used as a
means of inferring novel D-T associations.
Subgraph Q4, shown in Fig. 5.4, shows a four node semantic subgraph derived using
the semantic shortest path approach. This subgraph represented the semantic shortest
path for 252 D-T pairs in DB3Rel. This subgraph uses the assumption that if a drug
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Figure 5.4: Q4, a four node semantic subgraph created using the semantic
shortest path. Dashed red line represents the inferred binds_to relations, square
represents a Compound and circle a Target. For relation types: bi to = binds_to.
binds to two targets then these targets are likely similar, or at least possess similar
binding sites. Although target proteins will likely possess more than one small molecule
binding site, the number of these that are ‘useful’ in a therapeutic context is often one.
These ‘useful’ binding sites, however, are likely to interact with several compounds.
Although the assumption made by this subgraph may not hold true in protein targets
with a great number of binding sites, it would for those that have a single target
site. Therefore, inferences made using this subgraph have the potential to unveil some
interesting potential D-T associations.
Subgraph Q6, shown in Fig. 5.5, shows a four node semantic subgraph derived using
the semantic shortest path approach. This subgraph represented the semantic shortest
path for 130 D-T pairs in DB3Rel. Like, subgraph Q1 (Fig. 5.3), this subgraph makes
inferences using the assumption that targets with similar structures will bind the
same compounds. Unlike Q1, however, which makes one similarity ‘step’, Q6 assumes
that this assumption will hold as more similarity steps are added, in this instance
two. As the number of similarity steps from the original target to the novel target
increases, the likelihood that these two targets share a similar sequence decreases,
making the assumption that the sequences are still highly similar less likely. It may be,
however, that binding site domains, or other structurally important domains relevant
to a proteins ability to bind a compound are maintained as extra similarity steps are
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Figure 5.5: Q6, a four node semantic subgraph created using the semantic
shortest path. Dashed red line represents the inferred binds_to relations, square
represents a Compound, circle a Target and diamond a Protein. For relation types:
bi to = binds_to and h s s = has_similar_sequence.
added, meaning that subgraphs that make use of these extra steps may still be able
to make some interesting inferences that may be missed by semantic subgraphs that
use a single similarity step.
Compound
Compound
Target
Disease
ma_tr bi_to
ma_tr
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Q9
Figure 5.6: Q9, a four node semantic subgraph created using the semantic
shortest path. Dashed red line represents the inferred binds_to relations, square
represents a Compound, circle a Target and hectagon a Disease. For relation types:
bi to = binds_to and ma tr = may_treat.
Subgraph Q9, shown in Fig. 5.6, shows a four node semantic subgraph derived using
the semantic shortest path approach. This subgraph represented the semantic shortest
- 123 -
Chapter 5: Application of DReSMin to the identification of novel drug-target
interactions
path for 70 D-T pairs in DB3Rel. This subgraph makes D-T inferences using the
assumption that drugs used to treat the same disease also bind to the same target.
This is a bold assumption, and likely not true, especially in multigenic disorders that
tend to have a more complex genetic causation, such as Crohn’s. The assumption,
may, however, hold true in less complex disorders, that tend to be more monogenic
in causation. Cystic fibrosis, for example, is caused by the presence of mutations in
both copies of the gene for the cystic fibrosis transmembrane conductance regulator
(CFTR) protein. Treatments for Cystic Fibrosis, tend to focus on the CFTR, such as
ivacaftor plus lumacaftor (Orkambi; Vertex) [10]. Therefore, in certain situations, this
semantic subgraph may be useful for the purpose of D-T interaction prediction.
Target
h_s_s
bi_to
h_s_s
Target
Compound
Compound
bi_to
Q27
Target bi_to bi_to
Figure 5.7: Q27, a five node semantic subgraph created using the semantic
shortest path. Dashed red line represents the inferred binds_to relations, square
represents a Compound and circle a Target. For relation types: bi to = binds_to and
h s s = has_similar_sequence.
Subgraph Q27, shown in Fig. 5.7, shows a five node semantic subgraph derived us-
ing the semantic shortest path approach. This subgraph represented the semantic
shortest path for 11 D-T pairs in DB3Rel. This subgraph makes assumptions using
the logic captured in two previously introduced subgraphs: (1) the assumption that
targets or proteins with similar sequences are likely to bind the same compounds, as
described in subgraph Q1 (Fig. 5.3); and (2) the assumption that if a drug binds to
two targets they are similar, as captured in subgraph Q4 (Fig. 5.4). Like subgraph
Q4 (Fig. 5.4), the serious limitation of this subgraph is the fact that some protein
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targets are known to have multiple ligand binding sites. It is possible, therefore, that
CompoundX may bind TargetY at BindingSiteA, whilst CompoundZ may bind the same
protein at BindingSiteB, in which case the inference made would be incorrect. In the
instances where this subgraph identifies protein targets with single binding sites, or
at least where compounds are binding to the same binding site, inferences are more
likely to be meaningful. It can, therefore, be seen that this subgraph may be able to
unveil novel D-T associations.
TargetDisease
bi_to
Target
Compound Target
bi_to bi_to
sim
inv_ininv_in
bi_to bi_to simbi_to
Q36
Target Compound Compound Compound
Figure 5.8: Q36, a nine node semantic subgraph created using the semantic
shortest path. Dashed red line represents the inferred binds_to relations, square
represents a Compound, hectagon a Disease and circle a Target. For relation types:
bi to = binds_to, sim = similar_to and inv in = involved_in.
Subgraph Q36, shown in Fig. 5.8, shows a nine node semantic subgraph derived using
the semantic shortest path approach. This subgraph represented the semantic shortest
path for six D-T pairs in DB3Rel. Like subgraph Q4 (Fig. 5.4), this subgraph makes
the assumption that if a drug binds to two targets these targets are likely similar. It
also uses the SPP, which states compounds with similar structure will affect proteins
in similar ways [52]. Finally, the subgraph makes the rather adventurous assumption
that if two targets are involved in the same disease then they are likely similar (sharing
properties associated with their ability to bind compounds). Although this may hold
true somewhat in certain cancers, where numerous kinases (a target class known to be
highly conserved) have been linked to their pathogenesis and progression [178], it is
simply not the case in many other diseases. Diseases such as the autoimmune disor-
der, multiple sclerosis, have a variety of different target proteins associated with their
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development, such as proteins that make up the major histocompatability complex
and various interleukin receptors, to name but a few [179]. Due to the fact that this
semantic subgraph makes so many assumptions, it is probably not the most accurate
representation of a sub-component containing putative D-T interactions.
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Figure 5.9: Q74, a four node semantic subgraph created using the semantic
shortest path. Dashed red line represents the inferred binds_to relations, square rep-
resents a Compound, hectagon a Disease and circle a Target. For relation types: bi to
= binds_to, ma tr = may_treat, has pa = has_parent and inv in = involved_in.
Subgraph Q74, shown in Fig. 5.9, shows a four node semantic subgraph derived using
the semantic shortest path approach. This subgraph represented the semantic short-
est path for two D-T pairs in DB3Rel. Q74 makes D-T association inferences using
the assumption that parent diseases have similar targets associated with them when
compared to their child diseases (parent and child in terms of their position in the
MeSH hierarchy). Although this may be the case in variations of similar, less com-
plex, disorders, it will very rarely be the case in more complex multigenic disorders.
It can be seen that the logic behind this semantic subgraph will hold true only in rare
situations.
Finally, subgraph Q140, shown in Fig. 5.10, shows a four node semantic subgraph
derived using the semantic shortest path approach. This subgraph represented the
semantic shortest path for one D-T pair in DB3Rel. Q140 makes D-T association
inferences by combining multiple assumptions. First of all, like Q1 (Fig. 5.3), this
subgraph uses the assumption that targets with similar structures will bind the same
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Compound
Target
Target
Protein
bi_to
h_s_s
Protein
BioProc
Q140
h_s_s
bi_to
has_par
has_par
h_s_s
h_s_s
Figure 5.10: Q140, a four node semantic subgraph created using the se-
mantic shortest path. Dashed red line represents the inferred binds_to relations,
square represents a Compound, diamond a Protein, circle a Target and V a Biologi-
cal_Process. For relation types: bi to = binds_to, h s s = has_similar_sequence
and has par = has_participant.
compounds. It then makes the valorous assumption that proteins involved in the same
biological process will be structurally similar, before making use of the assumption
that targets with similar structures will bind the same compounds once more. Being
involved in the same biological process does not necessarily mean structural similarity
between proteins. Although, functionally, the proteins will be similar it is a large
assumption to state that because of this proteins will likely bind the same compounds.
Individually, some of the semantic subgraphs created using the automated approach
described here may not, upon closer inspection, appear to be the best biological rep-
resentation of sub-components relevant to D-T interaction prediction. It can be seen,
however, that in certain situations they may be able to make interesting inferences
with varying numbers of false positives. It was, therefore, important to develop scor-
ing metrics that considered the inferences made by all semantic subgraphs, but that
also penalised inferences that were made by semantic subgraphs that identified great
numbers of false positives. The metrics used during this approach are described next.
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5.3.3 Ranking inferred interactions
After an exhaustive search of Dat with the 194 semantic subgraphs a set of mappings
(or instances) of each subgraph was identified. It is in these mappings that inferred D-T
interactions are captured. To score inferred interactions, it was first necessary to score
the semantic subgraphs whose mappings capture the potential interactions. Scoring
of a semantic subgraph, Q, was achieved by determining the number of known D-T
interactions in the predicted total set of D-T interactions inferred by Q. The complete
set of inferred interactions was referred to as Q(I ). A score, RS, was calculated based
on the ability of Q to identify D-T interactions captured in DBv3Rel (Equation 5.1).
RS(Q) =
|Q(I) ∩DBv3Rel|
|Q(I)| (5.3)
Once RS is calculated for each semantic subgraph, individual D-T interactions, i,
are scored based on the cumulative score of all semantic subgraphs whose mappings
predicted i. This score, RD(i), allows for interactions to be ranked.
RD(i) =
∑
i∈Q′(I)
RS(Q′) (5.4)
DReSMin is an exhaustive algorithm, as such, scoring inferred interactions allows for
ranking, with those ranked higher inferred with greater confidence than those ranked
lower.
5.3.4 Mining using DReSMin
A search of Dat with the set of 194 semantic subgraphs described above resulted in
906,152,721 mappings. These mappings capture the potential drug target interac-
tions in the structure of the mapping subgraph. The 906,152,721 mappings predicted
9,643,061 D-T interactions. Semantic subgraphs were scored on their ability to iden-
tify D-T interactions captured in DBv3Rel using Equation 5.3 (see Fig. 5.11A), with
these scores ranging from 0.0 to 0.06589 (Fig. 5.12). A single D-T interaction, i,
can be inferred by mappings of more than one query semantic subgraph, thus adding
confidence to the prediction that a D-T interaction exists. Therefore, to rank the D-T
- 128 -
Chapter 5: Application of DReSMin to the identification of novel drug-target
interactions
A B
DBv3Rel Q1 Q1  (RS = 0.29) 
Q2  
(RS = 0.13) 
RS (Q1) =      = 0.29 RD (i1) = (0.29 + 0.13) = 0.42
   
i1
2
7
Figure 5.11: Semantic subgraph (A) and individual D-T interaction (B) scor-
ing. (A) A semantic subgraph, Q1, is scored by dividing the size of the intersection
of its inferred associations and those captured in DB3Rel (2) by the total number of
inferences captured in mappings of Q1 (using Equation 5.3). (B) An individual D-T
interaction, i, is scored by summing the scores of all semantic subgraphs whose map-
pings inferred i1 (using Equation 5.4). Note: squares represent drugs, circles represent
proteins and dashed red lines represent inferred D-T interactions.
interactions in terms of confidence, the scores assigned by all query semantic subgraphs
that produced a mapping containing a potential D-T interaction were summed using
Equation 5.4 (see Fig. 5.11B). The
∑
Rq of the scores of all 194 query semantic sub-
graphs was 0.9499 (Fig. 5.12) and so inferred D-T interaction scores contained within
mappings could potentially, range from 0.0 to 0.9499, with the higher the score, the
greater the confidence in the prediction.
Unsurprisingly, the interactions from DBv3Rel that were used to create the semantic
subgraphs are identified. Importantly, however, these interactions score highly, which
indicates that a single interaction was identified by multiple semantic subgraphs. The
D-T interactions from DBv3Rel consistently scored better and ranked higher than
the unsupported inferred associations (Fig. 5.13A and Fig. 5.13B). It was also ob-
served that the D-T interactions subsequently annotated and captured in DBv3Rel
are identified, on average, by two-fold the number of semantic subgraphs that infer
D-T associations not present in DBv3Rel (Fig. 5.13C).
However, to quantify the predictive power of DReSMin the number of high scoring
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Figure 5.12: Distribution of semantic subgraph scores. Boxplot shows the dis-
tribution of semantic subgraph scores, with the mean score captured as a red diamond
(0.005). The scatterplot shows individual scores, with the higher scoring subgraphs
(those with a score above 0.15) labelled in red; these labels correspond to the name
assigned to the semantic subgraph.
D-T predictions that were subsequently annotated in DBv4.2 was investigated. These
333 new interactions had not been used to construct the semantic subgraphs used for
searching Dat. Of the 333 D-T interactions captured in DBv4Rel, 309 were successfully
identified in the set of inferences made by DReSMin (94%). A high ranking and
scoring of the 309 D-T interactions from DBv4Rel that were successfully identified
by DReSMin is also observed (Fig. 5.13D and Fig. 5.13E). The average number of
semantic subgraphs that have mappings inferring the 309 annotated D-T associations
captured in DBv4Rel is increased >4 fold in comparison to the number of semantic
subgraphs that produce mappings that infer interactions not captured in DBv4Rel
(Fig. 5.13F).
Looking in more detail at the top 20 inferred D-T interactions (Table 5.2) 12 different
drugs and eight targets are presented. Drugs include: three antiarrhythmic calcium
channel blockers (verapamil, mibefradil and bepridil); three phenothiazine antipsy-
chotic agents (promazine, perphenazine and thioridazine); three atypical antipyschotic
agents (propiomazine, clozapine and quetiapine); two anticonvulsants (zonisamide and
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levetiracetam) and one antiarrhythmic adrenergic beta-antagonist (propranolol). It
can be seen that in the top ranked D-T interaction inferences, the 12 drugs captured
are involved in, on average, 13 D-T interactions in Dat. Such a high number of D-T
interactions is in contrast to the average for all drugs in Dat, which is closer to three.
The contrast highlights the fact that the top 20 inferred D-T interactions involve drugs
that are well studied and highly annotated.
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Figure 5.13: Validation of inferred D-T associations with known D-T associ-
ations from DBv3 and DBv4.2. (A), (B) and (C) show how DReSMin identifies
and ranks the 2,919 known interactions from DBv3 when searching Dat. (D), (E)
and (F) show how DReSMin identifies and ranks the 333 known interactions from
DBv4.2. For (A) and (D) hypergeometric distribution of inferred knowns was cal-
culated using the scores of the validated associations. All inferred D-T interactions
were grouped based on their association scores and association scores were ranked in
ascending order, shown on the x axis. Hypergeometric calculations were made at in-
tervals of 1,000 association scores. The -log10 probability of identifying more knowns
than were observed at this point (P [x > X]) is shown on the y axis. For (B) and
(E) hypergeometric distribution of inferred knowns was calculated using the ranked
position of the validated interactions. All inferred D-T interactions were ranked from
highest scoring interaction (Rank pos = 1) to lowest scoring interaction (Rank Pos =
9,643,061), shown on the x axis. Hypergeometric calculations were made at intervals
of 10,000 associations. The black line shows the -log10 probability of identifying more
knowns than were observed at this point (P [x > X]) (left y axis) whilst the red line
shows the score of the associations (right y axis). (C) and (F) show the number of
semantic subgraphs that inferred knowns in comparison to the number of semantic
subgraphs that inferred novel interactions. Note: Blue line shows the highest scoring
semantic subgraph; all scores above this line are inferred by more than one semantic
subgraph.
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Targets include four voltage-dependant calcium channels (VDCCs) and four G-Protein
coupled receptors (GPCRs). VDCCs display selective permeability to calcium (Ca2+)
ions which enter a cell through the pore formed by the a1 subunit when the receptor
is activated. Three sub-types of VDCC are represented in Table 5.2, being: L-type
(CAC1C and CAC1D); P/Q Type (CAC1A) and N-type (CAC1B). Members of the
GPCR superfamily in Table 5.2 include receptors activated by the neurotransmitters:
serotonin (5HT7R and 5HT2B); epinephrine (ADA1A) and dopamine (DRD1).
5.3.5 Drug-target interaction prediction evaluation
The ranked set of predicted D-T interactions were then compared to those produced by
another state-of-the-art method for drug target interaction prediction - a ligand-based
method. One implementation of such an approach is provided by ChEMBL9 [180, 181].
ChEMBL provides two models for target prediction, using bioactivity data with a cut-
off of 1 micromole (µM) and 10µM respectively. These models allow for n predicted
interactions to be made for a given drug. Inferred interactions are also scored and
ranked, allowing for a direct comparison to DReSMin. Predictions using the ChEMBL
models can be found in compound report cards, accessed via their website.
DReSMin inferred D-T associations for 2,223 drugs common to both DrugBank and
ChEMBL. In the comparison presented in Fig. 5.14, only D-T interaction inferences
involving this set of 2,223 drugs are considered. For each of the drugs, the top 100 D-T
associations involving single proteins were identified using the ChEMBL Web resource
client10. The set of inferences from DReSMin contained a total of 2,456 protein targets
(of which 1,133 are from Homo sapiens and 1,323 from other organisms). The set of
ChEMBL inferences involves 870 human protein targets, of which 362 are also captured
in DReSMin inferred D-T associations.
Any interactions which were already caught in Dat, involved targets from organisms
other than humans or were not captured in the overlapping 362 protein targets, were
excluded from the analysis. This process was repeated for both the 1µM and the 10µM
ChEMBL models, giving two sets of predicted D-T associations. For a fair comparison
9www.ebi.ac.uk/chembl
10www.github.com/chembl/chembl webresource client Accessed:22-06-2015
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to be made for each of the 2,223 drugs the top x 11 inferred single protein targets
were collated and ranked. This process resulted in three sets of 215,075 ranked D-T
interactions; DReS, Chem1 and Chem10.
First, the number of D-T interactions predicted by both methods (co-prediction) was
examined using interactions captured in the sets DReS, Chem1 and Chem10. 35% of
the top x D-T interactions inferred by DReSMin are found in the top x D-T inter-
actions predicted by ChEMBL models (Fig.5.14A and Fig. 5.14B). More interestingly
DReSMin successfully infers 10% more of the knowns from DBv4Rel than ChEMBL,
for both models (Fig.5.14C and Fig. 5.14F). It was found that DReSMin was able to
rank the known D-T interactions more effectively than ChEMBL, with a mean ranking
position of known D-T interactions from DBv4rel of 16,977, as opposed to the 47,618
achieved by ChEMBL (47,746 for 1µM model and 47,490 for 10µM model). It is im-
portant, however, to point out that the semantic subgraphs used during this work were
derived using DrugBank data and the ChEMBL models trained on ChEMBL data.
5.3.6 Target class comparison
After classifying all human proteins in Dat, the following were identified: 826 GPCRs;
343 ion channels; 638 kinases; and 560 proteases (Table 5.3). Interestingly, when
analysing the average connectivity of the target classes in Dat (Table 5.3), it can be
seen that the kinase class has, on average, the most associated edges. Not surprising
given their evolution, kinases have by far the greatest number of has similar sequence
edge types in Dat. More interesting is the fact that kinases have the least binds to
edges in Dat when compared to the other target classes.
Of the 9,643,061 D-T interactions inferred by DReSMin, 4,780,935 (49.6%) involve hu-
man protein targets. Within these associations, there are 103 GPCRs; 85 ion channels;
89 kinases; 60 proteases; and 782 ‘others’. Fig. 5.15A shows how the target classes de-
fined are represented in the inferences made by DReSMin. 89% of proteins are classed
as ‘other’, and make up the targets in 69% of the human protein inferences. GPCR’s
make up only 4% of all human proteins and yet are involved in nearly 10% of all human
inferences. Only 3.2% of human proteins are classed as kinases, yet these are captured
11x=100 or, if DReSMin inferred <100 targets for this drug, x=number of DReSMin inferred targets
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Figure 5.14: DReSMin inferred D-T associations in comparison to those
inferred using the ligand-based similarity models provided by ChEMBL.
Top graphs, (A), (B) and (C), show comparison to those using the 1µM model from
ChEMBL and bottom graphs, (D), (E) and (F), show comparison with the 10µM
model. (A) and (D) show the % crossover between the top-ranked x associations from
each method for each drug. (B) and (E) show the comparative ranking of the 2,919
known D-T interactions from DBv3Rel. (C) and (F) show the comparative ranking of
the 333 known D-T interactions from DBv4Rel. In (B), (C), (E) and (F) red diamonds
show the mean ranking and numbers in red show the number of knowns captured by
each method. Only associations inferred by the 2,223 drugs with a mapping between
DrugBank and ChEMBL and those that contain the overlapping set of target proteins
are included in the comparison.
in 7.9% of all human inferences. Proteases make up 2.8% of human proteins and are
shown to be part of 5.4% of all DReSMin inferences involving human proteins. Finally,
ion channels make up 1.7% of human proteins and are contained in 7.4% of all human
predicted D-T associations.
Ion channels make up the second smallest set of comparative inferences, behind only
proteases. However, 5.15A shows that this class is inferred by, on average: the highest
scoring predictions (using Equation 5.4); the highest ranked inferences; and the most
semantic subgraphs per inference. Second are the GPCRs, followed by proteases,
‘others’ and, finally, kinases.
5.15B shows how highly ranked the D-T interactions captured in DBv3Rel are ranked
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Figure 5.15: Target class distribution in Dat. Human proteins in Dat were as-
signed to one of five target classes: kinases; ion channels; G protein-coupled receptors
(GPCR); proteases; or other. (A) % of the total set of human proteins assigned to
each class (Percent HUMAN), what % of all DReSMin inferred associations contained
a protein target from that class (Percent INF), the % of the unique targets inferred by
DReSMin that were from that class (Percent nrINFTARGS) and the % of the human
target class for which an inference was made (Percent CLASS). (B) How the known
associations captured in DBv3Rel were ranked in the DReSMin inferred D-T interac-
tions, with 1 being the highest ranked association. Note: Sets of numbers above each
class in (A) represent how the target class ranked in performance in comparison to
the other classes in the following measures: the average score of inferred interactions;
the average ranking of inferences for that class; and the average number of semantic
subgraphs that made an individual inference for that class. One represents the best
performing target class and five the worst.
in each of the classes. D-T associations captured in DBv3Rel are ranked highest for
GPCRs, followed by: ion channels; proteases; other; and kinases. Known associations
from all classes are, on average, ranked in the top 6% of all inferred associations.
5.3.7 Completing the drug-target-disease pathway
The highest ranked D-T interaction identified by DReSMin, with a score of 0.49211,
is supported by the literature and, therefore, known to the scientific community [182].
This D-T interaction is between one of the antiarrhythmic calcium blockers, vera-
pamil, and the Voltage-dependent L-type calcium channel subunit alpha-1C, CAC1C.
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Table 5.3: Frequency and connectivity of target classes in Dat.
Target Class Dat Freq. ¯Connectivity ¯bi to ¯h s s Mapping Freq.
GPCR 826 33.45 (4) 8.08 (1) 11.53 (5) 103
Ion Channel 343 49.78 (2) 4.46 (2) 36.97 (2) 85
Kinase 638 74.38 (1) 2.66 (5) 54.55 (1) 89
Protease 560 41.41 (3) 3.97 (3) 14.59 (4) 60
Other 19,974 33.06 (5) 3.47 (4) 14.60 (3) 782
Note: Connectivity is rounded to 2 d.p. Brackets show ranks for the classes. bi to =
binds_to, h s s = has_similar_sequence.
Within Dat eight indications are associated with verapamil and 12 diseases associated
to CAC1C. One indication, hypertension, shares a has_Indication edge with vera-
pamil and an edge of type involved_in with CAC1C. Although verapamil is already
used to treat hypertension, and the inferred D-T interaction already known, it can be
observed that DReSMin may be used to help understand the molecular mechanism
of a drug and thus complete the ‘drug-target-disease’ pathway. Understanding the
molecular mechanisms of drugs can aid the identification of repositioning opportuni-
ties. In Fig. 5.16 examples of unsupported, and, therefore, novel, DReSMin inferred
D-T interactions that allow the understanding of molecular mechanisms involved in a
drug’s ability to treat a disease are shown.
A
Hypertension
Bepridil
B
CAC1C Perphenazine
Schizophrenia
5HTR7
C
Quetiapine
Schizophrenia
5HTR7
Figure 5.16: Drug-target-disease pathways completed via inferred D-T as-
sociations. Data presented is extracted from Dat with one association extracted
from the literature. Note: Dashed lines represent the inferred binds_to relations,
zig-zag lines represent has_Indication relation not captured in Dat and extracted
from literature [183], squares represent compound, circles target and octagon diseases.
Like verapamil, bepridil is also a calcium channel blocker with known antiarrhythmic
activities and has been used as a treatment for hypertension. Table 5.2 shows an
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inferred D-T association involving bepridil and CAC1C. Bepridil is one of the two drugs
from Table 5.2 that have been withdrawn from the market due to safety concerns, and
as such bepridil is not a strong candidate for repositioning. However, using the inferred
association involving bepridil, a better understanding of the molecular mechanism of
the drugs use as a treatment for hypertension (Fig. 5.16A) can be achieved.
Dat captures three indications for quetiapine (Psychotic Disorders, Bipolar Disor-
ders and Autistic Disorders) and three involved_in associations involving 5HT7R
(Schizophrenia, Pain and Muscular Diseases). Although not captured in Dat, queti-
apine is approved for the treatment of Schizophrenia. By integrating this knowledge
with Dat and the DReSMin inferred associations another drug-target-disease path-
way (Fig.5.16C) can be completed. Although Schizophrenia, along with many other
diseases, is classified as a psychotic disorder, the inferred knowledge enables a better
understanding of drug-target-disease pathways in more specific disease areas.
Propranolol One inferred D-T interaction in Table 5.2 involves the antiarrhythmic
adrenergic beta-antagonist, propranolol, and the GPCR, D(1A) dopamine receptor,
DRD1. Dat captures 12 indications for propranolol and 17 disease associations for
DRD1, with Hypertension captured as both an indication for propranolol and an asso-
ciated disease for DRD1 (Fig. 5.17). Of the remaining 16 involved_in edges involving
DRD1 five of the diseases represent known off-label indications for propranolol: Bipo-
lar disorders; Psychotic Disorders (particularly Schizophrenia); Alcoholism; and as
a non-stimulant treatment for ADHD [184]. The remaining 11 diseases present and
support some interesting repositioning opportunities for propranolol.
Three of the 11 potential indications of propranolol proposed using inferences made by
DReSMin are currently being investigated by the scientific community through various
clinical trials. Dat contains an association between DRD1 and cocaine-related disor-
ders, with multiple clinical trials being undertaken to analyse the use of propranolol as
a treatment for cocaine addiction [185] as well as cocaine cravings [186]. A trial look-
ing at the use of propranolol as a treatment for Autism is also, at the time of writing,
recruiting [187]. Finally, a clinical trial has also been undertaken to investigate the
effects of using propranolol as a treatment for drug-induced movement disorders [188].
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Pheochromocytoma 
Tachycardia Ventricular
Essential Tremor
Hypertension Portal
Heart Failure
Myocardial Infarction 
Anxiety Disorders
Bipolar Disorder
Hallucinations
Alcoholism
Autistic Disorder
Hypotension
Catelepsy
Movement Disorders
Alzheimer Disease
Attention Deficit Disorder with 
Hyperactivity 
Dyskenisia Drug Induced
Cocaine Related Disorders
DRD1
Huntington Disease
Schizophrenia
Substance Related Disorders
Pyschotic Disorders
Amphetamine Related Disorders
Hypertension
Tachycardia supraventricular
Panic Disorder
Propranolol
Angina Pectoris
Esophageal and Gastric Varices
Figure 5.17: Diseases associated with Propranolol and DRD1 in Dat . Drug-
disease has_Indication edges involving propranolol and gene-disease involved_in
edges were extracted from Dat. Note: Dashed lines represent the inferred binds_to
edges, squares represent compound, circles target and octagon diseases.
DReSMin inferred D-T interactions allow for the prediction of repositioning opportu-
nities that are currently being investigated in the clinical setting.
After removing currently investigated indications, eight potentially novel uses for pro-
pranolol are inferred, including: Amphetamine-Related Disorders; Alzheimer Disease;
Catalepsy; Dyskinesia Drug Induced; Hallucinations; Huntingdon Disease; Hypoten-
sion; and Substance-Related Disorders. As previously mentioned, propranolol is used
to treat high blood pressure, Hypertension. It is, therefore, unlikely that propranolol
will prove a useful treatment for low blood pressure or hypotension. Hypotension
would only be exacerbated through the administration of propranolol. Studies have
shown that propranolol may be helpful as a means of controlling the aggressive be-
haviour associated with patients in the advanced stages of the disease Huntingdon
Disease [189]. Although no clinical trials are currently underway, work on cell cultures
has investigated the effect of cardiovascular drugs, such as propranolol on the prime
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target for Alzheimer’s prevention, amyloid β peptides [190]. These peptides are of
interest as it has been shown that decades before the onset of dementia this small pro-
tein accumulates in clumps in the brain. The work carried out in [190] demonstrated
that propranolol (as well as nicardipine) exert in vitro amyloid β- lowering activity and
supports an interesting hypothesis that can be made via the approach that propranolol
may be used as a treatment for Alzheimers.
5.3.8 Instance information
A single D-T association, i, can be inferred by multiple mapping instances of the
same semantic subgraph Q. The number of these instances is not considered during
the approach described previously, where the score of Q is added to the sum score
of i regardless of the number of instances of Q that predict i. The effect of instance
information on the scoring and ranking of D-T interactions inferred by DReSMin was,
therefore, investigated (Fig. 5.18). Instead of scoring i using the sum of the scores
of the semantic subgraphs that inferred that i, instance information also multiplies
individual semantic subgraph scores by the number of mappings that inferred i. For
example, if i was inferred via 34 mappings of semantic subgraph Q, which achieved a
RS(Q) (see equatp ion 5.3) of 0.1, Q would account for 0.1 of RD(i) (using equation
5.4). Considering instance information, Q would account for 3.4 of RD(i) (0.1× 34).
Using instance information, D-T interaction scores ranged between 0.0 - 624.13. An
unsupported interaction between the approved small molecule atorvastatin (DB01076 )
and the GPCR Histamine H1 receptor (P35367 ) identified is ranked top and identi-
fied by the greatest number of mapping instances, 1,750,194. The same interaction
is ranked 60,615 when instance information is not considered. When comparing the
ability of the standard approach to prioritise knowns (Fig. 5.13) in comparison to an
approach that considers instance information (Fig. 5.18), some notable differences can
be observed. It was noted that instance information performed poorly in comparison
when looking at the probability of higher scores identifying more of the knowns. Un-
surprisingly, it was also shown that when comparing the ability of the approaches to
rank the knowns higher than the unknowns, the standard approach outperformed an
approach considering instance information. Finally, there is little difference between
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Figure 5.18: Validation of inferred D-T associations, ranked using instance
information, with known D-T associations from DBv3 and DBv4.2. (A), (B)
and (C) show how DReSMin identifies and ranks the 2,919 known interactions from
DBv3 when searching Dat. (D), (E) and (F) show how DReSMin identifies and ranks
the 333 known interactions from DBv4.2. For (A) and (D) hypergeometric distribution
of inferred knowns was calculated using the scores of the validated associations. All in-
ferred D-T interactions were grouped based on their association scores and association
scores were ranked in ascending order, shown on the x axis. Hypergeometric calcu-
lations were made at intervals of 1,000 association scores. The -log10 probability of
identifying more knowns than were observed at this point (P [x > X]) is shown on the
y axis. For (B) and (E) hypergeometric distribution of inferred knowns was calculated
using the ranked position of the validated interactions. All inferred D-T interactions
were ranked from highest scoring interaction (Rank pos = 1) to lowest scoring interac-
tion (Rank Pos = 9,643,061), shown on the x axis. Hypergeometric calculations were
made at intervals of 10,000 associations.The black line shows the -log10 probability
of identifying more knowns than were observed at this point (P [x > X]) (left y axis)
whilst the red line shows the score of the associations (right y axis). (C) and (F) show
the total number of instances of semantic subgraph mappings that inferred knowns
in comparison to the total number of instances of semantic subgraph mappings that
inferred novel interactions.
the average number of mapping instances that identify validated D-T interactions and
the number that identify those that are not validated. Such a small difference between
the number of mappings that identify validated and non-validated D-T interactions
was not observed in the standard approach, where the number of subgraphs that in-
fer the validated associations is significantly higher than the number inferring D-T
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interactions that are not validated.
5.4 Discussion
DReSMin can identify known D-T interactions regardless of the class to which the
target belongs. It was shown that kinases are the highest connected class in Dat.
Kinases represent a highly conserved protein class and as such contain a large number of
associations describing their structural similarities. Conversely, kinases have the least
amount of data regarding known interactions with drugs. Known D-T associations
involving GPCR and ion channels fall, on average, in the top 2% of inferred D-T
interactions. Although known D-T associations involving other classes, such as kinases
are still, on average, captured in the top 6% of all DReSMin inferred D-T associations;
the approach does favour target classes where there exists a relatively high amount
of drug interaction information. The methodology presented makes use of the holistic
view of an entity, and so if less is known about a target it will be captured in fewer
semantic subgraphs, and thus D-T interactions that it is predicted to be involved in
will obtain a lower score. As more and more data is produced for target classes, such
as proteases and kinases, bias in the approach will also be reduced.
DReSMin is able to prioritise known D-T interactions, however, for inferences made to
be useful to drug repositioning, there are still some limitations that must be discussed.
These restrictions are introduced here with some examples provided.
First of all, DReSMin infers an interaction between dexrazoxane (DB00380 ) and dacti-
nomycin (DB00970 ) and the Sodium channel protein type 1 subunit α (P35498 ). The
Sodium channel protein type 1 subunit α target is located predominantly in the brain
and is heavily associated with epilepsy [191, 192]. To reach the brain, a drug must
cross the Blood-Brain Barrier (BBB). Multiple drugs, such as dexrazoxane and dacti-
nomycin [193], are restricted by their pharmacokinetics and are unable to cross the
BBB and so this inference is unlikely to highlight any realistic repositioning opportu-
nity.
Secondly, DReSMin infers D-T interactions involving drugs from a range of marketed
statuses. Examples include drugs that have been withdrawn as they are not as effec-
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tive as first thought, such as drotrecogin alfa (DB00055 ) in the treatment of sepsis, or
due to poor sales, such as halazepam (DB00801 ). These represent interesting candi-
dates for repositioning. Drugs that have been withdrawn from the market for reasons
involving safety concerns prove a more problematic repositioning opportunity. Some
examples are included in DReSMin inferences, such as drugs that have been withdrawn
from the market due to potentially fatal side-effects, such as: metamizole (DB04817 );
grepafloxacin (DB00365 ); and temafloxacin (DB01405 ).
Protein similarities are calculated by doing an all against all BLAST using Protein
sequences captured in Dat. Only those similarities with an E-value of less than 1e-4 are
included in Dat as an edge of type has_similar_sequence(see Table A.2). Perhaps a
more stringent protein similarity cut-off could be used to ensure paralogs; as already
mentioned kinases can appear very similar but may have very different functions.
Finally, DReSMin inferred an association between domperidone (DB01184 ) and the
Beta-1 adrenergic receptor (P08588 ). Heart palpitations are a known side-effect of
domperidone and Beta-1 adrenergic antagonists, such as propranolol have been ad-
ministered to those suffering heart palpitations. It can, therefore, be deduced that
domperidone may have some agonistic action upon the Beta-1 adrenergic receptor.
With these examples in mind, other properties must be considered in further exten-
sions to the approach. Drug properties, such as pharmacokinetics, in relation to the
target location, must be considered, as well as the implementation of a pre-filtering
step to remove all drugs from the search that are likely to be unsafe. Post-filtering of
results based on the likelihood of a D-T interaction prediction leading to a potential
side-effect would also be a useful addition and would need to consider a drugs action
(be it an agonist, antagonist, etc.).
When comparing DReSMin to other state-of-the-art D-T prediction methods an aver-
age co-prediction of 35% is observed. Although this still leaves a large proportion of
unique inferences, it is shown that DReSMin inferences identify >16% of the knowns
when using DBv3, and >10% of the knowns when using DBv4, in comparison to
ChEMBL. The ability of DReSMin to identify more of the knowns than ChEMBL
supports the approach and provides evidence that it produces an improved prediction
set. After directly comparing and contrasting the results it was found that DReSMin
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outperformed the ChEMBL models at inferring annotated DrugBank D-T interac-
tions. Considering DReSMin is a general algorithm, not specifically developed for the
inference of D-T interactions, this highlights its potential. Although the semantic sub-
graphs used to search Dat were derived from the shortest paths between a drug and
target from D-T interactions in DBv3, these interactions were inferred, on average,
by around 40 different semantic subgraphs; in contrast to the 15 semantic subgraphs
that inferred D-T interactions not captured in DBv3. Again, the fact that known
interactions are captured by a far greater number of semantic subgraphs than those
not in DBv3 further validates the approach employed during this work. Annotated
D-T interactions were not only captured by the semantic subgraph derived from the
semantic shortest path between their drug and target but also by many more semantic
subgraphs.
5.5 Conclusion
In this Chapter, an approach for the identification of novel D-T interactions using
DReSMin was introduced. A set of 194 relevant semantic subgraphs were derived from
the semantic shortest paths between known D-T and subsequently searched for in Dat.
Mining resulted in the identification of 9,643,061 potential D-T interactions which were
then scored and ranked before being validated against more recent DrugBank data sets.
It was shown that these inferred D-T interactions can be used to identify novel drug
repositioning leads, while also supporting repositioning investigations currently being
undertaken. Comparison of the approach described with other dedicated, state-of-
the-art D-T prediction methods also positively highlighted the potential of the work.
Furthermore, it was shown that instance information does not provide as accurate an
inference set as the ‘typical’ approach described.
Like the DReSMin algorithm, the approach presented in this Chapter, including se-
mantic subgraph development and inferred edge scoring, is not limited to the drug
repositioning setting. Although the data set and historical data used here were spe-
cific to drug repositioning, the approach is generic enough to enable the prediction of
edges from any data set providing relevant historical data sets are available.
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Regarding drug repositioning, future extensions of the work would require more focus
on ensuring a satisfactory drug candidate set as well as post-filtering of likely irrational
predictions. Examples of irrational predictions have been previously described and
include: those that involve drugs that are unable to reach their predicted target (such
as targets that require a drug to cross the BBB); predictions that involve drugs that
have failed to reach the market or have been withdrawn from the market due to safety
concerns; and predictions that involve a drug likely to exacerbate a condition (i.e. a
disease is caused by a Loss of Function (LoF) mutation and the drug inferred is an
antagonist). Furthermore, semantic subgraphs should be expanded to not only include
semantic types but also include properties that may be relevant to research question
being asked.
Considering the limitations of the approach described, it would be beneficial to consider
filtering potential side-effects from an inference set. As well as filtering likely side-
effects it would also be beneficial to include, where possible, information regarding
a drug’s action, i.e. is the drug an agonist or an antagonist? These limitations are
considered in the approach presented in Chapter 6 where ranked Gene-Disease (G-D)
associations are integrated with other relevant drug repositioning data. The resulting
data set is then mined using a predefined semantic subgraphs and DReSMin to identify
novel Drug-Disease (Dr-D) indications. In the approach described in Chapter 6, the
DReSMin algorithm is extended to include attributes and a means of filtering potential
side-effects is described.
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6.1 Introduction
Prediction of novel Drug-Disease (Dr-D) associations can be achieved by ‘filling in’ all
the blanks between a drug and a disease in the drug-target-phenotype-disease pathway
(described in Fig. 2.1). Target-based approaches to drug discovery (see Fig. 2.1B)
focus on identifying links between targets and their associated diseases, in the hope
that identifying these links will allow for completion of the drug-disease pathway. As
such, understanding the molecular mechanisms of diseases is vital within the field of
target-based drug discovery.
A causal association between a gene target and a disease describes a situation where
a gene is directly or indirectly responsible for disease risk via one or more mecha-
nisms [194]. Monogenic disorders, such as Huntington’s disease, are identified simply
through the presence, or absence, of single gene mutations; in this case a mutation
in the Huntingtin protein, HTT [195]. Conversely, multigenic, or complex, disorders
are caused by multiple genetic variants, which may affect pleiotropic genes and be
influenced by various environmental factors [196]. Due to the complexity of multi-
genic diseases, allele associations are more probabilistic and less deterministic; the
presence of a high-risk allele may only mildly increase the chance of disease [196] [197].
For these reasons identifying causal links between a gene and disease experimentally
is expensive and time-consuming. Association studies, however, identify disease sus-
ceptibility variants that do not necessarily mean the variant is important in disease
causation and instead are associative— present as a consequence of the disease state
as opposed to being responsible for causing the disease state. It is an easier task
to identify susceptibility Gene-Disease (G-D) associations as opposed to causal G-D
associations [198].
The shift to large-scale sequencing of individual genomes and the availability of new
techniques for probing thousands of genes provide new means for identifying these
susceptibility G-D associations (from here in G-D associations will refer to associative
associations as opposed to causal associations). Experimental techniques such as po-
sitional cloning and/or microarray analysis can return tens to hundreds of candidate
genes [98]. Managing and integrating these data has thus become an important task
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within bioinformatics, and numerous G-D databases have been developed to aid this.
Entries in databases are mainly obtained through manual curation of the biomedical
literature [199]. To capture data that may have been missed by manual curation of
the literature, automated text mining approaches can also be used [124]. Although
automated text mining approaches improve recall, precision is drastically reduced in
comparison to manual extraction. Genetic associations can also be extracted directly
from experimental data, such as Genome-Wide Association Studies (GWAS), and
stored in dedicated databases. Furthermore, predictive methods may also be used
to populate databases identifying associations through statistical inference, including
cross-species inferences derived from animal models. Mouse and rat models have been
used to predict human G-D associations for many years, and there exists a wealth
of cross-species G-D association data available [200–202]. Cross-species models can
be complicated by diverse types of phenotype representations in terms of physiolog-
ical and anatomical differences between species. However, this knowledge cannot be
ignored [203]. To create a state-of-the-art view of current knowledge regarding G-D
associations, integration of these heterogeneous data sources is required.
A holistic view of the field allows for emergent properties that would otherwise be in-
visible to be realised [204]. Efforts such as DisGeNET [205, 206] and MalaCards [207],
already integrate associations from multiple primary resources that have been curated,
predicted and derived computationally from the text. DisGeNET applies a system-
atic scoring to these associations. However, the chosen metric fails to give a relative
view of known G-D associations. A complete ranking of G-D associations from pri-
mary resources, taking into consideration the reliability of each data set using current
knowledge, would allow inevitable bias present in data sets, that were all developed for
different purposes, to be reduced. Furthermore, an exhaustive ranking of G-D associ-
ations would also aid tasks such as computational target-based drug discovery [208],
Despite historically being discovered via phenotypic approaches [5], target-based ap-
proaches to drug discovery came to prominence after sequencing of the human genome.
It was believed that target-based drug discovery would allow for a more rational ap-
proach to drug design, and thus increase research and development (R&D) success and
productivity [5, 209]. Target-based approaches are still heavily prominent and exten-
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sively used in the pharmaceutical industry [210], with successes including the tyrosine
kinase inhibitors imatinib (Glivec; Novartis) and gefitinib (Iressa; AstraZeneca) [211].
Overall, due to increased costs and reduced productivity, there is a general acceptance
that the current state of R&D needs to change [14]. Part of the solution, in the short
term, is drug repositioning which is described in detail in Chapter 2.
In this Chapter, an exhaustive, novel approach for identifying new uses for existing
drugs, with a focus on G-D associations is introduced. A Bayesian statistics approach,
developed by Lee and colleagues [212] is utilised for the purpose of integrating and
ranking G-D associations captured in 10 primary data sources. These scored G-D
associations, which provide a state-of-the-art view of G-D knowledge, are then in-
tegrated with other biological entities to produce a semantic network, GenDat, for
target-driven drug repositioning. A method for the automated detection of thera-
peutic areas of interest is also introduced. Finally, a four-node semantic subgraph
(semantic subgraphs are formalised in Section 4.2.1) is introduced, and instances of
this are identified in GenDat, using Drug Repositioning Semantic Mining (DReSMin),
described in Chapter 4. Novel Dr-D interactions inferred from the integrated network
are then ranked, with those involving diseases from the therapeutic area of interest
discussed in more detail. The work presented in this Chapter has also been described
in Mullen et al. [213].
6.2 Background
6.2.1 Gene-disease association databases
Several existing primary databases focus on G-D associations. These databases typi-
cally contain associations obtained through manual curation of the biomedical litera-
ture. One well-established source of G-D associations is the Online Mendelian Inheri-
tance in Man (OMIM) database [121]. More recent projects include the Comparative
Toxicogenomics Database (CTD) [131] and UniProtKB [214]. Another source, Or-
phanet [215], focusses primarily on rare diseases and orphan drugs. Databases pop-
ulated with associations extracted directly from the literature, using text mining ap-
proaches, also exist [199], such as BeFree [124] and SemRep [216]. Although the
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accuracy of automatically extracted associations is lower than manually curated data,
the systematic approach to their construction means they are more inclusive of true
positives.
BeFree [124] provides a good example of a text mining resource. BeFree, along with
supporting statements and provenance is available for download and uses the EU-ADT
and GAD corpora to extract associations from the text. Focussing on a subset of ab-
stracts returned from PubMed, BeFree uses their own query (only querying about 3
% of current MEDLINE databases). After applying filtering, BeFree captures 330,888
associations involving 13,402 genes and 10,557 diseases [124]. SemRep [216] also pro-
vides text mined associations. Like BeFree, SemRep provides G-D, drug-disease and
drug-target associations, but unlike BeFree has been designed to identify a large va-
riety of semantic predictions. When using the same corpus as BeFree, SemRep has a
higher precision but a lower recall [124]. Other approaches to collecting G-D associa-
tions involve cataloguing data directly from genetic experiments (such as GWAS), or
inferring associations from animal models.
Over the last decade, GWAS have produced data on thousands of Single-Nucleotide
Polymorphisms (SNPs). These SNPs are associated with the risk of hundreds of dis-
eases. Originally developed as a means to identify causal SNPs, GWAS data are
non-trivial to work with; they identify marker SNPs that are often simply associative
SNPs as opposed to causal SNPs. The assignment of SNPs to associative genes is
often difficult due to factors such as the SNPs being present in regulatory regions.
Furthermore, GWAS data only contains associations derived from a subset of diseases
for which genetic studies have been conducted. As with any exercise in data collection,
the data captured in data sources may be biased, depending on the intended purpose
of the data. Bias is especially true of GWAS data [217], which is particularly biased
to diseases such as Crohn’s disease that are of interest to the industry. Neverthe-
less, GWAS data are available for download via the GWAS catalogue [122]. The Rat
Genome Database (RGD) [201] and the Mouse Genome Database (MGD) [200] provide
G-D associations that have been identified in animal models but are statistically in-
ferred to represent human associations. One limitation of the various G-D association
data sets is the lack of associations annotated with the gene functionality associated
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with the disease state (i.e. Gain of Function (GoF) or Loss of Function (LoF)).
6.2.2 Controlled vocabulary of diseases
Before working with G-D associations, it is important to determine a standardised
representation of both genes and diseases. Due to work completed by the Human
Genome Organization (HUGO) Gene Nomenclature Committee (HGNC), it is a fairly
straightforward task to identify a strict representation of human genes [218]. To iden-
tify a satisfactory disease representation is more complicated since there are numer-
ous disease classifications and ontologies competing with one another. These disease
classifications are designed for different purposes and are mutually inconsistent. Con-
sequently these are poorly integrated with each other. One example is the Disease
Ontology (DO) [219] which is part of the Open Biomedical Ontologies (OBO) Foundry
Initiative. The DO has extensive cross-referencing. However, the DO maps poorly to
diseases captured in data sets such as DisGeNET. Another example comes is the Sys-
tematized Nomenclature of Medicine-Clinical Terms (SNOMED-CT) which cross maps
to several revisions of the International Classification of Diseases— used in the clinical
setting [208]. SNOMED-CT is one of the many terminologies that is combined with
the even broader Unified Medical Language System (UMLS) Metathesaurus. UMLS
contains many distinct concepts that are very close in meaning, and as a result, even
human annotation using UMLS concepts is problematic [220]. Finally, the Medical
Subject Headings (MeSH) is a comprehensive controlled vocabulary displaying a hier-
archical data structure [120]. MeSH was developed for the purpose of indexing journal
articles and books in the life sciences and like SNOMED-CT is also combined with the
UMLS Metathesaurus.
Identifying a standardised disease representation is a current challenge for large-scale
disease data integration which aims to gather a comprehensive coverage of disease to
enable systematic interoperability across biomedical domains [124].
6.2.2.1 MeSH therapeutic areas
The MeSH hierarchy contains 16 top-level categories, each assigned a letter descriptor.
For example, the Disease top-level category is assigned the letter C. Underneath these
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top-level descriptors are more specific MeSH codes which describe more specific areas
in the categories. For example, there are 26 MeSH codes in the C category. C06, for
example, is used to capture digestive system diseases. Terms become more specific as
depth in the hierarchy increases— C06.405.205.731.500, for example, is the entry for
Crohn Disease. Furthermore, three concepts of the F top-level category (Psychiatry
and Psychology) also describe diseases; F01 (behaviour and behaviour mechanisms),
F02 (psychological phenomena and processes) and F03 (mental disorders). This leaves
29 top-level categories in MeSH that can be used to define therapeutic areas.
6.2.3 Calculating disease similarities
Although alot ‘cleaner’ than UMLS, the MeSH hierarchy is more verbose than dis-
ease representations such as the DO. As such, the specificity of terms is a potential
problem. Two diseases may be synonymous yet captured in multiple parts of the tax-
onomy. In order to quantify the semantic similarities of two terms in the hierarchy
ontology-based similarity measures may be used. Ontology-based similarity measures
may be structure-based (e.g. path length, depth of concept or LCS (lowest common
subsumer)) or content-based, whereby a corpus of terms is used, and information
content is analysed). One example of a structure-based similarity measure is that de-
veloped by Leacock and Chodorow [221]. This measure is used to quantify the distance
between two instances in an ontology or hierarchy. Although originally developed to
measure the distance between nouns in WordNet, an electronic lexical database [221],
the method has previously been applied to MeSH [222].
6.2.4 Ranking disparate data
Gold standards are used as a reference point for many approaches to predictive and
scoring methodologies due to the belief that they offer superior quality to other sources
of similar data. For areas whereby a gold standard does not exist, such as the G-D
setting, this set becomes subjective to the field of use and the task at hand. Different
approaches exist for ranking disparate data; some do not use a gold standard, such as
that described by Weile and colleagues [223], and some that do utilise a gold standard,
like the work completed by Lee and co-workers [212]. The approach described by
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Lee and co-workers make use of a log-likelihood score (LLS), which is calculated for
each data source that is to be integrated using the gold standard. The LLS score
can be interpreted as the likelihood of a linkage (or association) existing conditioned
on the given evidence and corrected for background expectations of linkages. By
cumulatively summing the LLS score from each data set that contains an association
a confidence score can be assigned to an association. Furthermore, these LLS scores
can be summed using a D parameter. This parameter allows for higher weighting to
be given to data sets with a higher LLS— facilitating dependencies between the data
sets. Division of the score by a computed D parameter means that, while the highest
score is integrated unchanged, subsequent LLS scores are progressively down-weighted.
Down-weighting subsequent LLS scores are particularly relevant to G-D associations,
whereby it is standard practice primarily to populate a database with associations from
other curated sources before extending it (CTD, Orphanet and UniProt all collect a
subset of associations captured in OMIM).
6.2.5 Graph model
To view G-D associations in the biological context, it is important to define a data
structure that will aid in this task. Graph representations of complex systems are
widely used in computer science, social and technological network analysis, and is es-
pecially relevant to many studies in bioinformatics [96]. Semantically-rich networks,
which implement a graph-based representation, are ideal for representing integrated
data [144]. In semantic graphs, each edge (or relation) and vertex (or node) are as-
signed a single type from a predefined set to describe their meaning semantically. In
such a representation, node v1 may represent cGMP-specific 3’,5’-cyclic phosphodi-
esterase and is assigned the type Protein, while node v2 represents sildenafil and is
thus assigned the type Small_Molecule. If v1 is a known target of v2, this interaction is
captured in a directed edge, e1, of type binds_to. Nodes and edges of semantic graphs
may also be annotated with attributes. For example, a node of type Small_Molecule
may be annotated with a Group attribute that would be used to describe whether
the drug was approved, investigational or withdrawn. Furthermore, an edge of type
binds_to could indicate that a drug binds to a particular target with attributes of
- 154 -
Chapter 6: Identification of novel uses for drugs with focus on gene-disease
associations
type Activity Type and Activity Value used to describe the type of activity, such as
IC50, Kd, Ki or Potency and the associated activity value, such as 1nM, respectively.
6.3 Materials and methods
An implementation of DReSMin, described by Mullen et al. [146] (and in Chapter 4),
was used in the work presented in this Chapter. The algorithm was extended to
allow for attribute comparison and implemented. GenDat was built using the Drug
Repositioning Network Integration Framework (DReNInF) (as described in Chapter 3).
A Java implementation of the structure-based ontology measure developed by Lee and
colleagues [212] was completed as part of this work.
G-D associations included were taken from all four database types as previously de-
scribed (curated, experimentally derived, literature derived, and those inferred from
animal models), to reduce bias in the integrated set. G-D associations were extracted
from the sources listed in Table 6.1. Only G-D associations that contained diseases
mappable to MeSH Unique Identifiers (UIs) were included in the work. The map-
ping between UMLS R© Concept Unique Identifiers (CUIs) and MeSH was done us-
ing the Metathesaurus R© and was used for associations captured in BeFree, CTD
and SemRep. In SemRep associations were extracted between gene and disease that
were of the following predicates: AFFECTS; ASSOCIATED WITH; AUGMENTS;
CAUSES; PREDISPOSES; COEXISTS WITH and NEG ASSOCIATED WITH as
described in [124]. Next, all 2,208 mappings present between OMIM and MeSH iden-
tifiers were extracted from ORDO. This set of mappings was extended to 3,967 using a
manually curated mapping set of 3,029 (with overlap). The mapping between OMIM
and MeSH was then used to parse associations captured in MGD, OMIM and UniProt.
For G-D associations in GWAS, a manually curated mapping between 1,131 GWAS
traits and MeSH UI was used with a threshold of 1e-7 [224]. G-D associations from
RGD required no mapping as diseases were already mapped to MeSH UIs. Associations
from MGD and RGD were done so using the same parameters used by DisGeNET.
GoF and LoF searches were performed across Medline abstracts using automatic text
mining with Linguamatics I2E. Sentences needed to contain three semantic entities: a
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Table 6.1: Summary of integrated gene-disease associations.
Source Version/Accessed Type #Ass. #Map % Map
CTD [225] Jul 02 2015/Aug ’15 Curated 24,346 23,813 97.8
OMIM R© [121] 18-08-2015/Aug ’15 Curated 5,143? 3,375 65.6
Orphanet [215] 2015 07 31/Jul ’15 Curated 6,094 1,744 28.6
UniProt [214] 2015 08 Curated 4,679 3,203 68.5
GWAS Cat [122] 24 08 2015/Aug ’15 Experimental 13,326 5,112 38.4
BeFree [124] 24-Aug-2015/Aug ’15 Literature 330,888 233,264 70.5
GoF/LoF/ -/Oct ’15 Literature 4,793 3,459 72.2
SemRep [216] 25/Feb ’15 Literature 96,024 72,908 75.9
MGD[200, 202] 24 08 2015/Aug ’15 Predicted 1,943 1,577 81.2
RGD[201] 21 08 2015/Aug ’15 Predicted 7,667 7,667 100
Note: Data sources used for G-D associations. Note: ‘# Ass.’ = Associations from source,
‘#Map’ = number mapped to MeSH, ‘% Map’ = percentage mapped to MeSH. ‘Curated’
refers to manually curated associations, ‘Experimental’ refers to associations drawn directly
from genetic experimental observations, ‘Literature’ refers to associations automatically
mined from literature and ‘Predicted’ refers to associations statistically inferred from
animal models. ? Not including 1,397 associations for which the molecule basis is unknown.
/ See Table. C.2 for a breakdown of these.
disease, a gene and a loss or gain of function phrase. For the gain of function any of the
following phrases were sought: “gain-of-function”; “gain of function”; and “activating
mutation” (and morphological variants of activating). Similar phrases were sought for
the loss of function. To increase accuracy, disease and gene semantic terms were filtered
to exclude the most ambiguous terms (by using Linguamatics I2E’s disambiguation
score ≤ 75). The disease terms were automatically mapped to MeSH Tree Terms and
the genes to NCBI Entrez Gene Id. Data was prepared as a triplet: disease, gene,
GoF/LoF1. MeSH tree terms had to be mapped to MeSH UIs.
All sources included in the integrated data set as well as the data types included in
the network are detailed in Table C.1.
6.4 Results
An approach to identify novel Dr-D associations from an integrated target network
was developed as part of this project. Moving away from typical manual hypothesis
generation the approach described uses data to inspire hypothesis generation. The
1These associations were produced on 16th October 2015.
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approach is made up of five main components which are described in Fig. 6.1.
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Figure 6.1: Overview of approach to identify novel drug-disease (Dr-D) as-
sociations. Gene-disease associations from 10 sources are first integrated and ranked
(red). These scored associations are then integrated with protein, gene, disease and
drug data to produce an integrated drug repositioning data set, GenDat (blue). A
therapeutic area of application is then identified (green) before the data set is mined
for instances of a semantic subgraph whose mappings contain inferred Dr-D associ-
ations (yellow). Finally, any Dr-D associations that are likely side-effects (SEs) are
filtered using a MeSH distance measure (orange), before all ranked Dr-D associations
are returned.
These components comprise: (i) Integration and ranking of G-D associations (ii) Cre-
ation of a semantically integrated data set for target-based drug repositioning, using
scored G-D associations, protein, gene, disease, and drug data (iii) Identifying a ther-
apeutic area of application, this method uses only the integrated network (iv) Mining
of a semantic subgraph whose mappings in the integrated network allows novel uses
for existing drugs to be inferred (v) Calculating MeSH distance, a method for calculat-
ing the semantic equivalence between two diseases within the MeSH hierarchy is also
described and is used during the filtering of results.
6.4.1 Integrating and ranking of gene-disease associations
This component of the approach is shown in red in Fig. 6.1. After mapping all G-D
associations to MeSH, a relatively even spread of G-D associations across all 29 thera-
peutic areas of the MeSH hierarchy was observed, with C04, C10, C16 and C23 being
slightly overrepresented (Fig. 6.2A.). Associations from OMIM and UniProt are, on
average, captured in more than three of the other data sources, while, on average,
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there is little crossover between associations captured in BeFree, GoF/LoF, RGD and
SemRep (Fig. 6.2B.).
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Figure 6.2: Comparison of gene-disease (G-D) sources. (A) Shows the percent-
age spread of G-D associations from each integrated data source across the 29 MeSH
therapeutic areas. (B) A boxplot showing the overlap of G-D associations between
the ten data sources. 1,000 associations were picked at random from each data source,
listed on the x axis. For each of these associations the number of the remaining nine
data sources that also contained this association were counted. Overlap could therefore
be between zero (the association was not captured in any other dataset) and nine (the
association was present in all data sources), shown on the y axis. NOTE: n = number
of data sources checked, red diamonds show the mean, open circles are outliers and
the median is represented by the thick horizontal black lines.
Once G-D associations were standardised in the format ‘[HUGO gene ID][MeSH Dis-
ease UI]’, the next step was to rank these associations based on the evidence that
supported them. First a log-likelihood score (LLS) used to score each data set was
defined and is shown in Equation 6.1:
llsL(E) = log
(
P (L|E)/¬P (L|E)
P (L)/¬P (L)
)
(6.1)
In Bayesian terms, the ratios P (L)/¬P (L) represents the prior odds ratio, which is
the ratio of the probability of the G-D linkage (L) and its negation before the evidence
(E ) is seen. The ratio P (L|E)/¬P (L|E) represents the posterior odds ratio, that
is the probability of the G-D linkage in the light of the new data. For the prior
odds ratio P (L) was calculated by dividing the total number of true positives in E
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(the number of G-D associations in both E and the gold standard) over all possible
G-D combinations (calculated using all genes and all diseases captured in the gold
standard) whilst ¬P (L) was calculated by dividing the total number of false positives
in E (the number of G-D associations in E but not in the gold standard) over all
possible G-D combinations. For the posterior odds ratio P (L|E) was calculated by
dividing the number of true positives in E over the total number of associations in
E whilst ¬P (L|E) was calculated by dividing the total number of false positives in
E over the total number of associations in E. The LLS is, therefore, proportional to
the accuracy of the data source and is estimated by counting the number of G-D pairs
with a known interaction and those without any shared annotation among all possible
G-D pairs captured in the data.
The confidence scores were then integrated using the weighted sum (WS) as described
by [212] and summarised in Equation 6.2:
WS =
n∑
i=1
Ci
(Di−1)
(6.2)
where C1 is the highest confidence score and Cn the lowest confidence score computed
from a set of n data sets and allows for the integration of data sets in order of their
confidence scores.
Due to the fact that there exists no gold standard for G-D associations, each of the ten
G-D association data sources listed in Table. 6.1 were investigated to evaluate their
suitability for use as a ‘gold standard’ during this work. To do this, each data set in
turn was selected as the gold standard and an LLS was calculated for each of the other
nine data sources. The nine data sources that received an LLS were then ranked in
descending order (the highest scoring data source was ranked number one, whilst the
lowest scoring data source received a rank of nine). When using each G-D data source
as the gold standard UniProt, on average, ranked first for the score attributed by the
LLS (Table. C.3). Because of its consistently high ranking, G-D associations from
UniProt were used as the gold standard for the scoring of G-D associations. Using
UniProt, LLS scores for the data sets ranged from 16.57 for OMIM to 10.95 for GWAS.
After testing a range of D parameters, a D value of 5.0 was used for this work as it
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was deemed to optimise the area under the curve (AUC) value (see Fig. C.1). Using
a D value of 5.0 resulted in a total of 309,885 unique scored G-D associations, with
scores ranging from 10.95 to 20.29.
6.4.2 Calculating MeSH distance
The MeSH hierarchy is rather verbose, and thus the specificity of terms is a potential
problem. Due to the complexity and coverage of the MeSH hierarchy, two diseases may
be synonymous yet captured in multiple parts of the taxonomy. Therefore, an imple-
mentation of the structure-based approach described by Leacock and Chodorow [221]
was used to measure the distance between two diseases in the MeSH hierarchy. This
component of the approach is shown in orange in Fig. 6.1. The formula used to calcu-
late the difference is shown below in Equation. 6.3.
Sim(Ci, Cj) =
(
1
MAX
)
×
(
−logDist(Ci, Cj)
2depth
)
(6.3)
Where MAX is the maximum mapping score, depth is the max depth of the hierarchy
and Dist is the shortest path length between the two concepts, Ci and Cj. Reducing
the stringency at which diseases are mapped to those in the MeSH hierarchy allows
better filtering of potential noise caused by has_side_effect edges. For example, an
inferred has_indication edge is made between drugX and diseaseY, while a known
side-effect of drugX is diseaseZ, a child term of diseaseY in the MeSH hierarchy. As
one of drugXs known side-effects is semantically similar to the inferred indication, it is
fair to assume that drugX is not a reasonable candidate for the treatment of diseaseY.
In this instance Sim(diseaseY, diseaseZ) would give a value of 0.768. Using 0.768
as the equivalence threshold (ET) during filtering means all inferred associations that
are one node away, in the MeSH hierarchy, from known side-effects will be removed.
Therefore, the Sim value allows for the identification of semantic ‘equivalence’ using
a certain threshold or leniency, the ET.
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6.4.3 Integrated data set, GenDat
This component of the approach is shown in blue in Fig. 6.1. Ranked and scored G-D
associations were then integrated with protein, gene, disease and drug data to create
a semantically-rich network, GenDat to aid in the identification of potential drug
repositioning opportunities. GenDat contains 57,453 nodes and 528,930 edges. To
distinguish between rare (generally monogenic) and common (often complex) diseases
the Orphanet Rare Disease Ontology (ORDO) was also included. 1,779 MeSH UI were
captured as synonyms within the ORDO. Wherever a Rare_Disease node contained
a MeSH UI, the MeSH node was integrated with the ORDO disease and resulted
in a Rare_Disease node with the synonymous MeSH UI becoming attributes. The
metagraph for GenDat is shown in Fig. 6.3.
GenDat contains approved drugs, Small_Molecules, and binds_to interactions from
these to single Protein targets. Wherever possible these binds_to associations are
annotated with activity types (IC50, Kd, Ki and Potency) and the corresponding ac-
tivity values (nM). For each Protein, the Gene which it is encoded_by is also included.
A Gene may also be linked to diseases, either a Rare_Disease or a Common_Disease,
via involved_in edges. These involved_in edges are annotated with values produced
during the G-D association ranking described previously. Finally, diseases and drugs
may share has_indication and has_side_effect edges. GenDat includes data types
to enable target-based drug repositioning opportunities to be identified.
6.4.4 Identifying a therapeutic area of application
Using both G-D associations and Dr-D associations from GenDat a therapeutic area
unmet score Therapeutic Area Unmet Score (TAU) was calculated, using the formula
in Equation 6.4;
TAU(ta) = ¬P (DD)× P (GD)×
(
1− 1
MAX
× |ta|
)
(6.4)
Where ta is the therapeutic area being looked at, e.g. C01, P(GD) is the probability
that the data contains a G-D association for a disease in that ta, ¬ P(DD) is the
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Figure 6.3: Metagraph of GenDat. Metagraph shows the node types and the edge
types used in GenDat and how they interact to one another.
probability that the data does not contain a Dr-D association for a disease in that
ta and MAX represents the size of the greatest ta. The TAU, in theory, can range
from 0 to 1. A score of 0 represents a therapeutic area that contains few, highly
drugged diseases, with little knowledge captured in GenDat. A score of 1 represents
a therapeutic area that contains a great number of diseases that have relatively few
marketed treatments and have high levels of knowledge describing them in GenDat.
A simple equation to calculate a Rich Therapeutic Area (RTA) score was defined and
is shown in Equation 6.5. Equation 6.5 uses the same notation as Equation 6.4 and
can also produce scores from 0 (areas with little knowledge captured in the data set)
to 1 (areas with a lot of knowledge captured in GenDat), using the following:
RTA(ta) = P (DD)× P (GD) (6.5)
In order to identify a therapeutic area of focus for this work a therapeutic area of
unmet need first needed to be identified. To do this two relevant data types from
GenDat, G-D associations and Dr-D associations were utilised. As the approach to
inferring novel Dr-D associations described in this Chapter utilises G-D associations
for predicting target-based drug repositioning, it is important to target therapeutic
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areas for which a large proportion of the contained diseases have data supporting their
genotypic mechanisms. Indications cannot be inferred for areas where there is no
data describing them in the network. The percentage of each therapeutic area that
was involved in at least one is_involved_in edge was, therefore, calculated; this is
shown in Fig. 6.4A. It was then necessary to identify a therapeutic area that had G-D
associations describing the diseases, but also had fewer small therapeutic molecules.
The percentage of each area for which there already exists a marketed small therapeutic
molecule was calculated. The percentage was calculated using the has_indication
relations present in the network (see Fig. 6.4B).
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Figure 6.4: Gene-disease association and indications data captured in Gen-
Dat for each therapeutic area. (A) Dark grey bars show the frequency of diseases
in each therapeutic area of the MeSH hierarchy. Light grey portions of the bar show
the number of those diseases that are not involved in any of the gene-disease associ-
ations captured in GenDat. Red shows the percentage of diseases in that therapeutic
area involved in one or more gene-disease association(s). (B) Dark grey bars shows
the number of diseases in each therapeutic area of the MeSH hierarchy. Light grey
portions of the bar show the number of those diseases that currently do not have a
small molecule treatment on the market. Red shows the percentage of diseases in that
therapeutic area that has one or more treatment(s) on the market, as captured in
GenDat. Note: please see Table C.4 for therapeutic area descriptions.
When calculating a therapeutic area which had a relatively large amount of knowledge
captured in GenDat, its size, or cardinality, also has to be considered. For example, the
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Figure 6.5: Ranking therapeutic areas in terms of their TAU score. Using
Equation 6.4 each therapeutic area in the MeSH hierarchy was scored. The TAU score
considers how much data is captured in GenDat and the percentage of diseases in that
therapeutic area that do not have a marketed small therapeutic molecule. The higher
the TAU the more likely the therapeutic area is to be an area of unmet need.
therapeutic area C25 (chemically-induced disorders) has Dr-D associations for 52 %
of the disorders which are contained within the term, as well as G-D associations for
65 %. Looking at these two values alone it can be seen that there is a relatively
large amount of data for this area. However, it is made up of only 108 diseases and
makes up only 0.4 % of diseases in GenDat. To avoid identifying such small areas, the
focus was placed only on therapeutic areas that represent over 3.44 % (there are 29
therapeutic areas and so 100/29) of the total diseases captured in GenDat to identify
a rich therapeutic area.
With a TAU (Equation 6.4) of 0.53, it is shown that C16 (hereditary diseases) is the
largest unmet therapeutic area (Fig. 6.5) and C10 (diseases of the central nervous
system) achieves the second highest TAU of 0.38. The work here focusses on approved
small molecules, as these drugs have already passed safety tests and are easier to
reposition. Many genetically simple hereditary diseases, such as those captured in
the MeSH therapeutic area C16 are not suited to this type of treatment, as some are
untreatable, and others are caused by gene knockouts. Instead, hereditary diseases
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Figure 6.6: Ranking therapeutic areas in terms of their RTA score. Using
Equation 6.5 each therapeutic area in the MeSH hierarchy was scored. The RTA score
considers how much data is captured in GenDat for each therapeutic area. Note: red
diamonds show the therapeutic areas which include <3.44 % (100/29) of all diseases.
For the purpose of this exercise, they will not be considered for analysis as they do
not offer a fair representation of the data included in the work. The higher the RTA
the more likely the therapeutic area is to be well ‘drugged’.
tend to be better treated using metabolic manipulation, protein augmentation and
gene therapy [226]. It is for this reason that the approach here is not applied to
hereditary diseases and instead to the therapeutic branch C10. The therapeutic area
C04 (Neoplasms) is identified as having the greatest RTA (Equation 6.5) of therapeutic
areas containing more than 3.44 % of the total number of diseases in GenDat (Fig. 6.6).
Therefore, the approach is applied to C10, an area of unmet need, and C04, an area
relatively rich in data.
6.4.5 Mining integrated data set
GenDat took 64 minutes to build on a local machine (8Gb RAM and 1.8GHz Intel
Core i5). Mining used an initial candidate set of 1,188 nodes (approved, small molecule
drugs that target humans or other mammals) and took 13 minutes to complete. An
exhaustive search returned 539,162 mappings.
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The subgraph depicted in Fig. 6.7 was used as it is the most simple schematic repre-
sentation of a drug-disease pathway. Searching for instances of the four-node subgraph
will allow novel drug-disease associations to be identified, essentially by ‘filling in the
blanks’. This component of the approach is shown in yellow in Fig. 6.1.
Small MoleculeProtein
Gene Disease
has_indication encoded_by 
involved_in 
 Association score (0-1) 
binds_to 
 Activity value (1nM – 1x1019nM) 
Figure 6.7: Semantic subgraph used to infer novel drug-disease associations
from the GenDat. Subgraph represents the simplest approach to schematically
representing the route from drug to disease using target-based approaches to drug
repositioning. Through identifying mappings of the subgraph in the GenDat the aim
is to infer the red has_indication relations. Mappings are scored using the values
captured in the Activity value and Association score attributes (shown in green) found
on the binds_to and the involved_in relations, respectively. Note: in mappings
‘Disease’ can be either a Common_Disease or a Rare_Disease and a ‘Drug’ is an
approved Small_Molecule.
Mappings, M , were scored and ranked using the Activity value and Association score
values attached to the involved_in and binds_to relations respectively, using equa-
tion 6.6:
Score(M) =
Activity value (M) + Association score (M)
2
(6.6)
The Association score captured on the involved_in relations were created during the
G-D ranking section of the approach, and ranged between 0-1. The Activity value,
attached to the binds_to relation was extracted from ChEMBL and included val-
ues associated to: IC50; Ki; Kd and potency, all of which had values ranging from
1nM - 1× 1019 nM. The Activity value for each binds_to association was normalised
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Figure 6.8: Calculating Sim threshold for pruning potential side-effects from
inferred indications. This figure provides a graphical representation of the data cap-
tured in Table C.5. For each threshold, the F-Measure, F1 (using precision and recall
of known indications captured in the network), shown in black, as well as the average
ranking position of the excluded potential side-effects, shown in red, were calculated.
To calculate the ranking positions of those excluded, all associations inferred by the
methodology were ranked before any filtering, and it was these rankings used through-
out all subsequent analysis. The aim of filtering out potential side-effects was to reduce
noise in the results while also ensuring potential indications were not excluded. It was
assumed that the associations scoring higher, and thus rank higher (highest being 1),
are predicted with more confidence, and thus potential side-effects are excluded from
the highest ranking associations.
to the same range as the Association score, to give Activity value; this was done
simply by subtracting log10(Activity value) × 0.1 from 1, where 1 is the maximum
log10(Activity value) captured in GenDat. The mean Activity value from ChEMBL
was 0.8 and this value was assigned to binds_to relations taken from DrugBank which
do not come with Activity value data.
Steps were then taken to filter results in order to remove as much ‘noise’ as possi-
ble. Mappings containing predicted has_indication edges that were known side-
effects (captured as has_side_effect relations in GenDat) were removed. Map-
pings that predicted has_indication edges with a Sim value ≥ 0.768 to known
has_side_effect edges were also dismissed as potential side-effects. An equivalence
threshold of 0.768 was used as it gave the best balance between precision and re-
call of the known has_indication edges while also pruning, on average, the highest
ranked inferred associations (Fig. 6.8 and Table C.5). Of the 539,162 mappings, 42,689
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were classed as potential side-effects. A further 4,947 mappings were removed as the
mechanism of the drug, and the G-D association directionality (LoF or GoF data)
contradicted one another (e.g. the drug was an agonist and the gene was associated to
a disease via a GoF relation). Finally, 41,798 mappings containing one of the 298 ab-
sorption, distribution, metabolism, and excretion (ADME) genes [227] were dismissed.
After filtering, 451,269 mappings inferring 275,934 unique(some associations were iden-
tified by more than one mapping) has_indication edges were left. Of all the mappings
that inferred the same has_indication edge, the mapping that achieved the highest
score was kept and used for all analysis. Inferred indications covered every therapeutic
area of the MeSH hierarchy, ranging from 72,613 for neoplasms (C04) to 2 for disor-
ders of environmental origin (C21) (Table C.4). 219,623 unique associations involved
Common_Disease (inferred from 369,124 mappings) whilst 56,311 associations involved
Rare_Diseases (inferred from 82,145 mappings) (see Table 6.2).
Table 6.2: Number of mappings for each disease type and therapeutic area post filter-
ing.
All Diseases Common Disease Rare Disease
All Therapeutic Areas 275,934 (451,269) 219,623 (369,124) 56,311 (82,145)
C04: Neoplasms 55,875 (102,832) 39,383 (73,501) 16,492 (29,331)
C10: Nervous System 54,635 (84,213) 41,241 (66,536) 13,394 (17,677)
Note: After applying filtering a set of mappings that inferred unique (no repeats)
drug-disease associations are left. Numbers in brackets denote how many mappings inferred
the unique associations.
The ability of the approach to identify known has_indication edges captured in
GenDat was then investigated. All has_indication edges (from the four sources
listed in Table C.6) that involved the 1,188 approved small molecules used during
the search were extracted. Fig. 6.9 shows how the approach performs in identifying
known has_indication edges for different therapeutic areas (all, C04 and C10) and
different disease types (Common_Diseases and Rare_Diseases). Of the 18,889, known
has_indication edges, 1,006 involved 63 drugs that although were part of the 1,188
investigated, returned no mappings, leaving 17,883 that could potentially be validated.
For mapping, known has_indication edges to those inferred by the approach a Sim
threshold of 0.633 was used, the equivalent of a two-node distance within the MeSH
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hierarchy. It is believed a Sim threshold of 0.633 provides the best trade-off between
the verbosity of the MeSH hierarchy while also ensuring inferred diseases are close
enough in disease mechanism for the proposed therapeutic small molecule to be rele-
vant. Using the Sim threshold of 0.633, the approach identifies 12,955 of the known
has_indication edges (72.65 %) (Table C.7). An AUC of 0.73 was achieved when
looking at all of the inferred Dr-D associations (Fig. 6.9). The number of knowns
identified by the approach can be increased to 97.6 % if the Sim value is relaxed to
0.231, which represents a node distance of nine in the MeSH hierarchy (Table C.7).
- 169 -
Chapter 6: Identification of novel uses for drugs with focus on gene-disease
associations
0.0 0.2 0.4 0.6 0.8 1.0
1 - Specificity
0.0
0.2
0.4
0.6
0.8
1.0
S
en
si
tiv
ity
0.730 ALL_ALL
0.699 C04_ALL
0.747 C10_ALL
random
Figure 6.9: Validating inferred has_indication edges. All 18,889
has_indication edges captured in GenDat were extracted. These associations
were used as means of validating the ability of the approach to identify known
has_indication edges. Note: For each disease category (ALL, C04 and C10) the
set of known indications were pruned to only include those relevant, mapping was
done using a Sim value of 0.633, this is equivalent to a distance of two nodes in the
MeSH hierarchy.
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Figure 6.10: Validating inferred has_indication edges using different MeSH
distance measures. The Sim threshold used to map inferred has_indication edges
to the 18,889 known has_indication edges was altered. For each of the Sim values
investigated the number of known has_indication edges they manage to identify is
shown in Table C.7.
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6.4.5.1 C04: Neoplasms
55,875 unique has_indication inferred edges involved neoplasms (therapeutic are C04
of the MeSH hierarchy). 16,492 of these unique associations involve Rare_Diseases
(inferred from 29,331 mappings) while 39,383 unique has_indication edges involving
Common_Diseases were identified (inferred from 73,501 mappings). Of the 2,856 known
has_indication Dr-D associations the approach identifies 1,927 of these or 68 %. 455
of the knowns involve 28 drugs that this approach was unable to infer associations for,
due to lack of data, giving an 80 % identification rate for known Dr-D associations
involving neoplasms, with an AUC of 0.69 (Fig. 6.9).
Of the top 10 ranked inferred Dr-D associations involving neoplasms (Table 6.3), it
can be seen that three map exactly to indications in GenDat. Furthermore, one is
currently being investigated in a clinical trial [229], one has been previously studied
in the clinic [228], one is now approved for the indication proposed and the literature
supports another. Of the top 10 inferred indications, three are novel and are currently
not supported by evidence. One of those indications is the use of pazopanib (Votrient;
Novartis) in the treatment of Mastocytosis.
Pazopanib as a treatment for Mastocytosis? Pazopanib is a small molecule
inhibitor of multiple protein tyrosine kinases and is approved for the treatment of ad-
vanced renal cell carcinoma and advanced soft tissue sarcomas. Mastocytosis, classed
as a rare disease, is a mast cell activation disorder of both children and adults caused
by the presence of too many mast cells (mastocytes) and CD34+ mast cell precursors.
The cause of mastocytosis is not known but activating mutations in the proto-oncogene
receptor tyrosine kinase, KIT, are found in most patients with mastocytosis [231]. The
mutation makes mast cells more sensitive to stem cell factor (SCF). SCF plays an im-
portant role in stimulating the production and survival of cells such as blood cells
and mast cells, inside the bone marrow. When bone marrow is exposed to SCF, it
produces more mast cells than the body can cope with, leading to symptoms of mas-
tocytosis [231]. Although no official treatment exists for mastocytosis many drugs are
prescribed off-label, including the tyrosine kinase inhibitors, dasatinib, imatinib and
masitinib [231]. Due to the fact that that pazopanib displays inhibitory effects on the
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KIT enzyme similar to those that have been used as off-label treatments, it poses an
interesting alternative in the treatment of mastocytosis.
6.4.5.2 C10: Nervous System Diseases
54,635 unique has_indication inferred edges involved diseases of the nervous sys-
tem (therapeutic area C10 of the MeSH hierarchy). 13,394 of these unique associa-
tions involve Rare_Diseases (inferred from 17,677 mappings) whilst 41,241 unique
has_indication edges involving Common_Diseases were identified (inferred from
66,536 mappings). Of the 4,249 known has_indication Dr-D associations the ap-
proach identifies 2,846 of these. 125 of the knowns involve 37 drugs that, due to holes
in the data, the approach was unable to infer associations for, a 69.0 % identification
rate for known Dr-D associations involving nervous system diseases, with an AUC of
0.75 (Fig. 6.9).
Of the top 10 ranked inferred Dr-D associations involving diseases of the nervous
system (Table 6.4), it can be seen that only one maps exactly to an indication in
GenDat while another maps with a Sim of 0.66 (MeSH distance of two nodes). Another
eight are novel and are currently not supported by evidence. One of those indications
is the use of lisinopril (Zestril; AstraZeneca) in the treatment of Alzheimer Disease.
Lisinopril as a treatment for Alzheimer Disease? Alzheimer Disease is a
chronic neurodegenerative disease that usually starts slowly and gets worse over time
and currently has no cure. Lisinopril, a potent, competitive inhibitor of angiotensin-
converting enzyme (ACE), is used to treat hypertension and symptomatic congestive
heart failure. There is evidence to suggest that Angiotensin-converting enzyme in-
hibitors and the reduced risk of Alzheimer’s disease in the absence of apolipoprotein
E4 allele [232]. As such, lisinopril is proposed as a potential treatment for Alzheimer’s
disease.
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6.5 Discussion
In this Chapter, an approach for inferring novel drug repositioning leads was explored.
As part of this approach diseases of the nervous system were identified as a therapeutic
area in need of more treatments. G-D associations were integrated and ranked from
multiple data sources and as a consequence, the need for a standard representation of
G-D associations was made apparent. These ranked associations were used to create
GenDat, a semantically-rich integrated network for drug repositioning. It was also
shown how mining GenDat for semantic subgraphs can enable the inference of novel
Dr-D interactions.
The UMLS contains over 3 million concepts (covering anatomical structure, biological
function, chemical, disease or syndrome, laboratory or test result, medical device,
and organism), MeSH therapeutic areas are made up of 11,735 concepts and the DO
10,905 concepts. As part of this work, calculations showed that of the diseases caught
in DisGeNET, 100% mapped to UMLS, 60% mapped to MeSH and 24% mapped to the
DO. At present, it appears that MeSH offers the best trade-off between interoperability
and semantic clarity. It was for this reason that MeSH was used during this work.
Two MeSH therapeutic areas were identified to focus on, one, neoplasms, or C04, with
a relatively rich knowledge base, and one, diseases of the nervous system, or C10,
containing many diseases that are currently in need of a therapeutic molecule. It is
seen, as expected, that the approach performs better when looking at C04 diseases in
comparison to the less treated and less informed C10 diseases; highlighting the fact
that systems approaches are limited by the data available. Limited data may become
more of a problem in the long term, especially when it comes to developing treatments
for diseases of the central nervous system. Clinical trials are very expensive in the area
of nervous system diseases, due to the placebo effect, meaning that great numbers of
trialists are needed. As a result, many companies are withdrawing their development
efforts from this area, making nervous system diseases a great area of opportunity for
repositioning, and in particular in silico approaches. The approach does not address
the problems caused by the placebo effect. Rather, by bringing data together, in a
similar fashion to the clinician, it is hoped that as more data becomes available, this
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approach can reduce the attrition rates while also improving efficacy.
The approach presented here makes use of a MeSH distance measure, Sim (see Equa-
tion 6.3). The Sim measure is used twice during the approach. A Sim value of
0.768 is used for filtering potential has_side_effect edges, equivalent to a one node
path from a known side-effect. A lower Sim value of 0.633 is used to validate in-
ferred has_indication edges against the known indications captured in the network,
equivalent to a two node path. The two values vary as they are used for different
purposes. If the stringency was reduced to filter potential side-effects, a lot of the true
positives are quickly lost (Table C.5). Indeed by filtering potential side-effects using
a Sim of 0.633 instead of 0.768 would result in a loss of 31% of true positive inferred
has_indication associations. When validating inferred has_indication edges, the
lower the Sim value, the greater the AUC (Fig. 6.10). It is believed that, in this
instance, a Sim value of 0.633 gives the best trade-off between AUC and maintaining
semantic ‘equivalence’, when it comes to validation. These differing Sim values reflect
the manner in which drugs are marketed, with indications being as high level as pos-
sible for marketing reasons. On the other hand, side-effects tend to map to a greater
level of granularity and so do not require less stringent mapping.
Possible extensions to this approach should include more thorough analysis regarding
the identification of disease areas of interest. Instead of simply identifying a therapeutic
area that appears to be relatively untreated one could consider other factors for disease
prioritisation. For example, not all diseases have the same impact on society and so
integrating data that considers the stress a disease places on society would be useful.
For example, the WHO global burden of disease measures burden of disease using the
disability-adjusted-life-year (DALY).
As well as a more thorough disease prioritisation step, more focus must be placed on
directionality, both regarding the effect on function of the gene mutation and the drug
functionality (e.g. agonist, antagonist). No data source details the effect of function
that a gene mutation has; i.e. does it result in LoF (the gene product has less or
no function) or GoF mutation (product of mutated gene gains a new and abnormal
function). Although a text mining approach was used as part of this work to try
and identify the effect on gene function of a mutation (see Section 6.3) this was not
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exhaustive. Drug functionality must also be considered if this work is truly to provide
detailed inferences. It was possible to get drug functionality for around 500 drugs from
ChEMBL, but this did not cover all drugs in GenDat. Problems arising from limited
drug functionality data are highlighted by the first ranked inferred association from the
diseases of the central nervous system (Table 6.4). Nitrendipine, a potent blocker of
the calcium channel (CACNA1S), is proposed as a treatment for Hypokalemic periodic
paralysis. Although both the binds_to and involved_in edges are correct, the lack
of directionality attached to the G-D association makes this particular inference a
poor one. Nitrendipine is annotated as being an inhibitor of CACNA1S in the data
set, as such if the mutation involved of CACNA1S had been correctly annotated as a
LoF mutation, this inference would have been filtered as contradictory. As such, the
administration of Nitrendipine as a treatment for Hypokalemic periodic paralysis is
likely to exacerbate the condition as opposed to treating it.
Despite this approach allowing for an initial reduction of the search space the next
step would require a more robust filtering of the results. One would need to ensure
that the target could indeed be reached by the drug, i.e. if a compound is unable to
pass the membrane the target must be located on the surface of the cell. Looking at
the cellular location of targets, which could be extracted from GOA, as well as the
physiochemical properties of the compound, from DrugBank or ChEMBL, may allow
for more accurate inferences to be made.
A strategy for mining for potential drug repositioning opportunities was introduced in
this Chapter, however, at the moment, it can be seen that this is limited by the data
available. The approach paves the way for more stringent ontological representation
of G-D associations; like the Experimental Factor Ontology (EFO) work being carried
out at the Centre for Therapeutic Target Validation (CTTV). Furthermore, the Open
Targets Platform2, which at the time of writing is still in its infancy, will utilise the
EFO and provide systematic access to a mass set of integrated of G-D associations. It
is believed that as the quality of data increases this in silico approach will complement
target identification and validation; reducing target attrition through efficacy.
2https://www.opentargets.org
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6.6 Conclusion
This Chapter has presented a method for integrating and ranking G-D associations
from numerous data sources. Scored G-D associations were then integrated with
other relevant data to produce GenDat, a target-based drug repositioning network.
A method for the automated identification of therapeutic areas of interest was intro-
duced, enabling data-driven hypotheses to be generated. A simple four-node semantic
subgraph was described that best represents, schematically, an abstract view of the
drug-disease pathway. Instances of this subgraph were searched for in GenDat, using
the previously described DReSMin algorithm. Mappings were scored based on the
evidence supporting the G-D associations and the known binding values of the drugs.
The work presented in this Chapter provides some interesting feedback to the wider
community. First, a method for identifying therapeutic areas of unmet need is pre-
sented. A state-of-the-art view of G-D associations is provided and includes data that
is otherwise inaccessible to the community (such as those annotated as being caused
by either a GoF or LoF mutation). Furthermore, by using the disease prioritisation
metrics (TAU and RTA scores), future projects can identify areas of application for
drug discovery projects. Finally, the method for filtering potential side-effects means
that other projects can further prune inferred Dr-D associations— something that can
only increase the accuracy of the final prediction set.
Future work would need to focus on: applying extra dimensions to the prioritising
of therapeutic areas; as datasources become more plentiful and the depth of coverage
greater, the inclusion of directionality data is required, for both G-D associations and
Drug-Target (D-T) associations. Furthermore, the differentiation between causal G-D
associations and susceptibility associations. Differentiating G-D associations in such a
manner would enable an extra dimension of scoring to be achieved, with those known
to be causal given greater preference.
The approach described highlights disease areas of need that would benefit greatly
from more data. As such, the future work discussed is heavily reliant on data avail-
ability, something that is currently lacking. There are, however, some interesting and
relevant efforts, such as the public-private initiative from the CTTV; The Open Tar-
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gets Platform3. At the time of writing this platform is still in its infancy, however, it
has the potential to provide a powerful G-D association accession point. Finally, to
investigate the proposed indications more thoroughly, they would need to be validated
in a clinical setting. Future work is discussed in more detail in Chapter 7.
3https://www.opentargets.org
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7.1 Introduction
In this thesis, methodologies that enable a systems approach (as defined in Sec-
tion 2.2.3) to drug repositioning have been described. There are two major require-
ments to take such an approach: integrated data sets; and automated algorithms for
the systematic exploration of these data sets. During this project, a Drug Repo-
sitioning Network Integration Framework (DReNInF) was developed to enable the
creation of integrated data sets relevant to drug repositioning. This integration
framework makes use of a high-level Drug Repositioning Network Integration On-
tology (DReNInO). An application data set, Drug Repositioning Network Integra-
tion (DReNIn), created using the DReNInF was also made available as an Resource
Description Framework (RDF) data set with a dedicated Web front-end. Further-
more, sub-components of a target network that represent a particular function were
introduced and formalised as semantic subgraphs. Drug Repositioning Semantic Min-
ing (DReSMin), a custom data mining algorithm, was also developed in order to allow
integrated networks to be systematically mined for instances of a predefined seman-
tic subgraph. DReSMin was then used for the inference and prioritisation of novel
Drug-Target (D-T) associations as well as novel Drug-Disease (Dr-D) associations.
Furthermore, DReSMin was shown to perform better than other state-of-the-art ap-
proaches when applied to D-T interaction prediction, identifying >10% more of a set
of known D-T associations than the approach developed by ChEMBL1 [180, 181].
In this Chapter, the outcomes of the project will first be described in the context of
the initial objectives. For each objective, project outcomes will be assessed in terms of
their contribution to the field. Limitations of the approaches developed as part of this
work will then be discussed. Project outcomes will then be reviewed in the broader
context of drug repositioning, focussing on recent developments in the field. Finally,
future opportunities will be identified and introduced.
1www.ebi.ac.uk/chembl
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7.2 Discussion
To fulfil the main aim of this project, three objectives were set at the beginning of the
project (as described in Section 1.3). These are:
1. To extend existing data integration platforms relevant to drug repositioning.
2. To research and implement appropriate strategies for semantic data integration
of network construction including Ondex, RDF and others.
3. To develop algorithms to search for topological and semantic network structures
indicative of repositioning opportunities.
7.2.1 Aim 1: Extend existing data integration platforms rel-
evant to drug repositioning
To extend existing data integration platforms relevant to drug repositioning, the in
silico drug discovery data set described by Cockell et al. [101] was expanded. This ex-
pansion involved the integration of further biological entities and interactions relevant
to drug repositioning (see Section 3.4.1). It was shown that Ondex was not an ideal
platform for the creation of large integrated data sets required for the project. The
necessity for time efficient data set builds with scalable integration led the project to
move to an alternative graph-based datastore, Neo4j.
Originally developed for in silico drug discovery, expansion of the original data set
using a single node type (Indication) and four edge types (has_parent, has_child,
may_treat, may_prevent and involved_in) enabled the data set to be used for drug
repositioning tasks (see Section 3.4.1). This resulted in Dat, the first Ondex drug
repositioning data set that can be both interrogated and extended by the community.
Furthermore, a greater understanding regarding the data types required to enable a
holistic approach to drug repositioning was achieved and the data types included are
represented by the metagraph (see Fig. 3.3). This metagraph did not only influence
further data set development during this project but provided the wider community
with an archetypal minimalistic representation of the data types and interaction types
required to enable a systems approach to drug repositioning.
- 182 -
Chapter 7: Discussion and future work
7.2.2 Aim 2: Research and implement appropriate strate-
gies for semantic data integration
Various strategies for graph-based semantic data integration were researched, includ-
ing Ondex, RDF and Neo4j (see Chapter 3). As mentioned, Ondex was used for the
expansion of an existing drug discovery data set, and it was this data set that was used
in Chapter 5 for the inference of novel D-T associations. Through benchmarking and
performance testing, it was shown that Ondex was not a viable option for ‘large’ data
set creation, i.e. highly connected graphs with over 1 million nodes. For this reason,
it was decided that Neo4j would be used as the integration platform and data storage
solution for further work. A typical graph database (as opposed to the triplestore)
and not RDF was used for data set development due to the size of the data sets to
be produced, the requirements of the data sets, and the need for exhaustive and com-
plex graph-theory based querying. Graph databases are designed to support property
graphs (graphs where properties may be assigned to either entities or their relation-
ships, or both) and although recently some triple stores have added this capability
their initial design did not make this an easy task. Graph databases, on the other
hand, build upon the mathematics of graph theory. Since subgraph pattern matching
was central to the mining approaches developed during this project, it was decided
that a typical graph based database would be the most appropriate.
Although alot more scalable than Ondex, Neo4j provides no semantic integration and
query features. Therefore, to control the semantics used during data set production, a
lightweight software module, Bioinformatics Semantic Integration Platform (BioSSIP),
was developed. This module sits between Neo4j and a data integration framework, en-
forcing strict semantic typing during data set production and later querying. There-
fore, BioSSIP allows a data integration project to take advantage of the inherent
scalability of Neo4j, whilst also maintaining semantic consistency.
With the underlying data storage and querying system in place, a framework for
the development of drug repositioning data sets was then designed and implemented:
DReNInF (see Section 3.4.4). This framework is made up of three components: a high-
level ontology, DReNInO; a suite of parsers for relevant data sets; and an integration
strategy. DReNInF was used to provide an RDF knowledge base (DReNIn) that can
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be queried by the community. DReNIn is accessible via a dedicated Web site and
can also be queried systematically by using a SPARQL Protocol and RDF Query
Language (SPARQL) endpoint.
DReNInF provided the first data integration framework for drug repositioning and
is open to the community. Including 21 parsers and 6 mappers as well as a well-
defined integration strategy, DReNInF is a rich resource for those wishing to create
integrated drug repositioning data sets. To create a local integrated drug repositioning
graph a user simply downloads the DReNInF source code as well as any version of the
data sets to be included and runs the integration strategy. Central to the integration
framework is DReNInO. DReNInO provides the field with the first high-level ontology
developed specifically for system approaches to drug repositioning. The ontology is
available to the community for extension and manipulation. Unlike other drug repo-
sitioning integration efforts, DReNInO supports the inclusion of data types that can
be used to further assess the validity of any inferences made using a data set devel-
oped using the ontology. Data types such as Clinical_ Trials and edge types such
as has_indication, has_side_effect and involved_in_clinical_trial allow for
pruning of potential Dr-D associations— something that is not made possible through
large consortium efforts such as Open PHACTS.
DReNIn was developed in DReNInF and contained 466,540 nodes connected via
2,688,436 edges before being exported to RDF. Made up of over 8.5 million triples
the RDF data set has a SPARQL endpoint, enabling questions to be posed that were
previously not possible to ask of any other integrated drug repositioning resource.
7.2.3 Aim 3: Develop algorithms to search for network
structures indicative of repositioning opportunities
Semantic subgraphs were first introduced and defined (see Section 4.2.1). An algo-
rithm, DReSMin, was then developed for the identification of mappings of semantic
subgraphs from an integrated target network. Furthermore, approaches making use of
this algorithm were developed to search for topological and semantic network structures
indicative of repositioning opportunities. DReSMin is an exhaustive, exact topologi-
cal matching algorithm to identify instances of pre-defined semantic subgraphs from
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a target network (see Section 4.4.1). In DReSMin, semantics can be matched to a
defined threshold provided by a user. Furthermore, this search algorithm was used
as a component in larger approaches for the automated identification of novel D-T
associations and novel Dr-D associations.
Semantic subgraphs and the DReSMin algorithm are not restricted to edge inferences
within the field of drug repositioning, rather they can be applied to any area of research
that can be captured in a semantically-rich graph-based representation as defined in
Section 4.4. Central to the algorithm is the Semantic Distance Calculator (SDC) (see
Section 4.4.1.3), which uses matrices to score the semantic similarity between target
graph entities (either edges or nodes) and their equivalent entities in a query semantic
subgraph. DReSMin is made up of many novel sub-components that improve searching
performance, making exhaustive searching tasks computationally tractable (such as
the identification of mappings of semantic subgraphs with a node set greater than
6). These steps include the semantic graph pruning step (see Section 4.4.1.1). This
optional step essentially removes all entities from the target network that are deemed
semantically distant from those elements represented in the query semantic subgraph,
thus reducing the search space to be examined by the algorithm. Furthermore, the
semantic subgraph split component (see Section 4.4.1.4) splits semantic subgraphs
whose node set is greater than 3 into sets of semantic subgraphs which are searched
for in separate queries. After all split semantic subgraphs are searched for instances are
then mapped back together. This component, in particular, has applications outside of
the drug repositioning setting and could be used to enable the exhaustive searching of
either topological or semantic subgraphs that were previously not tractable. This step
reduces the search time for a semantic subgraph with a nodeset of 6 from 60 seconds
to 8 seconds.
A method to infer novel D-T associations was also developed by making use of historical
data and this work was subsequently published [146]. This approach was shown to
be better at prioritising known D-T interactions than other state-of-the-art methods
developed specifically for the purpose of identifying D-T interactions, such as the
approach developed by ChEMBL2 [180, 181]. Unlike traditional methods for D-T
2www.ebi.ac.uk/chembl
- 185 -
Chapter 7: Discussion and future work
interaction prediction, the strategy presented in this work can be used to infer any
‘type’ of edge captured in the integrated network, and is not limited to the exemplar
application described in Chapter 5.
Computational methodologies reliant on a single data type have various limitations
(as described in Chapter 2). By taking a holistic view and considering all evidence
available to support a prediction more confident inferences can be made. The method
described in Chapter 5 allows for the inference of associations using the data types that
are captured in a network. The more relevant data that is collated, the more confident
one can be that an inference is likely to be a true positive. Unlike other approaches
to drug repositioning, semantic subgraphs may be designed to infer relations between
any node types in a data set. DReSMin enables the discovery of any relations that are
captured in the abstracted drug-disease connection (as presented in Fig. 2.1), so long
as suitable semantic subgraphs are identified. This is in contrast to many of the com-
putational approaches to drug repositioning described in Section 2.2.2. For example,
ligand structure-based approaches, as well as protein structure-based algorithms are
limited to the inference of drug-target associations; gene expression based approaches
along with genetic variation-based approaches have been limited to the application
of the inference of drug-disease associations. Similarly, phenotype-based approaches
(including disease and side-effect) tend to be used for the inference of drug-disease
associations. Although machine learning based approaches tend to take a more in-
tegrative approach to data and, therefore, have the ability to infer a wider range of
associations and even properties, the fact that they are effectively statistical ‘black
boxes’ means that interpreting the repositioning hypothesis is a difficult task. Using
semantic subgraphs and DReSMin allows for human-interpretable hypotheses to be
derived and for all evidence supporting a claim to be judged.
The work presented in Chapter 5 provides some useful feedback to the drug reposition-
ing field. First and foremost it was shown practically how semantic subgraphs may be
derived from historical data. The resulting set of 194 semantic subgraphs are available
to the community and can be used to mine semantic networks with similar properties
to those captured in Dat, the data set that was queried using these subgraphs. As well
as providing a method for the development of semantic subgraphs a method for rank-
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ing inferences is provided. Using the semantic subgraphs and the ranking methodology
the approach is general enough to be used to identify any associations relevant to drug
repositioning, such as the associations captured in the drug action ‘central dogma’
(see Fig. 2.1). The approach also highlights target classes that are in need of more
research, such as kinases, which the community can use to direct future investigational
work. A set of 9,643,061 novel D-T associations were identified and ranked. These
associations are available for download and can be used as a starting point for further
analysis. Furthermore, the approach developed was shown to outperform state-of-the-
art approaches dedicated to D-T association prediction, identifying >10% more of a
set of known D-T associations than the approach developed by ChEMBL.
A method to infer novel Dr-D associations, which also makes use of the DReSMin
algorithm, was developed and this work was subsequently published [213]. This strat-
egy, described in Chapter 6, predicts target-driven hypotheses for novel indications.
Central to any in silico target-driven approach to drug discovery is the integration and
ranking of all known Gene-Disease (G-D) associations. In this project, G-D ranking
was achieved using a Bayesian approach. Ranked G-D associations were then inte-
grated with other relevant data to produce a target-driven drug repositioning data set.
Novel strategies for identifying therapeutic areas of interest were described. Finally,
this integrated data set was mined for instances of a semantic subgraph representing
an abstract view of the target-driven drug-disease relationships as captured in the drug
action ‘central dogma’ in Fig. 2.1.
Although sources such as DisGeNET [206] and Malacards [207] integrate and score
G-D associations, they are scored in an arbitrary fashion. DisGeNET, for example,
score G-D associations based on the evidence supporting them. In this metric, scores
assigned to associations are the sum of the frequency of three ‘types’ of evidence
supporting them: i. manually curated sources capturing the association ii. model
organism databases that capture the association and iii. text-mined associations. The
problem with this metric is the fact that if a G-D association (even a negative associ-
ation) is well-studied it will score well based on the cumulative nature of the scoring
metric and the number of papers describing the well-studied association. The Bayesian
approach described in Chapter 6 allows for a more holistic, less biased view of the
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G-D data. Unlike DisGeNET, using the Bayesian approach described in this work, if
an association is captured in a text mining source it will receive one score from the
source (even if it has been captured 350 times by the source)— reducing the bias in
well-studied associations. The G-D ranking provided by this work can enable further
target-driven drug repositioning projects by taking a state-of-the-art view of the G-D
association landscape. The ranked set of 309,885 G-D associations are available to the
community and provide a resource capturing data that have been previously inacces-
sible, such as the 3,407 associations annotated with either Gain of Function (GoF) or
Loss of Function (LoF).
As well as the G-D associations, the approach described in Chapter 6 has many sub-
components that can enable future drug repositioning projects. The approach high-
lights therapeutic areas that would benefit from drug development projects (areas of
therapeutic need) using two metrics for ranking therapeutic areas in terms of approved
treatments available to treat them (see Section 6.4.4). The Therapeutic Area Unmet
Score (TAU) ranks therapeutic areas in terms of those that would benefit from more
treatments and the Rich Therapeutic Area (RTA) enables therapeutic areas to be
ranked based on how rich the set of marketed treatments is for that area. These met-
rics can be used to drive other drug repositioning projects and can also help industry to
identify areas of need for drug discovery projects. A method for scoring the similarity
of diseases captured in the MeSH hierarchy is also provided. This similarity measure is
used to filter novel Dr-D associations that are likely side-effects. The method for prun-
ing inferences can be used in any in silico drug repositioning project and can enable
for more accurate inference sets to be produced. Finally, a set of 275,934 unique novel
Dr-D associations was provided, with two of the most promising inferences (pazopanib
as a treatment for mastocytosis and lisinopril as a treatment for Alzheimers) discussed
and made available for future analysis.
7.2.4 Limitations of the approaches described
Throughout this thesis, computational approaches to drug repositioning have been
presented. To consider drugs in a systems setting, where a holistic view of their
interactions with multiple entities is required, simplified representations of drugs have
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been used. For example, the active form of a drug may differ from the marketed
compound, with many transformations occurring during drug metabolism. Like all in
silico strategies to analysing in vivo and in vitro systems, the accuracy of the systems
view is limited by the available domain knowledge. Overly-simplified reproductions
of a system innately struggle to accurately represent in vivo and in vitro systems. In
order to capture a more accurate representation of the drug landscape, other factors
may also need to be considered. Through integrating these factors with the work
presented, more confident inferences could possibly be made in the future. Some of
these limiting factors are introduced in the following section.
7.2.4.1 Drug selection
Drug repositioning tends to focus on approved drugs (however drugs that have failed
to reach the market for reasons other than safety concerns may also be considered),
yet there are still numerous factors aside from intellectual property or cost that can
limit the initial set of drugs to be investigated. These additional factors are briefly
mentioned here because they have not yet been presented or discussed. In the cases
presented in this work, post filtering could be used to take account of these factors.
For example, certain regulated substances, such as opiates and anabolic steroids, have
restrictions on handling and distribution, and as such may not be suitable for drug
repositioning [32]. Other approved drugs, such as magnesium chloride and the amino
acid arginine would not be classified as ‘therapeutic’ in most settings aimed at drug re-
use [32]. Furthermore, regulatory approval (European Medicines Agency (EMA) and
Food and Drug Administration (FDA)) approval is dependent on geographical location.
Therefore, opportunities to identify drugs approved in some locations but not others
exists [32]. Another factor that may be somewhat more difficult to implement is the
pharmacologically active form of a drug. Many drugs, such as the oestrogen antagonist,
tamoxifen (generic drug), are pro-drugs, either by design or are converted in vivo to
active metabolites [32]. It is, therefore, important to know the pharmacologically
active form of a drug [32].
One source that may enable the inclusion of such data in the future is ChEMBL [128].
At the time of writing the data source is making a concerted effort to annotate the
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active form of the drugs captured in the resource. Although the effort is not exhaustive
at present, in the future this data may prove priceless to drug selection in in silico
approaches to drug repositioning.
7.2.4.2 Dose levels
Arguably the most complicated aspect of drug repositioning is dosing. The dosage of
a drug can make a substantial difference due to the half-life of drugs varying widely.
In some drugs, there is a ‘binary’ therapeutic threshold, whereas in others this is
more graduated. Drugs are approved at well-defined dosage strength levels. The ideal
scenario for drug repositioning would be to use the existing approved specific prod-
uct [32] at the approved, or lower, dosage. If a drug needs to be administered at
dosages above these parameters, it would require substantial development costs. For
example, sildenafil, with dose strengths 25mg, 50mg, 100mg is marketed as Viagra
(Pfizer) for erectile dysfunction. Sildenafil was reformulated to dose strengths of 5mg
and 20mg when repositioned for the treatment of pulmonary arterial hypertension,
Revatio (Pfizer). Caution should be applied where in vitro concentrations are signif-
icantly higher than previously reported concentrations for the same drug observed in
clinical settings [32]. Therefore, the dose levels of potential repositioning opportunities
presented in this work must be considered before taken any further.
One way to predict dose ranges is by using pharmacological modelling, which enables
human dose-prediction; a fundamental for ranking lead-optimization in drug discovery
programs and to inform design of early clinical trials [233].
7.2.4.3 Data bias
Although the strategy described in Chapter 5 for the identification of novel D-T associ-
ations allows inferences involving multiple types of target, there are definite limitations
on those types that have less information available. Similarly, the approach described
in Chapter 6 for the identification of novel Dr-D associations, shows predictions involv-
ing diseases such as those of the central nervous system to be limited by the amount
of data that is currently available to describe them. Although the problems arising
from ‘missing data’ or low coverage are likely to become less of a hindrance as high
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throughput technologies continue to produce data at scale, this is presently an obvious
limitation to systems approaches.
Furthermore, every data set is biased based on the motivation for which it was devel-
oped in the first place. For example, Genome-Wide Association Studies (GWAS) data
are very much limited to diseases that are of interest to a particular field [146]. As such
there is a disproportionate amount of research into cancer and immuno-inflammatory
areas as well as infectious diseases. Although integration of multiple data sources cov-
ering the same ‘types’ of data (each source with different bias) can reduce the effects
of such bias, it can still be a problem.
Data bias is a common problem within the field of bioinformatics, with the less rep-
resented class, or category, often the one of interest. One method to avoid such bias
is to use data sampling. Data sampling involves selecting a subset of individuals from
within a population. By using data sampling techniques, a more evenly-spread subset
of data can be identified. Although this approach would result in a ‘fairer’ representa-
tion of associations involving a particular target class, or therapeutic area, it would also
remove data— something that is against the central idea of the approaches described
in this thesis.
7.2.4.4 Data reliability
Many types of data from multiple sources are included in the integrated data sets
developed during this project. There is always a risk that drug-related commercial or
open source projects contain errors; both automated and manual data curation can
introduce errors. As such there are tradeoffs in accuracy versus coverage. For example,
it is a well-known problem that the curation of a correct set of structures for approved
drugs is difficult, and arguably still not available at the required level of accuracy [234].
Problems with structure curation is an unavoidable problem at present.
As large pharmacological integration projects, such as Open PHACTS [130] and data
standards projects such as ELIXIR3 and eTRIKS4 continue to encourage the improve-
ment of data content, accessibility and format, it is hoped that the community will
3www.elixir-europe.org
4www.etriks.org
- 191 -
Chapter 7: Discussion and future work
benefit from an overall improvement in the near future.
7.2.4.5 Computational validation
The lack of a structured gold standard for drug repositioning makes it difficult to
compare, evaluate and validate the performance of computational methodologies [18].
Furthermore, there is little to no negative data available. The lack of a gold standard
leads to various approaches to the same problem using different means of validating
results. A lack of reliable validation data is highlighted in Chapter 5, where histori-
cal data was used as a means of validation. To help address this deficiency, DReNIn
includes both clinical trial data, side-effects and indications. These data enable valida-
tion questions to be posed that are currently not possible to query with other resources,
including large projects such as Open PHACTS. For example, DReNIn can answer a
question as such: ‘I have made a prediction that smallMoleculeA may be used to
treat commonDiseaseB— tell me if smallMoleculeA is currently marketed to treat
commonDiseaseB, furthermore tell me if commonDiseaseB is a side-effect of small-
MoleculeA. Finally, tell me if there are any stage 4 clinical trials that involve both
smallMoleculeA and commonDiseaseB’. It is hoped that this functionality will provide
a useful resource to the community.
Recent work has focussed on curating a comprehensive, public catalogue of existing
drug indications, that uses a crowd-sourcing approach [235, 236]. Although the ac-
curacy of such approach remains to be seen, this source has the potential to be an
interesting focus point for future drug repositioning approaches— a consensus set of
indications will enable cross-platform comparisons as well as validation.
7.2.5 Results in the broader context of recent developments
In this section, the results of the project will be discussed in terms of recent, external,
developments relevant to the work. Here, it will be shown how the work of this project
may benefit from work developed externally during the course of the project.
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7.2.5.1 DReNInF
The DReNInF provides a framework for the production of user specific drug reposi-
tioning data sets. This framework enables a user to create integrated data sets that
make use of historic versions of data sources. It is the historic versions of data sets
that enable sets of relevant semantic subgraphs to be created (see Chapter 5). Fur-
thermore, the framework can be easily extended to include data types that are not
currently accounted for.
At the time that this project commenced, these tasks were not possible to complete
with Open PHACTS. At present, Open PHACTS provides a Docker5 image that al-
lows a user to have a local instance of the Open PHACTS database. Furthermore,
at the time of writing, Open PHACTS are working on a framework for integrating
user-specific data that would enable RDF sub ‘graphs’ (such as UniProt) to be re-
moved from the local installation and be replaced with alternative versions of the data
source. Though useful, this approach has its limitations since many historical versions
of data sets are not available in RDF. Although this Open PHACTS feature is still
experimental, it has the potential to provide a fantastic source for the community.
However, the project still misses out on valuable data for the task of repositioning
that is included in DReNInF, such as indications and clinical trial data.
Other integration projects that have commenced since the start of this project in-
clude ONCOTrack6 for the identification of novel biomarkers in tumours, and eTOX7
which aims to enable the production of tools to better predict the toxicological pro-
files of small molecules in early stages of the drug development pipeline. These data
sources would provide useful additions— complementing the drug repositioning data
sets created using DReNInF.
7.2.5.2 Integration and ranking of gene-disease associations
Recently, the world of G-D associations has taken a large step forward, due to the
work completed by the Open Targets platform (OTP)8. This platform was in its in-
5www.docker.com
6http://www.oncotrack.eu/
7www.etoxproject.eu
8https://www.targetvalidation.org/
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fancy when the work presented in this thesis commenced but has recently made great
progress. Making use of the Experimental Factor Ontology, the OTP provides a state-
of-the-art view of G-D associations taken from multiple sources and scores these using
harmonic progression. Furthermore, at the time of writing, a remote API has been
launched, meaning that systematic querying of the data source can now be achieved.
This data source should be a great resource for the community and any extensions of
this work would need to utilise the work from those at the OTP.
7.2.5.3 The drug discovery climate is changing
As well as improving data set development and accessibility, many more external
factors have changed during the course of this project— to be expected in such a
fast-paced area of research. For example, new scientific areas of interest are coming to
the fore, such as epigenetic therapy. Epigenetics is the study of heritable changes in
gene expression that do not result in an alteration in the DNA sequence itself (such as
methylation) [237]. Epigenetic aberrations are particularly relevant to diseases such as
cancer, heart disease, diabetes and a variety of neurological disorders [237]. Epigenetic
modifications work in concert with genetic mechanisms to regulate transcriptional
activity in normal tissues and are often dysregulated in disease. Such changes can be
used as a diagnostic indicator— the epigentic changes often precede disease pathology.
Interestingly these modifications of DNA and histones are reversible, meaning they are
also good targets for therapeutic intervention [237]. Epigenetic therapies use drugs,
or other epigenome-influencing techniques, to treat medical conditions by influencing
pathways directly.
Furthermore, with the increased knowledge surrounding genomics data has come an
increased interest in personalised medicine. Specifically, the interest in personalised
medicine has come at a time when efforts such as the UK 100,000 Genomes Project
and the US Precision Medicine Initiative seek to scale up population-based genome
sequencing and integrate it with clinical data [30]. It is hoped that many of the
approaches presented in this thesis could also be transferable to this continually de-
veloping area of interest.
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7.3 Future work
This project has produced a number of novel algorithms and approaches as well as
drug repositioning data resources (described in Section 7.2). It has been shown that
for some tasks, such as D-T association prediction, our system is more capable than
other tools that are operating within the drug repositioning domain, identifying >10%
of a set of known D-T associations than the ChEMBL models9 [180, 181]. However,
there is plenty of scope for future improvements. A non-exhaustive discussion of a
number of interesting future directions is provided in the following section.
7.3.1 Extend the integration framework
Structural data is limited for both proteins and ligand binding sites. A lack of accuracy
also results in high levels of false positives for approaches that focus purely on these
data. However, it would be interesting to import structural data from sources such as
PDB [238] into DReNInF. Furthermore, PDTB is a database containing current and
potential drug targets with known 3D structures [36]. Structural data would offer an
alternative type of data in DReNInF. Using an holistic approach to semantic subgraph
development for mining of resulting integrated data sets (such as that described in
Chapter 5) it should be possible to reduce any associated false positives— inferences
made using the approaches presented in this thesis use all data types and not just one.
The inclusion of other genomic profile data, such as that captured in GEO [239] and
ArrayExpress [240] may also offer valuable input to drug repositioning data sets. In-
sights from ENCODE [241] and Fantom5 [242] provide information about the potential
regulatory effects of Single-Nucleotide Polymorphisms (SNPs) in non-coding regions,
which may offer interesting sources to be included in later data sets.
7.3.2 Extend applications
The approach described in Chapter 5 made use of historical data to create a set of
semantic subgraphs. These subgraphs were then searched for in a target network
9www.ebi.ac.uk/chembl
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using the DReSMin algorithm, with inferences scored and ranked using the scoring
framework described in the same Chapter. Although the use case presented considered
D-T associations, the approach can be used to identify any ‘type’ of interaction that
is both captured in the integrated network and has historical data sets available. It
would, therefore, be attractive to apply the strategy to the inference of interactions
such as G-D associations; Dr-D associations; or even use it to predict MoA. The only
limitation to the application of this methodology to the inference of alternative ‘types’
of associations is the requirement of historical data.
The analysis described in Chapter 6 infers Dr-D associations from an integrated data
set. The data set made use of integrated and ranked G-D associations as well as drug,
protein and gene data. A semantic subgraph that best represented the abstracted ‘cen-
tral dogma’ (see Fig. 2.1) was searched for using DReSMin and Dr-D inferences ranked.
Using the semantic subgraph from this approach, as well as the data types included
in the network, it would be interesting to infer novel G-D associations. These associa-
tions could be scored based on instance information (i.e. the number of instances that
inferred the association) and those scoring highly could then be integrated back into
the network. The approach could then be repeated to infer Dr-D associations using
these novel G-D associations.
7.3.3 Library of semantic subgraphs
A library of semantic subgraphs could be presented as an editable resource, open
to the public. The database would contain manually curated semantic subgraphs
as well as automatically generated semantic subgraphs, such as those presented in
Chapter 5. Furthermore, semantic subgraphs should be annotated with categories such
as ‘antidepressants’, ‘antiemetics’, ‘kinases’ or ‘G protein-coupled receptors (GPCR)’.
Semantic subgraphs can be drawn from real-life repositioning examples via manual
curation. The manual development of semantic subgraphs, such as the one described
in Fig. 4.2, is time-consuming. However, manually curated semantic subgraphs may
allow for more accurate representations of a functional module capturing a potential
drug repositioning opportunity, as opposed to those created via automated approaches.
Therefore, creating a library of semantic subgraphs curated from real world examples of
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repositioned drugs would be a great resource for the community. Manually developed
semantic subgraphs could be submitted to the database and be editable by other
members of the community whilst also being annotated manually with relevant sub-
categories of labels.
194 semantic subgraphs were defined in Chapter 5. It would be intriguing to examine
these further. For instance, to determine whether particular semantic subgraphs are
better at inferring D-T associations for different classes of drugs or indeed different
classes of target. Using the D-T association inference ranking, a simple metric could be
used to score a semantic subgraph based on their ability to prioritise D-T associations
involving (i) all drug classes and (ii) all target classes. Ranking positions of false
positives for the same class of interest would also need to be considered.
This semantic subgraph database would enable far more specific hypotheses to be
investigated. For example, if a user were interested in identifying potential D-T asso-
ciations involving the protein target class GPCR, the library would contain a subset
of semantic subgraphs that are ‘specialised’ for this purpose.
7.3.4 In vitro / In vivo validation
The ultimate goal of any drug in silico repositioning project is to take some of the
interesting hits identified into the clinic to show efficacy and to ultimately benefit
patients [18]. However, it is argued that drug repositioning is vastly more complicated
than typically imagined and thus many repositioning projects stop at the in vitro
level [32]. In vitro and in vivo models (e.g. cell-based targeted assays and mouse
models) are required to validate the candidate hits for preclinical drug evaluation [18].
In addition to the right model, the selection of the appropriate hits for validation is also
critical. Physicians or biologists may not favour some drugs due to reasons such as high
toxicity, high cost and low bioavailability. Also important is the cost of clinical trials
to show efficacy and companies are not likely to pay if a drug is off-patent. Once these
factors have been considered, it would be necessary to identify potential collaborations
to pursue some of the most promising ‘hits’ identified during this project.
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7.4 Conclusion
The methodologies and tools developed during the course of this project can facilitate
the integration of existing biological and pharmacological data to allow for a systems
approach to drug repositioning to be taken. Unlike the strategies described in Chap-
ter 2, the work described in this thesis has developed an approach that considers all
possible evidence about a set of drugs and their interactions. This holistic approach
has resulted in a set of tools and integrated data sets that, support the queries and
inferences outlined in the aims and objectives section at the start of this thesis (see
Section 1.3).
With the term ‘big data’ being used ever more frequently, in both industry as well
as academia, research focus is moving toward the way these vast amounts of data are
handled. As such, it is expected that in the near future, there will a huge amount of
accessible information to which the approaches implemented during this work can be
applied. Furthermore, the approaches presented here are not limited to the field of drug
repositioning. Searching for semantic subgraphs using the methodologies described has
a vast range of possible applications. Although applications such as gene regulatory
networks and social network analysis tend to analyse data with limited semantic types,
many applications that utilise semantically complex data sets could benefit greatly
from the research and approaches presented here.
Although the productivity of Research and Development (R&D) approaches to drug
discovery have improved dramatically since the start of this project, computational
drug repositioning is still of major importance to improving human health, through
discovering new uses for existing drugs. The work presented here will also benefit
greatly from the improved use of ontologies and controlled vocabularies pushed forward
via projects such as Open PHACTS [130], ELIXIR10 and eTRIKS11.
Finally, it is hoped that the work presented in this project will prove useful to the
wider community and in turn help to improve the lives of those who are suffering from
disease.
10www.elixir-europe.org
11www.etriks.org
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Figure A.1: Gene URL mapping in Open PHACTS. Open PHACTS RESTful
API v1.5 Map URL call maps the hepatic leukaemia factor gene (HLF) from Homo
sapiens to the nucleoside diphosphate kinase gene from Gallus gallus 1
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Figure A.2: DReNInO disease representation. (A) The Disease class in
DReNInO has two children, Rare_Disease and Common_Disease. (B) Object prop-
erties involving Disease (dashed lines) capture the relations between other classes
in DReNInO, such as Biological_Molecule, Drug_Molecule and Clinical_Trial.
Also shown are the superclasses of Drug_Molecule. Images were created in Protege
v4.3.
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Table A.1: Concept classes in Dat.
ConceptClass Nodes
Affymetrix Probe 20,522
Biological Process 19,046
Cellular Component 2,731
Compound (DrugBank) 4,842
Compound (KEGG) 1,607
Disease 14,535
Enzyme Classification 1,690
Enzyme 1,340
Gene 3,346
Kegg Orthologs Gene 2
Kegg Orthologs Protein 2
Molecular Function 7,674
Pathway 436
Protein Complex 196
Protein 22,665
Publication 45,059
Reaction 1,660
Target 3,500
Indication* 4,463
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Table A.2: Relation types in Dat.
RelationType Relations Details
part of catalyzing class 5,144 -
expressed by 673 -
ubiquitinated by 421 -
activated by 4,430 -
has function 50,922 -
regulated by 4,333 -
adjacent to 326 -
indirect effect 778 -
part of 5,332 -
produced by 1,816 -
derives from 210 -
has participant 62,146 -
has not function 113 -
4,813 -
repressed by 4 -
dephosphorylated by 410 -
share intermediate 4,979 -
dissociated from 51 -
interacts with 37,166 Annotated with G-Sesame semantic similarity
measures (no cutoff) (Du et al., 2009)
located in 50,382 -
phosphorylated by 1,537 -
binds to 10,742 -
is involved in 15,400 -
published in 109,061 -
is a 48,726 -
has similar sequence 299,416 BLAST (E-value cutoff 1e-4)
inhibited by 1,770 -
is not located in 338 -
is encoded by 3,347 -
state change from 260 -
binds to encoding mrna 22,514 -
protein family 23,060 -
sim 12,256 2D-Tanimoto co-efficient calculated using
(similarity cutoff 0.85) (O’Boyle et al, 2011)
is part of 573 -
member is part of 1,957 -
consumed by 1,845 -
participates not 109 -
has parent* 6,533 -
has child* 2,018 -
may treat* 3,744 -
may prevent* 343 -
disgenet involved in* 16,098 -
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Table A.3: Relation details in Dat
Relation Type From ConceptClass To ConceptClass
part of catalyzing class Enzyme Enzyme Classification
Protein Enzyme Classification
expressed by Protein Complex Protein Complex
Protein Protein
Protein Protein Complex
ubiquitinated by Protein Complex Protein Complex
Protein Protein
Protein Protein Complex
activated by Protein Compound (KEGG)
Protein Protein
Protein Complex Protein
Protein Protein Complex
has function Protein Molecular Function
regulated by Biological Process Biological Process
adjacent to Pathway Pathway
indirect effect Protein Protein
Protein Complex Protein
Protein Protein Complex
part of Cellular Component Cellular Component
Molecular Function Molecular Function
Biological Process Biological Process
Protein Protein Complex
produced by Compound (KEGG) Reaction
derives from Pathway Pathway
has participant Protein Biological Process
has not function Protein Molecular Function
catalyzed by Reaction Enzyme
repressed by Protein Protein
Protein Protein Complex
dephosphorylated by Protein Protein
Protein Complex Protein
share intermediate Reaction Pathway
Reaction Reaction
Protein Protein
Protein Complex Protein
Protein Protein Complex
dissociated from Protein Protein
Protein Complex Protein
interacts with Compound (KEGG) Protein
Protein Protein
located in Protein Cellular Component
phosphorylated by Protein Complex Protein Complex
Protein Protein
Protein Protein Complex
Continued on next page
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Relation Type From ConceptClass To ConceptClass
Protein Complex Protein
binds to Compound (KEGG) Protein
Protein Complex Protein Complex
Compound (DrugBank) Target
Protein Protein
Protein Protein Complex
is involved in Protein Disease
published in Protein Publication
is a Enzyme Protein
Cellular Component Cellular Component
Molecular Function Molecular Function
Biological Process Biological Process
Protein Target
Target Protein
has similar sequence Target Target
Target Protein
Protein Target
Protein Protein
inhibited by Protein Compound (KEGG)
Protein Complex Protein Complex
Protein Protein
Protein Complex Protein
Protein Protein Complex
is not located in Protein Cellular Component
is encoded by KEGG Orth Protein KEGG Orth Gene
Protein Gene
state change from Protein Protein
binds to encoding mrna Protein Affymetrix Probe
protein family Enzyme Classification Enzyme Classification
Protein Protein
sim Compound (DrugBank) Compound (DrugBank)
is part of KEGG Orth Protein Protein Complex
member is part of Reaction Pathway
consumed by Compound (KEGG) Reaction
participates not Protein Biological Process
has parent Indication Indication
has child Indication Indication
may treat Compound (DrugBank) Indication
may prevent Compound (DrugBank) Indication
disgnenet involved in Protein Indication
Target Indication
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Figure B.1: The effect of increasing the edge set of a semantic subgraph on
the search time (in seconds) of a search. Random semantic subgraphs were cre-
ated with |V (Q)| of 4. Edge sets (|E(Q)|) of the subgraphs ranged from 3-6. Random
target graphs were created with node sets ranging from 1× 104 to 1× 105. The algo-
rithm used one of two parameters: (A) all elements of the match must be greater than
ST (top) or (B) all elements must cumulatively be greater than the ST (bottom).
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Table C.2: GoF and LoF gene-disease associations.
Type #Ass. #Unique #Map
GoF 16.3k 1,734 1,248
LoF 29k 3,059 2,211
GoF and LoF Gene-disease associations captured using linguamatics. Note: ‘# Ass.’
= Associations from source, ‘#Map’ = number mapped to MeSH,
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Figure C.1: ROC curve when altering D value used to score associations
with UniProt as the gold standard. Using UniProt as the gold standard, all
G-D associations were scored using D-Values from 1.0 - 8.0. It is seen that a D-Value
(DV) of 5.0 (grey) gives the highest area under the curve AUC when validating using
UniProt.
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Table C.4: Number of mappings returned for each MeSH therapeutic area after filter-
ing.
Therapeutic Area # mapgs.
[C01] bacterial infections and mycoses 10,260
[C02] virus diseases 16,566
[C03] parasitic diseases 3,050
[C04] neoplasms 86,438
[C05] musculoskeletal diseases 20,531
[C06] digestive system diseases 42,802
[C07] stomatognathic diseases 7,139
[C08] respiratory tract diseases 21,695
[C09] otorhinolaryngologic diseases 3,005
[C10] nervous system diseases 95,898
[C11] eye diseases 12,776
[C12] urologic and male genital diseases 18,899
[C13] female genital diseases and pregnancy complications 23,405
[C14] cardiovascular diseases 44,206
[C15] hemic and lymphatic diseases 20,525
[C16] congenital, hereditary, and neonatal diseases and abnormalities 51,524
[C17] skin and connective tissue diseases 21,586
[C18] nutritional and metabolic diseases 27,929
[C19] endocrine system diseases 21,791
[C20] immune system diseases 19,652
[C21] disorders of environmental origin 2
[C22] animal diseases 785
[C23] pathological conditions, signs and symptoms 47,279
[C24] occupational diseases 380
[C25] chemically-induced disorders 7,410
[C26] wounds and injuries 2,849
[F01] behavior and behavior mechanisms 5,785
[F02] psychological phenomena and processes 1,394
[F03] mental disorders 27,574
Note: associations that include diseases that fall under multiple MeSH categories are
duplicated in the counts (if a disease has multiple mesh tree terms from the same
therapeutic area these are also counted multiple times). Only associations that
survived the filtering steps are included. mapgs. = mappings.
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Table C.6: Number of has_indication edges captured in GenDat involving the 1,188
approved small molecules.
Source # has indication (%)
CTD 14,761 (79.6)
SIDER4 3,641 (81.1 )
PREDICT 1,210 (95.7)
NDFRT 2,586 (58.8)
Note: the percentage in brackets reflects the percentage of associations from source x
that involves the drugs of interest. Sources cumulatively provide 18,889 unique
has_indication edges.
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Table C.7: Number of 18,889 known has_indication edges mapped to inferred asso-
ciations using altering Sim values.
Sim # known has indication (% of total)
1.0 6,114 (34.2)
0.768 9,188 (51.38)
0.633 12,955 (72.65)
0.537 15,527 (87.10)
0.462 16,689 (93.60)
0.401 17,122 (95.74)
0.350 17,321 (96.88)
0.305 17,388 (97.50)
0.266 17,401 (97.58)
0.2314 17,407(97.6)
Note: of the 18,889, known has_indication edges, 1,006 involved 63 drugs of the
1,188 investigated for which the approach returned no mappings, leaving 17,883 that
could potentially be validated.
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